US20020161001A1 - Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV - Google Patents

Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV Download PDF

Info

Publication number
US20020161001A1
US20020161001A1 US09/935,149 US93514901A US2002161001A1 US 20020161001 A1 US20020161001 A1 US 20020161001A1 US 93514901 A US93514901 A US 93514901A US 2002161001 A1 US2002161001 A1 US 2002161001A1
Authority
US
United States
Prior art keywords
dione
alkyl
benzyl
purine
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/935,149
Inventor
Anders Kanstrup
Lise Christiansen
Jane Lundbeck
Christian Sams
Marit Kristiansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to US09/935,149 priority Critical patent/US20020161001A1/en
Assigned to NOVO NORDISK A/S reassignment NOVO NORDISK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHRISTIANSEN, LISE BROWN, KANSTRUP, ANDERS BENDTZ, KRISTIANSEN, MARIT, LUNDBECK, JANE MARIE, SAMS, CHRISTIAN K.
Publication of US20020161001A1 publication Critical patent/US20020161001A1/en
Priority to US10/621,302 priority patent/US7235538B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Definitions

  • the present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity, as well as methods for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.
  • DPP-IV Dipeptidyl peptidase-IV
  • DPP-IV serine protease belonging to the group of post-proline/alanine cleaving amino-dipeptidases, specifically removes the two N-terminal amino acids from proteins having proline or alanine in position 2.
  • DPP-IV DPP-IV
  • DPP-IV has been implicated in the control of glucose metabolism because its substrates include the insulinotropic hormones Glucagon like peptide-1 (GLP-1) and Gastric inhibitory peptide (GIP). GLP-1 and GIP are active only in their intact forms; removal of their two N-terminal amino acids inactivates them.
  • GLP-1 and GIP are active only in their intact forms; removal of their two N-terminal amino acids inactivates them.
  • Diabetic dyslipidemia is characterized by multiple lipoprotein defects, including moderately high serum levels of cholesterol and triglycerides, small LDL particles, and low levels of HDL cholesterol.
  • the results of recent clinical trials reveal beneficial effects of cholesterol-lowering therapy in diabetic and non-diabetic patients, thus supporting increased emphasis on treatment of diabetic dyslipidemia.
  • the National Cholesterol Education Program's Adult Treatment Panel II advocated this need for intensive treatment of diabetic dyslipidemia.
  • Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension and diabetes. The incidence of obese people and thereby also these diseases is increasing throughout the entire industrialised world.
  • Such compounds have e.g. been disclosed in WO 98/19998, WO 00/34241, U.S. Pat. No. 6,124,305 (Novartis AG) and WO 99/38501 ( shareholders of Tufts University).
  • the compounds of the present invention constitutes a completely novel class of DPP-IV inhibitors, structurally unrelated to any DPP-IV inhibitors known so far. They are furthermore potent and stable and thus offers a solution to the problems associated with the presently known DPP-IV inhibitors.
  • each n is one or two independently
  • R 1 is C ⁇ O; C ⁇ S; C 1 -C 2 alkyl optionally substituted with one or more R 4 independently; C 2 alkenyl substituted with one or more R 4 independently; C 2 alkynyl; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; perhalo C 1 -C 10 alkyl; perhalo C 1 -C 10 alkyloxy;
  • R 2 is H; C 1 -C 7 alkyl optionally substituted with one or more R 4 independently; C 2 -C 7 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 7 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently, —SH; —SR 5 ; SOR 5 ; SO 2 R 5 ; —CHO; —CH(OR 5 ) 2 ; carboxy; —CO 2 R 4 ; NHCONNH
  • R 3 is H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently; C 1 -C 10 alkyl-NH(CH 2 ) 1-4 NH-aryl optionally substituted with one or more R 4 independently; C 1 -C 10 alkyl-NH(CH 2 )
  • R 4 is C 1 -C 10 alkyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 8 independently; aryl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; amino; amino substituted with one or more C 1 -C 10 alkyl optionally substituted with one or more R 8 ; amino substituted with one or two aryl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; ⁇ O; ⁇ S; —CO—R5; —COOR5; —O—CO-(C 1 -C 5
  • R 5 is C 1 -C 10 alkyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 8 independently; aryl optionally substituted with one or more R 8 independently; aryl C 1 -C 5 alkyl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; heteroaryl C 1 -C 5 alkyl optionally substituted with one or more R 8 independently;
  • R 6 is H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently;
  • R 7 is H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently;
  • R 8 is H, amidoxime; nitro, tetrazole; pentafluorophenyl; —CH 2 OH; —CHO; —C(OCH 3 ) 2 ; —COCH 3 ; —CF 3 ; —CCl 3 ; —OCF 3 ; —OCH 3 ; —CN; —CO 2 H; —CO 2 CH 3 ; —CONH 2 ; —CSNH 2 ; —CON 2 H 3 ; —SO 3 H; —SO 2 NH 2 ; —SO 2 NHCH 3 ; —SO 2 N(CH 3 ) 2 ; —SO 2 (1-piperazinyl);—SO 2 (4-methylpiperazin-1-yl); —SO 2 (pyrrolidin-1-yl); —SO 2 (piperidin-1-yl); —SO 2 (morpholin-4-yl); N-hydroxyimino; —NH 2 ; —NHCH 3 ; —NHCH 3
  • R 9 is H; halogen; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently
  • R 10 is H; halogen;
  • R 9 and R 10 may be connected to form a cyclopropyl ring
  • Compounds of formula I may be used for the manufacture of a medicament for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV.
  • the invention relates to the use of compounds of formula II
  • a 1 is a carbon or nitrogen atom
  • the A-ring may be substituted with one or more R 3
  • B 1 and B 2 are carbon or nitrogen atoms, independently,
  • each B 3 is a carbon, nitrogen, oxygen, or sulfur atom, independently, each n 1 , n 2 , n 3 , n 4 is one or two, independently,
  • D 3 , D 4 , and D 5 may be absent, in which case D 1 and D 2 may each be optionally substituted with one or two R 2 , independently,
  • D 1 , D 2 , D 3 , D 4 , and each D 5 may independently be a carbon, nitrogen, oxygen, or a sulfur atom, or C ⁇ O, or C ⁇ S;
  • the bonds in the B-ring may be saturated or unsaturated, such that the B-ring may be a five-membered or a six-membered carbocyclic or heterocyclic ring, which may be fully saturated, or partially or fully unsaturated;
  • the bonds in the D-ring when present, may be saturated or unsaturated, such that the D-ring may be a five-membered or a six-membered carbocyclic or heterocyclic ring, which may be fully saturated, or partially or fully unsaturated;
  • R 1 is C ⁇ O; C ⁇ S; C 1 -C 2 alkyl optionally substituted with one or more R 4 independently; C 2 alkenyl substituted with one or more R 4 independently; C 2 alkynyl; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; perhalo C 1 -C 10 alkyl; perhalo C 1 -C 10 alkyloxy;
  • Each R 2 is independently H; C 1 -C 7 alkyl optionally substituted with one or more R 4 independently; C 2 -C 7 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 7 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently, —SH; —SR 5 ; SOR 5 ; SO 2 R 5 ; —CHO; —CH(OR 5 ) 2 ; carboxy; —CO 2 R 4 ; NH
  • R 3 is H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 2 -C 6 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently; C 1 -C 10 alkyl-NH(CH 2 ) 1-4 NH-aryl optionally substituted with one or more R 4 independently; C 1 -C 10 alkyl-NH(CH 2 )
  • R 4 is C 1 -C 10 alkyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 8 independently; C 2 -C 6 cycloheteroalkyl optionally substituted with one or more R 8 independently; aryl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; amino; amino substituted with one or more C 1 -C 10 alkyl optionally substituted with one or more R 8 ; amino substituted with one or two aryl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; ⁇ O; ⁇ S; —CO—R5; —COOR5; —O—CO-(C 1 -C 5
  • R 5 is C 1 -C 10 alkyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 8 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 8 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 8 independently; aryl optionally substituted with one or more R 8 independently; aryl C 1 -C 5 alkyl optionally substituted with one or more R 8 independently; heteroaryl optionally substituted with one or more R 8 independently; heteroaryl C 1 -C 5 alkyl optionally substituted with one or more R 8 independently;
  • R 8 is H, amidoxime; nitro, tetrazole; pentafluorophenyl; —CH2OH; —CHO; —C(OCH 3 ) 2 ; —COCH 3 ; —CF 3 ; —CCl 3 ; —OCF 3 ; —OCH 3 ; —CN; —CO 2 H; —CO 2 CH 3 ; —CONH 2 ; —CSNH 2 ; —CON 2 H 3 ; —SO 3 H; —SO 2 NH 2 ; —SO 2 NHCH 3 ; —SO 2 N(CH 3 ) 2 ; —SO 2 (1-piperazinyl);—SO 2 (-4-methylpiperazin-1-yl); —SO 2 (pyrrolidin-1-yl); —SO 2 (piperidin-1-yl); —SO 2 (morpholin-4-yl); N-hydroxyimino; —NH 2 ; —NHCH 3 ; —NHCH 3
  • R 9 is H; halogen; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently
  • R 10 is H; halogen;
  • R9 and R10 may be connected to form a cyclopropyl ring
  • DPP-IV Dipeptidyl peptidase IV (EC 3.4.14.5; DPP-IV), also known as CD26. DPP-IV cleaves a dipeptide from the N terminus of a polypeptide chain containing a proline or alanine residue in the penultimate position.
  • treatment is defined as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
  • beta cell degeneration is intended to mean loss of beta cell function, beta cell dysfunction, and death of beta cells, such as necrosis or apoptosis of beta cells.
  • C 1 -C 10 alkyl refers to a straight or branched, saturated hydrocarbon chain having from 1-10 carbon atoms such as but not limited to e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec. Butyl, isobutyl, tert. Butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 4-methylpentyl, neopentyl, 2,2-dimethylpropyl and the like.
  • C 2 -C 10 -alkenyl used herein, alone or in combination, refers to a straight or branched, unsaturated hydrocarbon chain having from 2-10 carbon atoms and at least one double bond such as but not limited to vinyl, 1-propenyl, allyl, isopropenyl, n-butenyl, n-pentenyl and n-hexenyl and the like.
  • C 2 -C 10 alkynyl refers to an unsaturated hydrocarbon chain having from 2-10 carbon atoms and at least one triple bond such as but not limited to —C ⁇ CH, —C ⁇ CCH 3 , —CH 2 C ⁇ CH, —CH 2 —CH 2 —C ⁇ CH, —CH(CH 3 ) C ⁇ CH and the like.
  • C 1-10 -alkoxy as used herein, alone or in combination is intended to include those C 1-10 -alkyl groups of the designated length in either a linear or branched or cyclic configuration linked through an ether oxygen having its free valence bond from the ether oxygen.
  • linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy.
  • branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy and isohexoxy.
  • cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.
  • C 3 -C 10 cycloalkyl refers to a radical of one or more saturated cyclic hydrocarbon having from 3-10 carbon atoms such as but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like.
  • C 5 -C 10 cycloalkenyl refers to a radical of one or more cyclic hydrocarbon having at least one double bond having from 5-10 carbon atoms such as but not limited to cyclopentenyl, cyclohexenyl and the like
  • C 2 -C 6 cycloheteroalkyl refers to a radical of totally saturated heterocycle like a cyclic hydrocarbon containing one or more heteroatoms selected from nitrogen, oxygen and sulphur independently in the cycle such as pyrrolidine (1-pyrrolidine; 2-pyrrolidine; 3-pyrrolidine; 4-pyrrolidine; 5-pyrrolidine); pyrazolidine (1-pyrazolidine; 2-pyrazolidine; 3-pyrazolidine; 4-pyrazolidine; 5-pyrazolidine); imidazolidine (1-imidazolidine; 2-imidazolidine; 3-imidazolidine; 4-imidazolidine; 5-imidazolidine); thiazolidine (2-thiazolidine; 3-thiazolidine; 4-thiazolidine; 5-thiazolidine); piperidine (1-piperidine; 2-piperidine; 3-piperidine; 4-piperidine; 5-piperidine; 6-piperidine); piperazine (1-piperazine; 2-piperazine;
  • aryl as used herein includes carbocyclic aromatic ring systems. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems.
  • heteroaryl as used herein includes heterocyclic unsaturated ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur such as furyl, thienyl, pyrrolyl, heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated below.
  • aryl and “heteroaryl” as used herein refers to an aryl which can be optionally substituted or a heteroaryl which can be optionally substituted and includes phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • R 2 is preferably H; C 2 -C 7 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 7 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently, —SH; —SR 5 ; SOR 5 ; SO 2 R 5 ; —CHO; —CH(OR 5 ) 2 ; carboxy; —CO 2 R 4 ; NHCONNH 2 ; —NHCSNH 2 ;
  • R 2 may be H; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl optionally substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently, —SH; —SR 5 ; SOR 5 ; SO 2 R 5 ; —CHO; —CH(OR 5 ) 2 ; carboxy; —CO 2 R 4 ; NHCONNH 2 ; —NHCSNH 2 ; —NHCONH 2 ; —NHCOR 4 ; —NHSO 2 R 5 ; —O—CO-(C 1 -C 5 ) alkyl optional
  • R 2 may be H.
  • R 1 may preferably be C ⁇ O; C ⁇ S; C 1 -C 2 alkyl substituted with one or more R 4 independently; C 2 alkenyl substituted with one or more R 4 independently; C 2 alkynyl; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; aryl substituted with one or more R 4 independently; aryl C 1 -C 3 alkyl substituted with one or more R 4 independently; heteroaryl substituted with one or more R 4 independently; heteroaryl C 1 -C 3 alkyl substituted with one or more R 4 independently.
  • R 9 is preferably H
  • R 10 is preferably H
  • R 6 and R 7 may independently be H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloheteroalkyl optionally substituted with one or more R 4 independently; heteroaryl optionally substituted with one or more R 4 independently.
  • R 6 and R 7 may independently be H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently. More particularly, R 6 and R 7 may independently be H; C 1 -C 10 alkyl.
  • R 6 and R 7 may independently be H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently; C 3 -C 7 cycloalkyl optionally substituted with one or more R 4 independently.
  • R 4 may be piperidino optionally substituted with one or more R 8 independently; piperazino optionally substituted with one or more R 8 independently; morpholino optionally substituted with one or more R 8 independently; thiomorpholino optionally substituted with one or more R 8 independently; pyrrolidino optionally substituted with one or more R 8 independently.
  • R 6 and R 7 may independently be H; C 1 -C 10 alkyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkenyl optionally substituted with one or more R 4 independently; C 2 -C 10 alkynyl optionally substituted with one or more R 4 independently.
  • the invention provides compounds in one of the three groups A, B and C.
  • n and m is one or two independently;
  • R 1 is C ⁇ O; C ⁇ S; C 1 -C 2 alkyl; C 2 alkenyl; C 2 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl; heteroaryl-C 1 -C 3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl, or heteroaryl-C 1 -C 3 alkyl is optionally substituted with one or more R 4 independently;
  • R 2 is H; C 1 -C 7 alkyl; C 2 -C 7 alkenyl; C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR 5 ; —SOR 5 ; —SO 2 R 5 ; carboxy; —CO 2 R 4 ; —CON(R 5 ) 2 ; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryloxy,
  • R 3 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl-C 1 -C 3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a
  • R 4 , R 11 , R 12 , and R 17 are independently C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R 13 ) 2 ; ⁇ O; ⁇ S; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R 8
  • R 5 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 5 alkyl; heteroaryl; heteroaryl-C 1 -C 5 alkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R 14 independently;
  • R 6 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 15 independently;
  • R 7 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 16 independently;
  • R 8 , R 14 , R 15 , and R 16 are independently H; nitro; —OCH 3 ; cyano; halogen; —OH; —SH; —SCH 3 ;
  • R 9 is H; halogen; C 1 -C 10 alkyl or aryl, wherein alkyl or aryl is optionally substituted with one or more R 17 independently
  • R 10 is H; halogen;
  • R 9 and R 10 may be connected to form a cyclopropyl ring
  • R 13 is H; C 1 -C 10 alkyl or aryl;
  • n and m is one or two independently;
  • R 1 is C ⁇ O; C ⁇ S; C 1 -C 2 alkyl; C 2 alkenyl; C 2 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl; heteroaryl-C 1 -C 3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl, or heteroaryl-C 1 -C 3 alkyl is optionally substituted with one or more R 4 independently;
  • R 2 is H; C 1 -C 7 alkyl; C 2 -C 7 alkenyl; C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR 5 ; —SOR 5 ; —SO 2 R 5 ; carboxy; —CO 2 R 4 ; —CON(R 5 ) 2 ; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryloxy,
  • R 3 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl-C 1 -C 3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a
  • R 4 , R 11 , R 12 , and R 17 are independently C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R 13 ) 2 ; ⁇ O; ⁇ S; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R 8
  • R 5 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 5 alkyl; heteroaryl; heteroaryl-C 1 -C 5 alkyl , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R 14 independently;
  • R 6 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 15 independently;
  • R 7 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 16 independently;
  • R 8 , R 14 , R 15 , and R 16 are independently H; nitro; —OCH 3 ; cyano; halogen; —OH; —SH; —SCH 3 ;
  • R 9 is H; halogen; C 1 -C 10 alkyl optionally substituted with one or more R 17 independently
  • R 10 is H; halogen;
  • R 9 and R 10 may be connected to form a cyclopropyl ring
  • R 13 is H; C 1 -C 10 alkyl or aryl;
  • n and m is one or two independently;
  • R 1 is C ⁇ O; C ⁇ S; C 1 -C 2 alkyl; C 2 alkenyl; C 2 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl; heteroaryl-C 1 -C 3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl, or heteroaryl-C 1 -C 3 alkyl is optionally substituted with one or more R 4 independently;
  • R 2 is H; C 1 -C 7 alkyl; C 2 -C 7 alkenyl; C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR 5 ; —SOR 5 ; —SO 2 R 5 ; carboxy; —CO 2 R 4 ; —CON(R 5 ) 2 ; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryloxy,
  • R 3 is C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 3 alkyl; heteroaryl-C 1 -C 3 alkyl; heteroaryl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C 1 -C 3 alkyl, heteroaryl-C 1 -C 3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spir
  • R 4 , R 11 , R 12 , and R 17 are independently C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R 13 ) 2 ; ⁇ O; ⁇ S; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R 8
  • R 5 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; aryl-C 1 -C 5 alkyl; heteroaryl; heteroaryl-C 1 -C 5 alkyl , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R 14 independently;
  • R 6 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 15 independently;
  • R 7 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 16 independently;
  • R 8 , R 14 , R 15 , and R 16 are independently H; nitro; —OCH 3 ; cyano; halogen; —OH; —SH; —SCH 3 ;
  • R 9 is H; halogen; C 1 -C 10 alkyl optionally substituted with one or more R 17 independently
  • R 10 is H; halogen;
  • R 9 and R 10 may be connected to form a cyclopropyl ring
  • R 13 is H; C 1 -C 10 alkyl or aryl;
  • R 1 is C ⁇ O; C 1 -C 2 alkyl; C 2 alkenyl; C 2 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; or heteroaryl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R 4 independently.
  • R 1 is C ⁇ O; C 1 -C 2 alkyl; C 3 -C 7 cycloalkyl; aryl; or heteroaryl, wherein each alkyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R 4 independently.
  • R 1 is C ⁇ O or aryl optionally substituted with one or more R 4 independently.
  • R 1 is aryl optionally substituted with one or more R 4 independently.
  • R 1 is aryl
  • R 1 is phenyl
  • R 2 is H; C 1 -C 7 alkyl; C 2 -C 7 alkenyl; C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl; C 3 -C 7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR 5 ; —SOR 5 ; —SO 2 R 5 ; —CO 2 R 4 ; C 1 -C 10 alkyloxy; C 2 -C 10 alkenyloxy; C 2 -C 10 alkynyloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy, alkenyloxy, or alkynyloxy is optionally substituted with one or more R 11 independently.
  • R 2 is H; C 1 -C 7 alkyl; C 3 -C 7 cycloheteroalkyl; aryl; cyano; halogen; nitro; —SR 5 ; —SO 2 R 5 ; —CO 2 R 4 ; or C 1 -C 10 alkyloxy; wherein each alkyl, cycloheteroalkyl, aryl, or alkyloxy is optionally substituted with one or more R 11 independently.
  • R 2 is H; C 1 -C 7 alkyl; C 3 -C 7 cycloheteroalkyl; aryl; cyano; halogen; —CO 2 R 4 ; or C 1 -C 10 alkyloxy; wherein each alkyl, cycloheteroalkyl, aryl, or alkyloxy is optionally substituted with one or more R 11 independently.
  • R 2 is H; C 1 -C 7 alkyl; cyano; halogen; or C 1 -C 10 alkyloxy; wherein each alkyl or alkyloxy is optionally substituted with one or more R 11 independently.
  • R 2 is H; cyano or halogen.
  • R 3 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; aryl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
  • R 3 is H; C 1 -C 10 alkyl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; hydroxy; wherein alkyl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
  • R 3 is H or C 1 -C 10 alkyl optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
  • R 3 is H or C 1 -C 10 alkyl.
  • R 3 is methyl, ethyl, or isopropyl.
  • R 3 is H.
  • R 3 is C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; aryl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
  • R 3 is C 1 -C 10 alkyl; C 1 -C 10 alkyl-O-C 1 -C 5 alkyl; hydroxy; wherein alkyl, or alkyl-O-alkyl is optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
  • R 3 is C 1 -C 10 alkyl optionally substituted with one or more R 12 independently; two R 3 attached to the same carbon atom may form a spiro system.
  • R 3 is C 1 -C 10 alkyl.
  • R 3 is methyl, ethyl, or isopropyl
  • R 4 is C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R 8 independently.
  • R 4 is C 1 -C 10 alkyl; C 2 -C 10 alkenyl; or C 2 -C 10 alkynyl; wherein each alkyl, alkenyl, or alkynyl is optionally substituted with one or more R 8 independently.
  • R 4 is C 1 -C 10 alkyl optionally substituted with one or more R 8 independently.
  • R 4 is C 1 -C 10 alkyl.
  • R 4 is methyl
  • R 5 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; aryl; heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R 14 independently.
  • R 5 is C 1 -C 10 alkyl or aryl; wherein each alkyl or aryl is optionally substituted with one or more R 14 independently.
  • R 6 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 7 cycloalkyl; or aryl; wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, or aryl is optionally substituted with one or more R 15 independently.
  • R 6 is H; C 1 -C 10 alkyl; or C 2 -C 10 alkenyl; wherein each each alkyl or alkenyl is optionally substituted with one or more R 15 independently.
  • R 6 is H or C 1 -C 10 alkyl optionally substituted with one or more R 15 independently.
  • R 6 is H.
  • R 6 is C 1 -C 10 alkyl optionally substituted with one or more R 15 independently.
  • R 6 is C 1 -C 10 alkyl.
  • R 6 is methyl
  • R 7 is H; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; or C 2 -C 10 alkynyl, wherein each each alkyl, alkenyl, or alkynyl is optionally substituted with one or more R 16 independently.
  • R 7 is C 1 -C 10 alkyl optionally substituted with one or more R 16 independently.
  • R 7 is C 1 -C 10 alkyl.
  • R 8 is —OCH 3 .
  • R 9 is aryl
  • R 11 is C 1 -C 10 alkyl; aryl; cyano; halogen; wherein each alkyl or aryl is optionally substituted with one or more R 8 independently.
  • R 11 is halogen
  • R 12 is C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; wherein each alkyl, alkenyl, alkynyl, aryl, heteroaryl is optionally substituted with one or more R 8 independently.
  • R 12 is aryl; heteroaryl; or hydroxy; wherein each aryl and heteroaryl is optionally substituted with one or more R 8 independently.
  • R 12 is phenyl, pyridyl, or pyrrolidinyl.
  • R 12 is hydroxy
  • R 14 is halogen
  • a further aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising, as an active ingredient, at least one compound of the invention or a pharmaceutically acceptable salt or prodrug or hydrate thereof together with a pharmaceutically acceptable carrier or diluent.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of metabolic disorders.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for blood glucose lowering.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of Type 2 diabetes.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of impaired glucose tolerance (IGT).
  • ITT impaired glucose tolerance
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of impaired fasting glucose (IFG).
  • IGF impaired fasting glucose
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for prevention of hyperglycemia.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for delaying the progression of impaired glucose tolerance (IGT) to Type 2 diabetes.
  • ITT impaired glucose tolerance
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for delaying the progression of non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for increasing the number and/or the size of beta cells in a mammalian subject.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of beta cell degeneration, in particular apoptosis of beta cells.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of disorders of food intake.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of obesity.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for appetite regulation or induction of satiety.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of dyslipidemia.
  • a further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of functional dyspepsia, in particular irritable bowel syndrome.
  • a further aspect of the invention is a method for the treatment of diseases or disorders associated with proteins that are subject to inactivation by DPP-IV, the method comprising administering to a subject in need thereof an effective amount of a compound of the invention.
  • a further aspect of the invention is methods of treating the above mentioned diseases, the method comprising administering to a subject in need thereof an effective amount of a compound of the invention.
  • the compounds of the present invention may be prepared in the form of pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids.
  • salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like.
  • Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids and the like.
  • Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan.
  • the acid addition salts may be obtained as the direct products of compound synthesis.
  • the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
  • the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
  • the bonds in the B-ring may be unsaturated, such that the B-ring is a five-membered or a six-membered carbocyclic or heterocyclic ring, which is fully unsaturated.
  • D 3 , D 4 and at least one D 5 are present, and D 1 , D 2 , D 3 , D 4 , and each D 5 may independently be a carbon, nitrogen, oxygen, or a sulfur atom, or C ⁇ O, or C ⁇ S, and the bonds in the B-ring are unsaturated, such that the B-ring is a five-membered or a six-membered carbocyclic or heterocyclic ring, which is fully unsaturated.
  • the bonds in the D-ring are preferably unsaturated, such that the D-ring may be a five-membered or a six-membered carbocyclic or heterocyclic ring, which is fully unsaturated.
  • each n 1 , n 2 may be one or two, independently n 3 is one, and n 4 is two,
  • D 1 and D 2 may be carbon atoms
  • D 4 and one of the D 5 may be nitrogen atoms
  • D 3 and the other D 5 may be C ⁇ O, or C ⁇ S
  • the bonds in the B-ring may be unsaturated, such that the B-ring is a five-membered carbocyclic or heterocyclic ring, which is fully unsaturated.
  • n 1 is two and each of n 2 , n 3 , n 4 is one or two, independently.
  • the B-ring is a benzene ring
  • each n 1 , n 2 is one or two, independently,
  • D 3 , D 4 , and D 5 are absent, such that D 1 and D 2 may each be optionally substituted with one R 2 , independently.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one compound of the invention which inhibits the enzymatic activity of DPP-IV or a pharmaceutically acceptable salt or prodrug or hydrate thereof together with a pharmaceutically acceptable carrier or diluent.
  • Pharmaceutical compositions containing a compound of the invention of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy, 19 th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
  • compositions include a compound of the invention which inhibits the enzymatic activity of DPP-IV or a pharmaceutically acceptable basic addition salt or prodrug or hydrate thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
  • the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid container for example in a sachet.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatine, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
  • the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.
  • the route of administration may be any route, which effectively transports the active compound of the invention which inhibits the enzymatic activity of DPP-IV to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
  • the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • the preparation may contain a compound of the invention which inhibits the enzymatic activity of DPP-IV, dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
  • a liquid carrier in particular an aqueous carrier
  • the carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain:
  • Core Core Active compound (as free compound or salt thereof) 250 mg Colloidal silicon dioxide (Aerosil) ® 1.5 mg Cellulose, microcryst. (Avicel) ® 70 mg Modified cellulose gum (Ac-Di-Sol) ® 7.5 mg Magnesium stearate Ad. Coating: HPMC approx. 9 mg *Mywacett 9-40 T approx. 0.9 mg
  • the compounds of formula I and formula II may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of the various diseases as mentioned above, e.g. metabolic disorders, Type 2 diabetes, hyperglycemia, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), beta cell degeneration, apoptosis of beta cells, disorders of food intake, obesity, dyslipidemia, and functional dyspepsia, in particular irritable bowel syndrome.
  • the compounds of formula I or formula II are contemplated to be useful for the prevention or treatment of Type 2 diabetes.
  • the compounds of formula I or formula II may be useful for blood glucose lowering, prevention of hyperglycemia, delaying the progression of impaired glucose tolerance to Type 2 diabetes, delaying the progression of non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes, increasing the number and/or size of beta cells in a mammalian subject, or appetite regulation or induction of satiety.
  • the mammal to be treated with a compound of formula I or formula II is preferably a human, but may also be an animal, both a domesticated animal, e.g. household pet, and non-domesticated animal such as wildlife.
  • the compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, per day may be used. A most preferable dosage is about 0.5 mg to about 250 mg per day. In choosing a regimen for patients it may frequently be necessary to begin with a higher dosage and when the condition is under control to reduce the dosage. The exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
  • the compounds of the present invention are dispensed in unit dosage form comprising from about 0.05 to about 1000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
  • dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 0.05 mg to about 1000 mg, preferably from about 0.5 mg to about 250 mg of the compounds admixed with a pharmaceutically acceptable carrier or diluent.
  • the invention also encompasses prodrugs of a compound of the invention which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances.
  • prodrugs will be functional derivatives of a compound of the invention which are readily convertible in vivo into a compound af the invention.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
  • the invention also encompasses active metabolites of a compound of the invention.
  • the preparation of the compounds of formula I can be done in many ways.
  • the starting materials are either known compounds or compounds which may be prepared in analogy with the preparation of similar known compounds.
  • a particularly useful synthesis is outlined below.
  • the invention furthermore relates to the use of a compound according to the present invention for the preparation of a medicament for use in the treatment of diabetes in a regimen which additionally comprises treatment with another antidiabetic agent.
  • insulinidiabetic agent includes compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.
  • the antidiabetic agent is insulin or GLP-1 or any analogue or derivative thereof.
  • the antidiabetic agent is a hypoglycaemic agent, preferably an oral hypoglycaemic agent.
  • Oral hypoglycaemic agents are preferably selected from the group consisting of sulfonylureas, non-sulphonylurea insulin secretagogues, biguanides, thiazolidinediones, alpha glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potasium channel openers, insulin sensitizers, hepatic enzyme inhibitors, glucose uptake modulators, compounds modifying the lipid metabolism, compounds lowering food intake, and agents acting on the ATP-dependent potassium channel of the 1-cells.
  • sulfonylureas tolbutamide, glibenclamide, glipizide and gliclazide are preferred.
  • repaglinide and nateglinide are preferred.
  • metformin is preferred.
  • troglitazone rosiglitazone and ciglitazone are preferred.
  • acarbose is preferred.
  • glibenclamide glipizide
  • gliclazide gliclazide
  • repaglinide a group consisting of glibenclamide, glipizide, gliclazide, repaglinide.
  • CD26/DPP-IV Chemical compounds are tested for their ability to inhibit the enzyme activity of purified CD26/DPP-IV. Briefly, the activity of CD26/DPP-IV is measured in vitro by its ability to cleave the synthetic substrate Gly-Pro-p-nitroanilide (Gly-Pro-pNA). Cleavage of Gly-Pro-pNA by DPP-IV liberates the product p-nitroanilide (pNA), whose rate of appearance is directly proportional to the enzyme activity. Inhibition of the enzyme activity by specific enzyme inhibitors slows down the generation of pNA. Stronger interaction between an inhibitor and the enzyme results in a slower rate of generation of pNA.
  • Gly-Pro-pNA Gly-Pro-pNA
  • the degree of inhibition of the rate of accumulation of pNA is a direct measure of the strength of enzyme inhibition.
  • the accumulation of pNA is measured spectrophotometrically.
  • the inhibition constant, Ki, for each compound is determined by incubating fixed amounts of enzyme with several different concentrations of inhibitor and substrate.
  • Assay buffer 50 mM Tris pH7.4, 150 mM NaCl, 0.1% Triton X-100.
  • the Zucker Diabetic Fatty (ZDF) rat model can be used to investigate the effects of the compounds of the invention on both the treatment and prevention of diabetes as rats of this sub-strain are initially pre-diabetic although develop severe type 2 diabetes characterised by increased HbA1c levels over a period of 6 weeks.
  • the same strain can be used to predict the clinical efficacy of other anti-diabetic drug types.
  • the model predicts the potency and limited clinical efficacy of thiazolidinedione insulin sensitiser compounds.
  • a Valco column switch with a Valco actuator controlled by timed events from the pump is a Valco column switch with a Valco actuator controlled by timed events from the pump.
  • HPLC pump was connected to four eluent reservoirs containing:
  • samples contain approximately 500 ⁇ g/ml of the compound to be analysed in an acceptable solvent such as methanol, ethanol, acetonitrile, THF, water and mixtures thereof. (High concentrations of strongly eluting solvents will interfere with the chromatography at low acetonitrile concentrations.)
  • an acceptable solvent such as methanol, ethanol, acetonitrile, THF, water and mixtures thereof.
  • the detection data were acquired concurrently from the mass spectrometer, the UV detector and the ELS detector.
  • Step B Preparation of (2-Amino-propionylamino) Acetic Acid Methyl Ester Derivatives
  • Step E and F are described in J.Org.Chem. 50 (24); 1985; 4796-4799 while step D is as described above.
  • Step E Preparation of t-Boc-dipeptide Esters
  • the ethyl acetate phase is decanted to a new scintillations vessel.
  • the water/DMF-phase is then extracted with DCM (5 ml).
  • the DCM and ethyl acetate phase are combined and evaporated in a speedvac. The residue is used without any purification in the next step.
  • R 1 , R 3 , R 6 , R 7 , X and n are defined as in formula I.
  • Alkylation reagent R 6 -X (32 ⁇ mol) is dissolved in DMF (100 ⁇ l) and added to the above reaction mixture, followed by a solution of TMG in DMF (1.16 ml TMG diluted to 5.8 ml, 48 ul). The mixture is kept at 65° C. for 4 h.
  • the first reaction step is identical to Step A in general procedure (A)
  • the first reaction step is identical to Step A in general procedure (A)
  • 1,4-Dibenzyl-[1,4]diazepane-5,7-dione is converted to the Na-salt in THF with NaH as base, and reacted with the R 3 —X alkylating reagent e.g. benzyl bromide, at room temperature.
  • the product e.g. 1,4,6-Tribenzyl-[1,4]diazepane-5,7-dione is reduced to the 1,4,6-Tribenzyl-[1,4]diazepane by treatment with LiAlH4 in THF at elevated temperature.
  • the N-benzyl groups are removed by catalytic hydrogenation in EtOH:AcOH (1:1), using Pd/C as catalyst.
  • Step A Preparation of 1,4-dibenzyl-[1,4]diazepane-6-carboxylic Acid. Na-salt (1A)
  • N,N′-dibenzylethylenediamine (4.9 ml, 20.8 mmol) was dissolved in toluene (200 ml), triethylamine (8.94 ml, 64.5 mmol), and methanol (20 ml) and 3-bromo-2-bromomethylpropionic acid (5.12 g, 20.8 mmol) was added.
  • the reaction mixture was heated to reflux for 24 hours. The solvents were evaporated and the remaining was redissolved in water (150 ml) and ethyl acetate (150 ml).
  • the aqueous layer was washed with 4 ⁇ 150 ml of ethyl acetate, and then evaporated to dryness. The remaining was suspended in ethyl acetate (200 ml) and dry methanol (20 ml) and salts was filtered off.
  • the mother liquor was evaporated and purified by chromatography on silica, using 10% methanol in dichloromethane as the eluent. Fractions containing the product were evaporated, to afford 5.09 g of 1A as an yellow foam in 70% yield.
  • Step B Preparation of (1,4-dibenzyl-[1,4]diazepan-6-yl)methanol (1B)
  • Step D Preparation of 7-benzyl-8-(6-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione.
  • Step A Preparation of 1,4-dibenzyl-[1,4]diazepan-6-ol (2A)
  • N,N′-dibenzylethylenediamine (4.9 ml, 20.8 mmol) was dissolved in toluene (200 ml), triethylamine (8.94 ml, 64.5 mmol), and 1,3-dibromo-2-propanol (4.53 g, 20.8 mmol) was added.
  • the reaction mixture was heated to reflux for 4 days.
  • the solvents were evaporated and the remaining was redissolved in water (150 ml) and ethyl acetate (150 ml).
  • Step C Preparation of 7-Benzyl-8-(6-hydroxy-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione.
  • the aqueous layer was extracted with 3 ⁇ 50 ml of dichloromethane, and the combined organic material were added excess trifluoroacetic acid, and evaporated, to afford 123 mg of the title compound as a brown oil in 75% yield.
  • Step A Preparation of 1,4-dibenzyl-[1,4]diazepane-2-carboxylic Acid Methyl Ester (3A)
  • N,N′-Dibenzylpropane-1,3-diamine (Sandstroem, J. et al, Tetrahedron; EN; 34; 1978; 371-378) (2.0 g, 7.86 mmol), methyl 2,3-dibromopropionate (1.28 ml, 7.86 mmol), and potassium carbonate (2.17 g, 15.72 mmol) were dissolved in dry dimethylformamide (125 ml) and methanol (20 ml) and the mixture was heated to reflux for 6 days. The reaction mixture was allowed to cool to room temperature and water (200 ml) and ethyl acetate (200 ml) were added.
  • the aqueous layer was extracted with 2 ⁇ 200 ml of ethyl acetate, and the combined organic layers were dried with sodium sulfate, filtered and the solvent was evaporated.
  • the crude product was purified by chromatography on silica, using a mixture of ethyl acetate and heptane 1:6 as the eluent. Fractions containing the product were evaporated, to afford 180 mg of 3A as an clear oil in 7% yield.
  • Step B Preparation of (1,4-dibenzyl-[1,4]diazepan-2-yl)-methanol (3B)
  • Step D Preparation of 7-benzyl-8-(3-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione.
  • Step A Preparation of 7-benzyl-8-chloro-1,3-dimethyl-3,7-dihydro-purine-2,6-dione (4A)
  • Step B Preparation of 4-(7-Benzyl-1,3-dimethyl-2,6-dioxo-2,3,4,5-tetrahydro-1H-purine-8-yl)-piperazine-1-carboxylic acid tert-butylate (4B)
  • Step C Preparation of 4-(7-Benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione.
  • DMSO d6 d 10.90 (s, 1H); 8.65 (s br, 2H); 7.40-7.20 (m, 8H); 7.14 (d, 2H); 5.43 (s, 2H); 5.06 (s, 2H); 3.65 (m, 2H); 3.48 (m, 2H); 3.26 (m, 2H); 3.16 (s br, 2H); 1.97 (m, 2H)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity, as well as methods for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity

Description

    FIELD OF INVENTION
  • The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity, as well as methods for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. [0001]
    • BACKGROUND OF THE INVENTION
  • Dipeptidyl peptidase-IV (DPP-IV), a serine protease belonging to the group of post-proline/alanine cleaving amino-dipeptidases, specifically removes the two N-terminal amino acids from proteins having proline or alanine in position 2. [0002]
  • Although the physiological role of DPP-IV has not been completely established, it is believed to play an important role in neuropeptide metabolism, T-cell activation, gastric ulceration, functional dyspepsia, obesity, appetite regulation, impaired fasting glucose (IFG) and diabetes. [0003]
  • DPP-IV has been implicated in the control of glucose metabolism because its substrates include the insulinotropic hormones Glucagon like peptide-1 (GLP-1) and Gastric inhibitory peptide (GIP). GLP-1 and GIP are active only in their intact forms; removal of their two N-terminal amino acids inactivates them. [0004]
  • In vivo administration of synthetic inhibitors of DPP-IV prevents N-terminal degradation of GLP-1 and GIP, resulting in higher plasma concentrations of these hormones, increased insulin secretion and, therefore, improved glucose tolerance. Therefore, such inhibitors have been proposed for the treatment of patients with Type 2 diabetes, a disease characterised by decreased glucose tolerance. (Hoist, J. J.; Deacon, C. F. Diabetes 47 (1998) 1663-70) [0005]
  • Diabetic dyslipidemia is characterized by multiple lipoprotein defects, including moderately high serum levels of cholesterol and triglycerides, small LDL particles, and low levels of HDL cholesterol. The results of recent clinical trials reveal beneficial effects of cholesterol-lowering therapy in diabetic and non-diabetic patients, thus supporting increased emphasis on treatment of diabetic dyslipidemia. The National Cholesterol Education Program's Adult Treatment Panel II advocated this need for intensive treatment of diabetic dyslipidemia. [0006]
  • Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension and diabetes. The incidence of obese people and thereby also these diseases is increasing throughout the entire industrialised world. [0007]
  • Except for exercise, diet and food restriction no convincing pharmacological treatment for reducing body weight effectively and acceptably currently exist. However, due to its indirect but important effect as a risk factor in mortal and common diseases it will be important to find treatment for obesity or appetite regulation. Even mild obesity increases the risk for premature death, diabetes, hypertension, atherosclerosis, gallbladder disease and certain types of cancer. In the industrialised western world the prevalence of obesity has increased significantly in the past few decades. Because of the high prevalence of obesity and its health consequences, its prevention and treatment should be a high public health priority. [0008]
  • At present a variety of techniques are available to effect initial weight loss. Unfortunately, initial weight loss is not an optimal therapeutic goal. Rather, the problem is that most obese patients eventually regain their weight. An effective means to establish and/or sustain weight loss is the major challenge in the treatment of obesity today. Several compounds have been shown to inhibit DPP-IV, but all of these have limitations in relation to the potency, stability, and pharmacodynamic properties. [0009]
  • Such compounds have e.g. been disclosed in WO 98/19998, WO 00/34241, U.S. Pat. No. 6,124,305 (Novartis AG) and WO 99/38501 (Trustees of Tufts University). The compounds of the present invention constitutes a completely novel class of DPP-IV inhibitors, structurally unrelated to any DPP-IV inhibitors known so far. They are furthermore potent and stable and thus offers a solution to the problems associated with the presently known DPP-IV inhibitors. [0010]
    • SUMMARY OF THE INVENTION
  • The present invention provides compounds of formula I [0011]
    Figure US20020161001A1-20021031-C00001
  • wherein [0012]
  • each n is one or two independently [0013]
  • R[0014] 1 is C═O; C═S; C1-C2 alkyl optionally substituted with one or more R4 independently; C2 alkenyl substituted with one or more R4 independently; C2 alkynyl; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R4 independently; aryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently; heteroaryl C1-C3 alkyl optionally substituted with one or more R4 independently; perhalo C1-C10 alkyl; perhalo C1-C10 alkyloxy;
  • R[0015] 2 is H; C1-C7 alkyl optionally substituted with one or more R4 independently; C2-C7 alkenyl optionally substituted with one or more R4 independently; C2-C7 alkynyl optionally substituted with one or more R4 independently; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R4 independently; aryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently, —SH; —SR5; SOR5; SO2R5; —CHO; —CH(OR5)2; carboxy; —CO2R4; NHCONNH2; —NHCSNH2; —NHCONH2; —NHCOR4; —NHSO2R5; —O—CO-(C1-C5) alkyl optionally substituted with one or more R4 independently; cyano; nitro; halogen; hydroxy; perhalo C1-C7 alkyl; perhalo C1-C7 alkyloxy; —SO2NH2; —SO2NH(R5); —SO2(R5)2; —CONH2; —CSNH2; —CON2H3; —CONH(R5); —CON(R5)2; C1-C10 alkyloxy optionally substituted with R4 independently; C2-C10 alkenyloxy optionally substituted with R4; C2-C10 alkynyloxy optionally substituted with R4 independently, aryloxy optionally substituted with R4 independently; heteroaryloxy optionally substituted with R4 independently;
  • R[0016] 3 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-C10 alkenyl optionally substituted with one or more R4 independently; C2-C10 alkynyl optionally substituted with one or more R4 independently; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R4 independently; aryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently; C1-C10 alkyl-NH(CH2)1-4NH-aryl optionally substituted with one or more R4 independently; C1-C10 alkyl-NH(CH2)1-4NH-heteroaryl optionally substituted with one or more R4 independently; C1-C10 alkyl-O(CH2)1-4NH-aryl optionally substituted with one or more R4 independently, C1-C10 alkyl-O(CH2)1-4NH-heteroaryl optionally substituted with one or more R4 independently; C1-C10 alkyl-O(CH2)1-4O-aryl optionally substituted with one or more R4 independently; C1-C10 alkyl-O(CH2)1-4O-heteroaryl optionally substituted with one or more R4 independently; C1-C10 alkyl-S(CH2)1-4NH-aryl optionally substituted with one or more R4 independently; C1-C10 alkyl-S(CH2)1-4NH-heteroaryl optionally substituted with one or more R4 independently; C1-C10 alkyl-S(CH2)1-4S-heteroaryl optionally substituted with one or more R4 independently; C1-C10 alkyl-S(CH2)1-4S-heteroaryl optionally substituted with one or more R4 independently; C1-C10 alkyl-O-C1-C5alkyl optionally substituted with one or more R4; —NHCOR4; —NHSO2R5; —O—CO-(C1-C5) alkyl optionally substituted with one or more R4 independently; —SH; —SR5; —SOR5; —SO2R5; —CHO; —CH(OR5)2; carboxy; cyano; nitro; halogen; hydroxy; —SO2NH2; —SO2NH(R5); —SO2N(R5)2; —CONH2; —CONH(R5); —CON(R5)2; —CSNH2; —CONHNH2; —CO2R4; —NHCNHNH2; —NHCSNH2; —NHCONH2;
  • R[0017] 4 is C1-C10 alkyl optionally substituted with one or more R8 independently; C2-C10 alkenyl optionally substituted with one or more R8 independently; C2-C10 alkynyl optionally substituted with one or more R8 independently; C3-C7 cycloalkyl optionally substituted with one or more R8 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R8 independently; aryl optionally substituted with one or more R8 independently; heteroaryl optionally substituted with one or more R8 independently; amino; amino substituted with one or more C1-C10 alkyl optionally substituted with one or more R8; amino substituted with one or two aryl optionally substituted with one or more R8 independently; heteroaryl optionally substituted with one or more R8 independently; ═O; ═S; —CO—R5; —COOR5; —O—CO-(C1-C5) alkyl optionally substituted with one or more R8 independently; NH(CH2)1-4NH-aryl; NH(CH2)1-4NH-heteroaryl; —NHCOR5; —SOR5; SO2R5; carboxy; cyano; N-hydroxyimino; nitro; halogen; hydroxy; perhalo C1-C10 alkyl; perhalo C1-C10 alkyloxy; —SH; —SR5; —SO3H; —SO3R5; —SO2R5; —SO2NH2; —SO2NH(R5); —SO2N(R5)2; —CONH2; —CONH(R5); —CON(R5)2; C1-C10 alkyloxy optionally substituted with one or more R8 independently; C2-C10 alkenyloxy optionally substituted with one or more R8 independently; C2-C10 alkynyloxy optionally substituted with one or more R8 independently; aryloxy optionally substituted with one or more R8 independently; heteroaryloxy optionally substituted with one or more R8 independently; and two R4 attached to the same carbon atom may form a spiroheterocyclic system, preferably hydantoin; thiohydantoin; oxazolidine-2,5-dione;
  • R[0018] 5 is C1-C10 alkyl optionally substituted with one or more R8 independently; C2-C10 alkenyl optionally substituted with one or more R8 independently; C2-C10 alkynyl optionally substituted with one or more R8 independently; C3-C7 cycloalkyl optionally substituted with one or more R8 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R8 independently; aryl optionally substituted with one or more R8 independently; aryl C1-C5 alkyl optionally substituted with one or more R8 independently; heteroaryl optionally substituted with one or more R8 independently; heteroaryl C1-C5 alkyl optionally substituted with one or more R8 independently;
  • R[0019] 6 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-C10 alkenyl optionally substituted with one or more R4 independently; C2-C10 alkynyl optionally substituted with one or more R4 independently; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently;
  • R[0020] 7 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-C10 alkenyl optionally substituted with one or more R4 independently; C2-C10 alkynyl optionally substituted with one or more R4 independently; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently;
  • R[0021] 8 is H, amidoxime; nitro, tetrazole; pentafluorophenyl; —CH2OH; —CHO; —C(OCH3)2; —COCH3; —CF3; —CCl3; —OCF3; —OCH3; —CN; —CO2H; —CO2CH3; —CONH2; —CSNH2; —CON2H3; —SO3H; —SO2NH2; —SO2NHCH3; —SO2N(CH3)2; —SO2 (1-piperazinyl);—SO2 (4-methylpiperazin-1-yl); —SO2 (pyrrolidin-1-yl); —SO2 (piperidin-1-yl); —SO2 (morpholin-4-yl); N-hydroxyimino; —NH2; —NHCH3; —N(CH3)2; —NHCNHNH2; —NHCNHNHCH3; —NHCSNH2; —NHCSNHCH3; —NHCONH2; —NHCONHCH3; —NHCOCH3; —NHSO2CH3; piperazinyl; morhpolin-4-yl; thiomorpholin-4-yl; pyrrolidin-1-yl; piperidin-1-yl; halogen; -OH; —SH; —SCH3; -aminoacetyl; —OPO3H; —OPO2OCH3; —PO3H2; —PO(OCH3)2; PO(OH)(OCH3);
  • R[0022] 9 is H; halogen; C1-C10 alkyl optionally substituted with one or more R4 independently
  • R[0023] 10 is H; halogen;
  • or, R[0024] 9 and R10 may be connected to form a cyclopropyl ring;
  • or a salt thereof with a pharmaceutically acceptable acid or base; [0025]
  • with the exception of the following compounds: [0026]
  • 1,3-dimethyl-7-(2-oxo-propyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0027]
  • 1,3,1′,3′,7′-pentamethyl-8-piperazin-1-yl-3,7,3′,7′-tetrahydro-7,8′-methanediyl-bis-purine-2,6-dione, [0028]
  • 3,4,5-trimethoxy-benzoic acid 2-(1,3-dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydro-purin-7-yl)-ethyl ester, [0029]
  • 7-[2-Hydroxy-3-(4-methoxy-phenoxy)-propyl]-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0030]
  • 7-[2-hydroxy-2-(4-nitro-phenyl)-ethyl]-3-methyl-8-piperazin-1-yl-3,7,8,9-tetrahydro-purine-2,6-dione, [0031]
  • 7-Benzyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0032]
  • 7-(4-Chloro-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0033]
  • 7-(2-Chloro-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0034]
  • 7-Ethyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0035]
  • 3-Methyl-8-piperazin-1-yl-1,7-dipropyl-3,7-dihydro-purine-2,6-dione, [0036]
  • 3-Methyl-7-(3-methyl-butyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0037]
  • 7-Butyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0038]
  • 3-Methyl-7-(3-phenyl-propyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0039]
  • 7-But-2-enyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0040]
  • 7-(3-Chloro-but-2-enyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0041]
  • 7-Heptyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0042]
  • 3-Methyl-7-(1-phenyl-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0043]
  • 3-Methyl-7-(3-methyl-benzyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0044]
  • 3-Methyl-7-propyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, and [0045]
  • 3-Methyl-7-pentyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. [0046]
  • Compounds of formula I may be used for the manufacture of a medicament for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV. [0047]
  • In another aspect, the invention relates to the use of compounds of formula II [0048]
    Figure US20020161001A1-20021031-C00002
  • wherein [0049]
  • A[0050] 1 is a carbon or nitrogen atom
  • The A-ring may be substituted with one or more R[0051] 3
  • B[0052] 1 and B2are carbon or nitrogen atoms, independently,
  • each B[0053] 3 is a carbon, nitrogen, oxygen, or sulfur atom, independently, each n1, n2, n3, n4 is one or two, independently,
  • D[0054] 3, D4, and D5 may be absent, in which case D1 and D2 may each be optionally substituted with one or two R2, independently,
  • D[0055] 1, D2, D3, D4, and each D5 may independently be a carbon, nitrogen, oxygen, or a sulfur atom, or C═O, or C═S;
  • the bonds in the B-ring may be saturated or unsaturated, such that the B-ring may be a five-membered or a six-membered carbocyclic or heterocyclic ring, which may be fully saturated, or partially or fully unsaturated; [0056]
  • the bonds in the D-ring, when present, may be saturated or unsaturated, such that the D-ring may be a five-membered or a six-membered carbocyclic or heterocyclic ring, which may be fully saturated, or partially or fully unsaturated; [0057]
  • R[0058] 1 is C═O; C═S; C1-C2alkyl optionally substituted with one or more R4 independently; C2 alkenyl substituted with one or more R4 independently; C2 alkynyl; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R4 independently; aryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently; heteroaryl C1-C3 alkyl optionally substituted with one or more R4 independently; perhalo C1-C10 alkyl; perhalo C1-C10 alkyloxy;
  • Each R[0059] 2 is independently H; C1-C7 alkyl optionally substituted with one or more R4 independently; C2-C7 alkenyl optionally substituted with one or more R4 independently; C2-C7 alkynyl optionally substituted with one or more R4 independently; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R4 independently; aryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently, —SH; —SR5; SOR5; SO2R5; —CHO; —CH(OR5)2; carboxy; —CO2R4; NHCONNH2; —NHCSNH2; —NHCONH2; —NHCOR4; —NHSO2R5; —O—CO—(C1-C5) alkyl optionally substituted with one or more R4 independently; cyano; nitro; halogen; hydroxy; —SO2NH2; —SO2NH(R5); —SO2(R5)2; —CONH2; —CSNH2; —CON2H3; —CONH(R5); —CON(R5)2; C1-C10 alkyloxy optionally substituted with R4 independently; C2-C10 alkenyloxy optionally substituted with R4; C2-C10 alkynyloxy optionally substituted with R4 independently, aryloxy optionally substituted with R4 independently; heteroaryloxy optionally substituted with R4 independently;
  • R[0060] 3 is H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-C10 alkenyl optionally substituted with one or more R4 independently; C2-C10 alkynyl optionally substituted with one or more R4 independently; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C2-C6 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R4 independently; aryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently; C1-C10alkyl-NH(CH2)1-4NH-aryl optionally substituted with one or more R4 independently; C1-C10alkyl-NH(CH2)1-4NH-heteroaryl optionally substituted with one or more R4 independently; C1-C10alkyl-O(CH2)1-4NH-aryl optionally substituted with one or more R4 independently; C1-C10alkyl-O(CH2)1-4NH-heteroaryl optionally substituted with one or more R4 independently; C1-C10alkyl-O(CH2)1-4O-aryl optionally substituted with one or more R4 independently; C1-C10alkyl-O(CH2)1-4O-heteroaryl optionally substituted with one or more R4 independently; C1-C10alkyl-S(CH2)1-4NH-aryl optionally substituted with one or more R4 independently; C1-C10alkyl-S(CH2)1-4NH-heteroaryl optionally substituted with one or more R4 independently; C1-C10alkyl-S(CH2)1-4S-aryl optionally substituted with one or more R4 independently; C1-C10alkyl-S(CH2)1-4-S-heteroaryl optionally substituted with one or more R4 independently; C1-C10alkyl-O-C1-C5alkyl optionally substituted with one or more R4; —NHCOR4; —NHSO2R5; —O—CO-(C1-C5) alkyl optionally substituted with one or more R4 independently; —SH; —SR5; —SOR5; —SO2R5; —CHO; —CH(OR5)2; carboxy; cyano; nitro; halogen; hydroxy; —SO2NH2; —SO2NH(R5); —SO2N(R5)2; —CONH2; —CONH(R5); —CON(R5)2; —CSNH2; —CONHNH2; —CO2R4; —NHCNHNH2; —NHCSNH2; —NHCONH2; —NHCOR4; —NHSO2R5;
  • R[0061] 4 is C1-C10 alkyl optionally substituted with one or more R8 independently; C2-C10 alkenyl optionally substituted with one or more R8 independently; C2-C10 alkynyl optionally substituted with one or more R8 independently; C3-C7 cycloalkyl optionally substituted with one or more R8 independently; C2-C6 cycloheteroalkyl optionally substituted with one or more R8 independently; aryl optionally substituted with one or more R8 independently; heteroaryl optionally substituted with one or more R8 independently; amino; amino substituted with one or more C1-C10 alkyl optionally substituted with one or more R8; amino substituted with one or two aryl optionally substituted with one or more R8 independently; heteroaryl optionally substituted with one or more R8 independently; ═O; ═S; —CO—R5; —COOR5; —O—CO-(C1-C5) alkyl optionally substituted with one or more R8 independently; NH(CH2)1-4NH-aryl; NH(CH2)1-4NH-heteroaryl; —NHCOR5; —SOR5; SO2R5; carboxy; cyano; N-hydroxyimino; nitro; halogen; hydroxy; perhaloalkyl; perhaloalkyloxy; —SH; —SR5; —SO3H; —SO3R5; —SO2R5; —SO2NH2; —SO2NH(R5); —SO2N(R5)2; —CONH2; —CONH(R5); —CON(R5)2; C1-C10 alkyloxy optionally substituted with one or more R8 independently; C2-C10 alkenyloxy optionally substituted with one or more R8 independently; C2-C10 alkynyloxy optionally substituted with one or more R8 independently; aryloxy optionally substituted with one or more R8 independently; heteroaryloxy optionally substituted with one or more R8 independently; two R4 attached to the same carbon may form a spiroheterocyclic system such as hydantoin; thiohydantoin; oxazolidine-2,5-dione;
  • R[0062] 5 is C1-C10 alkyl optionally substituted with one or more R8 independently; C2-C10 alkenyl optionally substituted with one or more R8 independently; C2-C10 alkynyl optionally substituted with one or more R8 independently; C3-C7 cycloalkyl optionally substituted with one or more R8 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R8 independently; aryl optionally substituted with one or more R8 independently; aryl C1-C5 alkyl optionally substituted with one or more R8 independently; heteroaryl optionally substituted with one or more R8 independently; heteroaryl C1-C5 alkyl optionally substituted with one or more R8 independently;
  • R[0063] 8 is H, amidoxime; nitro, tetrazole; pentafluorophenyl; —CH2OH; —CHO; —C(OCH3)2; —COCH3; —CF3; —CCl3; —OCF3; —OCH3; —CN; —CO2H; —CO2CH3; —CONH2; —CSNH2; —CON2H3; —SO3H; —SO2NH2; —SO2NHCH3; —SO2N(CH3)2; —SO2 (1-piperazinyl);—SO2 (-4-methylpiperazin-1-yl); —SO2 (pyrrolidin-1-yl); —SO2 (piperidin-1-yl); —SO2 (morpholin-4-yl); N-hydroxyimino; —NH2; —NHCH3; —N(CH3)2; —NHCNHNH2; —NHCNHNHCH3; —NHCSNH2; —NHCSNHCH3; —NHCONH2; —NHCONHCH3; —NHCOCH3; —NHSO2CH3; piperazinyl; morhpolin-4-yl; thiomorpholin-4-yl); pyrrolidin-1-yl; piperidin-1-yl; halogen; —OH; —SH; —SCH3; -aminoacetyl; —OPO3H; —OPO2OCH3; —PO3H2; —PO(OCH3)2; PO(OH) (OCH3);
  • R[0064] 9 is H; halogen; C1-C10 alkyl optionally substituted with one or more R4 independently
  • R[0065] 10 is H; halogen;
  • R9 and R10 may be connected to form a cyclopropyl ring [0066]
  • or a salt thereof with a pharmaceutically acceptable acid or base; [0067]
  • for the manufacture of a medicament for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV. [0068]
    • DETAILED DESCRIPTION OF THE INVENTION
  • Definitions [0069]
  • The term “DPP-IV” as used herein is intended to mean Dipeptidyl peptidase IV (EC 3.4.14.5; DPP-IV), also known as CD26. DPP-IV cleaves a dipeptide from the N terminus of a polypeptide chain containing a proline or alanine residue in the penultimate position. [0070]
  • The term “treatment” is defined as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder. [0071]
  • The term “beta cell degeneration” is intended to mean loss of beta cell function, beta cell dysfunction, and death of beta cells, such as necrosis or apoptosis of beta cells. [0072]
  • The term “C[0073] 1-C10 alkyl” as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having from 1-10 carbon atoms such as but not limited to e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec. Butyl, isobutyl, tert. Butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 4-methylpentyl, neopentyl, 2,2-dimethylpropyl and the like.
  • The term “C[0074] 2-C10-alkenyl” used herein, alone or in combination, refers to a straight or branched, unsaturated hydrocarbon chain having from 2-10 carbon atoms and at least one double bond such as but not limited to vinyl, 1-propenyl, allyl, isopropenyl, n-butenyl, n-pentenyl and n-hexenyl and the like.
  • The term “C[0075] 2-C10 alkynyl” as used herein, alone or in combination, refers to an unsaturated hydrocarbon chain having from 2-10 carbon atoms and at least one triple bond such as but not limited to —C≡CH, —C≡CCH3, —CH2C≡CH, —CH2—CH2—C≡CH, —CH(CH3) C≡CH and the like.
  • The term “C[0076] 1-10-alkoxy” as used herein, alone or in combination is intended to include those C1-10-alkyl groups of the designated length in either a linear or branched or cyclic configuration linked through an ether oxygen having its free valence bond from the ether oxygen. Examples of linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy. Examples of branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy and isohexoxy. Example of cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.
  • The term “C[0077] 3-C10 cycloalkyl” as used herein refers to a radical of one or more saturated cyclic hydrocarbon having from 3-10 carbon atoms such as but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like.
  • The term “C[0078] 5-C10 cycloalkenyl” as used herein refers to a radical of one or more cyclic hydrocarbon having at least one double bond having from 5-10 carbon atoms such as but not limited to cyclopentenyl, cyclohexenyl and the like
  • The term “C[0079] 2-C6 cycloheteroalkyl” as used herein refers to a radical of totally saturated heterocycle like a cyclic hydrocarbon containing one or more heteroatoms selected from nitrogen, oxygen and sulphur independently in the cycle such as pyrrolidine (1-pyrrolidine; 2-pyrrolidine; 3-pyrrolidine; 4-pyrrolidine; 5-pyrrolidine); pyrazolidine (1-pyrazolidine; 2-pyrazolidine; 3-pyrazolidine; 4-pyrazolidine; 5-pyrazolidine); imidazolidine (1-imidazolidine; 2-imidazolidine; 3-imidazolidine; 4-imidazolidine; 5-imidazolidine); thiazolidine (2-thiazolidine; 3-thiazolidine; 4-thiazolidine; 5-thiazolidine); piperidine (1-piperidine; 2-piperidine; 3-piperidine; 4-piperidine; 5-piperidine; 6-piperidine); piperazine (1-piperazine; 2-piperazine; 3-piperazine; 4-piperazine; 5-piperazine; 6-piperazine); morpholine (2-morpholine; 3-morpholine; 4-morpholine; 5-morpholine; 6-morpholine); thiomorpholine (2-thiomorpholine; 3-thiomorpholine; 4-thiomorpholine; 5-thiomorpholine; 6-thiomorpholine); 1,2-oxathiolane (3-(1,2-oxathiolane); 4-(1,2-oxathiolane); 5-(1,2-oxathiolane); 1,3-dioxolane (2-(1,3-dioxolane); 4-(1,3-dioxolane); 5-(1,3-dioxolane); tetrahydropyrane; (2-tetrahydropyrane; 3-tetrahydropyrane; 4-tetrahydropyrane; 5-tetrahydropyrane; 6-tetrahydropyrane); hexahydropyridazine (1-(hexahydropyridazine); 2-(hexahydropyridazine); 3-(hexahydropyridazine); 4-(hexahydropyridazine); 5-(hexahydropyridazine); 6-(hexahydropyridazine)).
  • The term “aryl” as used herein includes carbocyclic aromatic ring systems. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems. [0080]
  • The term “heteroaryl” as used herein includes heterocyclic unsaturated ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur such as furyl, thienyl, pyrrolyl, heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated below. [0081]
  • The terms “aryl” and “heteroaryl” as used herein refers to an aryl which can be optionally substituted or a heteroaryl which can be optionally substituted and includes phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1,2,3-triazol-1-yl, 1,2,3-triazol-2-yl 1,2,3-triazol-4-yl, 1,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7-benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2,3-dihydro-benzo[b]furanyl), 6-(2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl), benzo[b]thiophenyl (2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl), 2,3-dihydro-benzo[b]thiophenyl (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro-benzo[b]thiophenyl), 4-(2,3-dihydro-benzo[b]thiophenyl), 5-(2,3-dihydro-benzo[b]thiophenyl), 6-(2,3-dihydro-benzo[b]thiophenyl), 7-(2,3-dihydro-benzo[b]thiophenyl), indolyl (1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), indazole (1-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1-benzoxazolyl, 2-benzoxazolyl), benzothiazolyl (1-benzothiazolyl, 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl (1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5H-dibenz[b,f]azepine (5H-dibenz[b,f]azepin-1-yl, 5H-dibenz[b,f]azepine-2-yl, 5H-dibenz[b,f]azepine-3-yl, 5H-dibenz[b,f]azepine-4-yl, 5H-dibenz[b,f]azepine-5-yl), 10,11-dihydro-5H-dibenz[b,f]azepine (10,11-dihydro-5H-dibenz[b,f]azepine-1-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-2-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-3-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-4-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-5-yl). [0082]
  • The term halogen as used herein refers to fluorine, chlorine, bromine or iodine. [0083]
  • In the compounds of formula I, R[0084] 2 is preferably H; C2-C7 alkenyl optionally substituted with one or more R4 independently; C2-C7 alkynyl optionally substituted with one or more R4 independently; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R4 independently; aryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently, —SH; —SR5; SOR5; SO2R5; —CHO; —CH(OR5)2; carboxy; —CO2R4; NHCONNH2; —NHCSNH2; —NHCONH2; —NHCOR4; —NHSO2R5;—NHCOR4; —NHSO2R5; —O—CO-(C1-C5) alkyl optionally substituted with one or more R4 independently; cyano; nitro; halogen; hydroxy; perhalo C1-C7 alkyl; perhalo C1-C7 alkyloxy; —SO2NH2; —SO2NH(R5); —SO2(R5)2; —CONH2; —CSNH2; —CON2H3; —CONH(R5); —CON(R5)2; C1-C10 alkyloxy optionally substituted with R4 independently; C2-C10 alkenyloxy optionally substituted with R4; C2-C10 alkynyloxy optionally substituted with R4 independently, aryloxy optionally substituted with R4 independently; heteroaryloxy optionally substituted with R4 independently.
  • More specifically, in the compounds of formula I, R[0085] 2 may be H; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl optionally substituted with one or more R4 independently; aryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl C1-C3 alkyl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently, —SH; —SR5; SOR5; SO2R5; —CHO; —CH(OR5)2; carboxy; —CO2R4; NHCONNH2; —NHCSNH2; —NHCONH2; —NHCOR4; —NHSO2R5; —O—CO-(C1-C5) alkyl optionally substituted with one or more R4 independently; cyano; nitro; halogen; hydroxy; perhalo C1-C7 alkyl; perhalo C1-C7 alkyloxy; —SO2NH2; —SO2NH(R5); —SO2(R5)2; —CONH2; —CSNH2; —CON2H3; —CONH(R5); —CON(R5)2; C1-C10 alkyloxy optionally substituted with R4 independently; C2-C10 alkenyloxy optionally substituted with R4; C2-C10 alkynyloxy optionally substituted with R4 independently, aryloxy optionally substituted with R4 independently; heteroaryloxy optionally substituted with R4 independently.
  • Alternatively, in the compounds of formula I, R[0086] 2 may be H. In this embodiment, R1 may preferably be C═O; C═S; C1-C2 alkyl substituted with one or more R4 independently; C2 alkenyl substituted with one or more R4 independently; C2 alkynyl; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; aryl substituted with one or more R4 independently; aryl C1-C3 alkyl substituted with one or more R4 independently; heteroaryl substituted with one or more R4 independently; heteroaryl C1-C3 alkyl substituted with one or more R4 independently.
  • In the compounds of formula I, R[0087] 9 is preferably H, and R10 is preferably H.
  • In the compounds of formula I, R[0088] 6 and R7 may independently be H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-C10 alkenyl optionally substituted with one or more R4 independently; C2-C10 alkynyl optionally substituted with one or more R4 independently; C3-C7 cycloalkyl optionally substituted with one or more R4 independently; C3-C7 cycloheteroalkyl optionally substituted with one or more R4 independently; heteroaryl optionally substituted with one or more R4 independently. In particular, R6 and R7 may independently be H; C1-C10 alkyl optionally substituted with one or more R4 independently. More particularly, R6 and R7 may independently be H; C1-C10 alkyl.
  • When R[0089] 10 is H, R6 and R7 may independently be H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-C10 alkenyl optionally substituted with one or more R4 independently; C2-C10 alkynyl optionally substituted with one or more R4 independently; C3-C7 cycloalkyl optionally substituted with one or more R4 independently.
  • In the compounds of formula I, R[0090] 4 may be piperidino optionally substituted with one or more R8 independently; piperazino optionally substituted with one or more R8 independently; morpholino optionally substituted with one or more R8 independently; thiomorpholino optionally substituted with one or more R8 independently; pyrrolidino optionally substituted with one or more R8 independently. In this embodiment, R6 and R7 may independently be H; C1-C10 alkyl optionally substituted with one or more R4 independently; C2-C10 alkenyl optionally substituted with one or more R4 independently; C2-C10 alkynyl optionally substituted with one or more R4 independently.
  • Preferred Compounds [0091]
  • 7-Benzyl-8-(6-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. [0092]
  • 7-Benzyl-8-(6-hydroxy-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione [0093]
  • 7-Benzyl-8-(3-hydroxymethyl-[1,4]diazepan- 1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione [0094]
  • 7-Benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0095]
  • 1,3-Dimethyl-7-(4-methylbenzyl)-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0096]
  • 3-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzonitrile [0097]
  • 2-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzonitrile [0098]
  • 1,3-Dimethyl-7-(1-phenylethyl)-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0099]
  • 7-(2-Iodobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0100]
  • 1,3-Dimethyl-8-piperazin-1-yl-7-(2-trifluoromethylbenzyl)-3,7-dihydropurine-2,6-dione [0101]
  • 1,3-Dimethyl-7-naphthalen-1-ylmethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0102]
  • 1,3-Dimethyl-7-naphthalen-2-ylmethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0103]
  • 7-(3-Bromobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0104]
  • 7-Benzyl-8-(3-isopropylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione [0105]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0106]
  • 1,3-Dimethyl-7-(2-oxo-2-pyrrolidin-1-yl-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0107]
  • 2-(8-[1,4]Diazepan-1-yl-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile [0108]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0109]
  • 7-(2-Difluoromethoxy-benzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0110]
  • 7-(2,3-Dimethoxy-benzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0111]
  • 1,3-Dimethyl-8-piperazin-1-yl-7-(2-trifluoromethoxy-benzyl)-3,7-dihydro-purine-2,6-dione [0112]
  • 1,3-Dimethyl-8-piperazin-1-yl-7-(2-trifluoromethylsulfanyl-benzyl)-3,7-dihydro-purine-2,6-dione [0113]
  • 4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydro-purin-7-yl)-butyronitrile [0114]
  • R)-7-Benzyl-8-(3-isopropylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione [0115]
  • S)-7-Benzyl-8-(3-isopropylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione [0116]
  • 7-Benzyl-8-(6,9-diazaspiro[4.5]dec-9-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione [0117]
  • 7-Benzyl-8-(piperazin-3-spiro-3′-bicyclo[2,2,1]heptane-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione [0118]
  • 8-[1,4]Diazepan-1-yl-7-(2-methoxy-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0119]
  • 8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-naphthalen-1-ylmethyl-3,7-dihydro-purine-2,6-dione [0120]
  • 8-[1,4]Diazepan-1-yl-7-(2-fluoro-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0121]
  • 8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-methyl-benzyl)-3,7-dihydro-purine-2,6-dione [0122]
  • 7-(2-Chloro-benzyl)-8-[1,4]diazepan-1-yl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0123]
  • 7-(2-Bromo-benzyl)-8-[1,4]diazepan-1-yl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0124]
  • 8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-trifluoromethyl-benzyl)-3,7-dihydro-purine-2,6-dione [0125]
  • 8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-nitro-benzyl)-3,7-dihydro-purine-2,6-dione [0126]
  • 3-Benzyl-8-piperazin-1-yl-7-(2-trifluoromethyl-benzyl)-3,7-dihydro-purine-2,6-dione [0127]
  • 3,7-Dibenzyl-1-(2-hydroxy-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0128]
  • 3-Benzyl-7-phenethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0129]
  • 3,7-Dibenzyl-8-[1,4]diazepan-1-yl-3,7-dihydro-purine-2,6-dione [0130]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione [0131]
  • 3,7-Dibenzyl-8-[1,4]diazepan-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione [0132]
  • 3,7-Dibenzyl-8-[1,4]diazepan-1-yl-1-(2-hydroxy-ethyl)-3,7-dihydro-purine-2,6-dione [0133]
  • 2-(3,7-Dibenzyl-8-[1,4]diazepan-1-yl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-N,N-diethyl-acetamide [0134]
  • 1,3,7-Tribenzyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0135]
  • 1,3,7-Tribenzyl-8-[1,4]diazepan-1-yl-3,7-dihydro-purine-2,6-dione [0136]
  • (S)-7-Benzyl-8-(3-benzyloxymethylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione [0137]
  • 3,7-Dibenzyl-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione [0138]
  • 3,7-Dibenzyl-8-[1,4]diazepan-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione [0139]
  • 3,7-Dibenzyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0140]
  • 3,7-Dibenzyl-8-[1,4]diazepan-1-yl-3,7-dihydro-purine-2,6-dione [0141]
  • 2-(3-Benzyl-2,6-dioxo-8-piperazin-1-yl-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile [0142]
  • 2-(3-Benzyl-8-[1,4]diazepan-1-yl-2,6-dioxo-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile [0143]
  • 2-(3-Benzyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile [0144]
  • 2-(3-Benzyl-8-[1,4]diazepan-1-yl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile [0145]
  • 3-Benzyl-7-(2-iodo-benzyl)-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione [0146]
  • 3-Benzyl-8-[1,4]diazepan-1-yl-7-(2-iodo-benzyl)-1-propyl-3,7-dihydro-purine-2,6-dione [0147]
  • 3-Benzyl-7-(2-iodo-benzyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0148]
  • 3-Benzyl-8-[1,4]diazepan-1-yl-7-(2-iodo-benzyl)-3,7-dihydro-purine-2,6-dione [0149]
  • 7-Benzyl-3-methyl-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione [0150]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-propyl-3,7-dihydro-purine-2,6-dione [0151]
  • 7-Benzyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0152]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione [0153]
  • 2-(3-Methyl-2,6-dioxo-8-piperazin-1-yl-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile [0154]
  • 2-(8-[1,4]Diazepan-1-yl-3-methyl-2,6-dioxo-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile [0155]
  • 2-(8-[1,4]Diazepan-1-yl-3-methyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile [0156]
  • 7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione [0157]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-propyl-3,7-dihydro-purine-2,6-dione [0158]
  • 7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0159]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0160]
  • 3-Benzyl-8-[1,4]diazepan-1-yl-1-(3-hydroxy-propyl)-7-(2-iodo-benzyl)-3,7-dihydro-purine-2,6-dione [0161]
  • 3-Benzyl-8-[1,4]diazepan-1-yl-1-(2-ethoxy-ethyl)-7-(2-iodo-benzyl)-3,7-dihydro-purine-2,6-dione [0162]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(3-phenyl-allyl)-3,7-dihydro-purine-2,6-dione [0163]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(2-oxo-2-phenyl-ethyl)-3,7-dihydro-purine-2,6-dione [0164]
  • 2-(7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-ylmethyl)-benzonitrile [0165]
  • (7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetonitrile [0166]
  • 3-Methyl-7-(2-methyl-thiazol-4-ylmethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0167]
  • 8-[1,4]Diazepan-1-yl-3-methyl-7-(2-methyl-thiazol-4-ylmethyl)-3,7-dihydro-purine-2,6-dione [0168]
  • 3-Methyl-7-(2-oxo-2-phenyl-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0169]
  • 8-[1,4]Diazepan-1-yl-3-methyl-7-(2-oxo-2-phenyl-ethyl)-3,7-dihydro-purine-2,6-dione [0170]
  • 8-[1,4]Diazepan-1-yl-3-methyl-7-phenethyl-3,7-dihydro-purine-2,6-dione [0171]
  • 8-[1,4]Diazepan-1-yl-1-(3-hydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0172]
  • 1-(3-Hydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0173]
  • 8-[1,4]Diazepan-1-yl-1-(2-ethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0174]
  • 1-(2-Ethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0175]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(2-phenoxy-ethyl)-3,7-dihydro-purine-2,6-dione [0176]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1-[2-(2-methoxy-ethoxy)-ethyl]-3-methyl-3,7-dihydro-purine-2,6-dione [0177]
  • 7-(2-Iodo-benzyl)-1-[2-(2-methoxy-ethoxy)-ethyl]-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0178]
  • 8-[1,4]Diazepan-1-yl-1-(3,5-dimethoxy-benzyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0179]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1-(3-methoxy-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0180]
  • 7-Biphenyl-2-ylmethyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione [0181]
  • 7-(2-Bromo-benzyl)-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione [0182]
  • 7-(2-Chloro-benzyl)-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione [0183]
  • 7-Benzyl-8-(3,5-dimethyl-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0184]
  • 7-(4-Methoxybenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0185]
  • (1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-yl)-phenylacetic acid methyl ester [0186]
  • 7-(5-Chloro-2-nitrobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0187]
  • 4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzonitrile [0188]
  • 7-(4-Methanesulfonylbenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0189]
  • 7-(2-Fluoro-6-nitrobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0190]
  • 7-(4-Benzyloxybenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0191]
  • 7-(2,4-Dichlorobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0192]
  • 1,3-Dimethyl-8-piperazin-1-yl-7-(4-trifluoromethylbenzyl)-3,7-dihydropurine-2,6-dione [0193]
  • 7-Biphenyl-4-ylmethyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0194]
  • 3-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzoic acid methyl ester [0195]
  • 4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzoic acid methyl ester [0196]
  • 7-Biphenyl-2-ylmethyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0197]
  • 7-(4-tert-Butylbenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0198]
  • 1,3-Dimethyl-8-piperazin-1-yl-7-(4-trifluoromethoxybenzyl)-3,7-dihydropurine-2,6-dione [0199]
  • 7-(3,4-Dichlorobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione [0200]
  • 1,3-Dimethyl-8-piperazin-1-yl-7-(4-[1,2,3]thiadiazol-4-ylbenzyl)-3,7-dihydropurine-2,6-dione [0201]
  • 4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl)-3-methoxybenzoic acid methyl ester [0202]
  • 7-Cyclohexylmethyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0203]
  • 7-Benzyl-8-(2,5-diaza-bicyclo[2.2.1]hept-2-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0204]
  • 8-(6-Benzyl-[1,4]diazepan-1-yl)-7-(2-iodo-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0205]
  • (S)-7-Benzyl-8-(3-hydroxymethylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione [0206]
  • 8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-oxo-2-pyrrolidin-1-yl-ethyl)-3,7-dihydro-purine-2,6-dione [0207]
  • 7-(2-Iodo-benzyl)-1,3-dimethyl-8-(6-pyridin-2-ylmethyl-[1,4]diazepan-1-yl)-3,7-dihydro-purine-2,6-dione [0208]
  • 7-(2-Bromo-benzyl)-1,3-dimethyl-8-(6-pyridin-2-ylmethyl-[1,4]diazepan-1-yl)-3,7-dihydro-purine-2,6-dione [0209]
  • (S) 7-Benzyl-8-(3-benzyl-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0210]
  • 7-Benzyl-1,3-dimethyl-8-(3-phenethyl-piperazin-1-yl)-3,7-dihydro-purine-2,6-dione [0211]
  • (R)-7-Benzyl-8-(3-benzylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione [0212]
  • 7-Benzyl-8(3-(2-hydroxy-benzyl)-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0213]
  • 7-Benzyl-8-(3-(2-methoxy-benzyl)-piperazin-1-yl)1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0214]
  • (R) 7-Benzyl-8-(3-(4-methoxy-benzyl)-piperazin-1-yl)1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0215]
  • (R)-7-Benzyl-8-(3-(4-hydroxy-benzyl)-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0216]
  • (R)-7-Benzyl-1,3-dimethyl-8-(3-(4-nitro-benzyl)-piperazin-1-yl)-3,7-dihydro-purine-2,6-dione [0217]
  • (R)-7-Benzyl-8-(3-(4-fluoro-benzyl)-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione [0218]
  • (R)-4-(4-(7-Benzyl-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-piperazin-2-ylmethyl)-benzonitrile [0219]
  • (R)-6-(8-(3-Benzyl-piperazin-1-yl)-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-nicotinonitrile [0220]
  • (R)-7-Benzyl-1,3-dimethyl-8-(3-thiazol-4-ylmethyl-piperazin-1-yl)-3,7-dihydro-purine-2,6-dione [0221]
  • (R)-2-[1,3-Dimethyl-2,6-dioxo-8-(3-thiophen-2-ylmethyl-piperazin-1-yl)-1,2,3,6-tetrahydro-purin-7-ylmethyl]-benzonitrile [0222]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(tetrahydro-furan-2-ylmethyl)-3,7-dihydro-purine-2,6-dione [0223]
  • 7-Benzyl-1-(2-cyclohexyl-ethyl)-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione [0224]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(5-methyl-hexyl)-3,7-dihydro-purine-2,6-dione [0225]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(3-methyl-butyl)-3,7-dihydro-purine-2,6-dione [0226]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-1-(2-ethoxy-ethyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0227]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(tetrahydro-furan-2-ylmethyl)-3,7-dihydro-purine-2,6-dione [0228]
  • 7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-(tetrahydro-furan-2-ylmethyl)-3,7-dihydro-purine-2,6-dione [0229]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(tetrahydro-pyran-2-ylmethyl)-3,7-dihydro-purine-2,6-dione [0230]
  • 7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-(tetrahydro-pyran-2-ylmethyl)-3,7-dihydro-purine-2,6-dione [0231]
  • 7-(2-Iodo-benzyl)-3-methyl-1-(2-phenoxy-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0232]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1-(2-methoxy-ethyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0233]
  • 7-(2-Iodo-benzyl)-1-(2-methoxy-ethyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0234]
  • 1-(2-Benzyloxy-ethyl)-8-[1,4]diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0235]
  • 1-(2-Benzyloxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0236]
  • 1-(3,5-Dimethoxy-benzyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0237]
  • 7-(2-Iodo-benzyl)-1-(3-methoxy-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0238]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(3-trifluoromethoxy-benzyl)-3,7-dihydro-purine-2,6-dione [0239]
  • 7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-(3-trifluoromethoxy-benzyl)-3,7-dihydro-purine-2,6-dione [0240]
  • 8-[1,4]Diazepan-1-yl-1-(2-hydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0241]
  • 8-[1,4]Diazepan-1-yl-1-(2,2-diethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0242]
  • 8-[1,4]Diazepan-1-yl-1-(2,2-dimethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0243]
  • 8-[1,4]Diazepan-1-yl-1-(2-[1,3]dioxolan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0244]
  • 1-(2-[1,3]Dioxolan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0245]
  • 1-[1,3]Dioxolan-2-ylmethyl-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0246]
  • 8-[1,4]Diazepan-1-yl-1-(2-[1,3]dioxan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0247]
  • 1-(2-[1,3]Dioxan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0248]
  • 8-[1,4]Diazepan-1-yl-1-(2,3-dihydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0249]
  • 1-(2,3-Dihydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0250]
  • 8-[1,4]Diazepan-1-yl-1-(3-hydroxy-2-methyl-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0251]
  • 1-(3-Hydroxy-2-methyl-propyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione [0252]
  • 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-[3-(tetrahydro-pyran-2-yloxy)-propyl]-3,7-dihydro-purine-2,6-dione [0253]
  • 8-[1,4]Diazepan-1-yl-1-(2-fluoro-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0254]
  • 7-Benzyl-8-[1,4]diazepan-1-yl-1-(3-hydroxy-propyl)-3-methyl-3,7-dihydro-purine-2,6-dione [0255]
  • 7-Biphenyl-2-ylmethyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione [0256]
  • In another aspect, the invention provides compounds in one of the three groups A, B and C. [0257]
  • Group A [0258]
  • In the compounds of group A, the invention provides compounds of formula I [0259]
    Figure US20020161001A1-20021031-C00003
  • wherein [0260]
  • n and m is one or two independently; [0261]
  • R[0262] 1 is C═O; C═S; C1-C2 alkyl; C2 alkenyl; C2 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl; heteroaryl-C1-C3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, or heteroaryl-C1-C3 alkyl is optionally substituted with one or more R4 independently;
  • R[0263] 2 is H; C1-C7 alkyl; C2-C7 alkenyl; C2-C7 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR5; —SOR5; —SO2R5; carboxy; —CO2R4; —CON(R5)2; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, heteroaryl-C1-C3 alkyl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R11 independently;
  • R[0264] 3 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; C1-C10alkyl-O-C1-C5alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl-C1-C3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system;
  • R[0265] 4, R11, R12, and R17 are independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R13)2; ═O; ═S; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R8 independently; two R4 attached to the same carbon atom may form a spiroheterocyclic system, preferably hydantoine; thiohydantoine; oxazolidine-2,5-dione;
  • R[0266] 5 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C5 alkyl; heteroaryl; heteroaryl-C1-C5 alkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R14 independently;
  • R[0267] 6 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R15 independently;
  • R[0268] 7 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R16 independently;
  • R[0269] 8, R14, R15, and R16 are independently H; nitro; —OCH3; cyano; halogen; —OH; —SH; —SCH3;
  • R[0270] 9 is H; halogen; C1-C10 alkyl or aryl, wherein alkyl or aryl is optionally substituted with one or more R17 independently
  • R[0271] 10 is H; halogen;
  • or, R[0272] 9 and R10 may be connected to form a cyclopropyl ring;
  • R[0273] 13 is H; C1-C10 alkyl or aryl;
  • or a salt thereof with a pharmaceutically acceptable acid or base; [0274]
  • with the exception of the following compounds: [0275]
  • 1,3-dimethyl-7-(2-oxo-propyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0276]
  • 1,3,1′,3′,7′-pentamethyl-8-piperazin-1-yl-3,7,3′,7′-tetrahydro-7,8′-methanediyl-bis-purine-2,6-dione, [0277]
  • 3,4,5-trimethoxy-benzoic acid 2-(1,3-dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydro-purin-7-yl)-ethyl ester, [0278]
  • 7-[2-Hydroxy-3-(4-methoxy-phenoxy)-propyl]-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0279]
  • 7-[2-hydroxy-2-(4-nitro-phenyl)-ethyl]-3-methyl-8-piperazin-1-yl-3,7,8,9-tetrahydro-purine-2,6-dione, [0280]
  • 7-Benzyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0281]
  • 7-(4-Chloro-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0282]
  • 7-(2-Chloro-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0283]
  • 7-Ethyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0284]
  • 3-Methyl-8-piperazin-1-yl-1,7-dipropyl-3,7-dihydro-purine-2,6-dione, [0285]
  • 3-Methyl-7-(3-methyl-butyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0286]
  • 7-Butyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0287]
  • 3-Methyl-7-(3-phenyl-propyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0288]
  • 7-But-2-enyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0289]
  • 7-(3-Chloro-but-2-enyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0290]
  • 7-Heptyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0291]
  • 3-Methyl-7-(2-phenyl-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0292]
  • 3-Methyl-7-(3-methyl-benzyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, [0293]
  • 3-Methyl-7-propyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, and [0294]
  • 3-Methyl-7-pentyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. [0295]
  • Group B [0296]
  • In the compounds of group B, the invention provides compounds of formula I [0297]
    Figure US20020161001A1-20021031-C00004
  • wherein [0298]
  • n and m is one or two independently; [0299]
  • with the proviso that if n is 2 then m is also 2; [0300]
  • R[0301] 1 is C═O; C═S; C1-C2 alkyl; C2 alkenyl; C2 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl; heteroaryl-C1-C3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, or heteroaryl-C1-C3 alkyl is optionally substituted with one or more R4 independently;
  • R[0302] 2 is H; C1-C7 alkyl; C2-C7 alkenyl; C2-C7 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR5; —SOR5; —SO2R5; carboxy; —CO2R4; —CON(R5)2; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, heteroaryl-C1-C3 alkyl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R11 independently;
  • R[0303] 3 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; C1-C10alkyl-O-C1-C5alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl-C1-C3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system;
  • R[0304] 4, R11, R12, and R17 are independently C1-C10 alkyl; C2-C10alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R13)2; ═O; ═S; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R8 independently; two R4 attached to the same carbon atom may form a spiroheterocyclic system, preferably hydantoine; thiohydantoine; oxazolidine-2,5-dione;
  • R[0305] 5 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C5 alkyl; heteroaryl; heteroaryl-C1-C5 alkyl , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R14 independently;
  • R[0306] 6 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R15 independently;
  • R[0307] 7 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R16 independently;
  • R[0308] 8, R14, R15, and R16 are independently H; nitro; —OCH3; cyano; halogen; —OH; —SH; —SCH3;
  • R[0309] 9 is H; halogen; C1-C10 alkyl optionally substituted with one or more R17 independently
  • R[0310] 10 is H; halogen;
  • or, R[0311] 9 and R10 may be connected to form a cyclopropyl ring;
  • R[0312] 13 is H; C1-C10 alkyl or aryl;
  • or a salt thereof with a pharmaceutically acceptable acid or base. [0313]
  • Group C [0314]
  • In the compounds of group C, the invention provides compounds of formula I [0315]
    Figure US20020161001A1-20021031-C00005
  • wherein [0316]
  • n and m is one or two independently; [0317]
  • R[0318] 1 is C═O; C═S; C1-C2 alkyl; C2 alkenyl; C2 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl; heteroaryl-C1-C3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, or heteroaryl-C1-C3 alkyl is optionally substituted with one or more R4 independently;
  • R[0319] 2 is H; C1-C7 alkyl; C2-C7 alkenyl; C2-C7 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR5; —SOR5; —SO2R5; carboxy; —CO2R4; —CON(R5)2; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, heteroaryl-C1-C3 alkyl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R11 independently;
  • R[0320] 3 is C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; C1-C10alkyl-O-C1-C5alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl-C1-C3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system;
  • R[0321] 4, R11, R12, and R17 are independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R13)2; ═O; ═S; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R8 independently; two R4 attached to the same carbon atom may form a spiroheterocyclic system, preferably hydantoine; thiohydantoine; oxazolidine-2,5-dione;
  • R[0322] 5 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C5 alkyl; heteroaryl; heteroaryl-C1-C5 alkyl , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R14 independently;
  • R[0323] 6 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R15 independently;
  • R[0324] 7 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R16 independently;
  • R[0325] 8, R14, R15, and R16 are independently H; nitro; —OCH3; cyano; halogen; —OH; —SH; —SCH3;
  • R[0326] 9 is H; halogen; C1-C10 alkyl optionally substituted with one or more R17 independently
  • R[0327] 10 is H; halogen;
  • or, R[0328] 9 and R10 may be connected to form a cyclopropyl ring;
  • R[0329] 13 is H; C1-C10 alkyl or aryl;
  • or a salt thereof with a pharmaceutically acceptable acid or base. [0330]
  • In a further embodiment of the compounds of group A, B and C, R[0331] 1 is C═O; C1-C2 alkyl; C2 alkenyl; C2 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; or heteroaryl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R4 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0332] 1 is C═O; C1-C2 alkyl; C3-C7 cycloalkyl; aryl; or heteroaryl, wherein each alkyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R4 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0333] 1 is C═O or aryl optionally substituted with one or more R4 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0334] 1 is aryl optionally substituted with one or more R4 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0335] 1 is aryl.
  • In a further embodiment of the compounds of group A, B and C, R[0336] 1 is phenyl.
  • In a further embodiment of the compounds of group A, B and C, R[0337] 2 is H; C1-C7 alkyl; C2-C7 alkenyl; C2-C7 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR5; —SOR5; —SO2R5; —CO2R4; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy, alkenyloxy, or alkynyloxy is optionally substituted with one or more R11 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0338] 2 is H; C1-C7 alkyl; C3-C7 cycloheteroalkyl; aryl; cyano; halogen; nitro; —SR5; —SO2R5; —CO2R4; or C1-C10 alkyloxy; wherein each alkyl, cycloheteroalkyl, aryl, or alkyloxy is optionally substituted with one or more R11 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0339] 2 is H; C1-C7 alkyl; C3-C7 cycloheteroalkyl; aryl; cyano; halogen; —CO2R4; or C1-C10 alkyloxy; wherein each alkyl, cycloheteroalkyl, aryl, or alkyloxy is optionally substituted with one or more R11 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0340] 2 is H; C1-C7 alkyl; cyano; halogen; or C1-C10 alkyloxy; wherein each alkyl or alkyloxy is optionally substituted with one or more R11 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0341] 2 is H; cyano or halogen.
  • In a further embodiment of the compounds of group A, B and C R[0342] 2 is H.
  • In a further embodiment of the compounds of group A and B, R[0343] 3 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; aryl; C1-C10alkyl-O-C1-C5alkyl; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
  • In a further embodiment of the compounds of group A and B, R[0344] 3 is H; C1-C10 alkyl; C1-C10alkyl-O-C1-C5alkyl; hydroxy; wherein alkyl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
  • In a further embodiment of the compounds of group A and B, R[0345] 3 is H or C1-C10 alkyl optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
  • In a further embodiment of the compounds of group A and B, R[0346] 3 is H or C1-C10 alkyl.
  • In a further embodiment of the compounds of group A and B, R[0347] 3 is methyl, ethyl, or isopropyl.
  • In a further embodiment of the compounds of group A and B, R[0348] 3 is H.
  • In a further embodiment of the compounds of group C, R[0349] 3 is C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; aryl; C1-C10alkyl-O-C1-C5alkyl; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
  • In a further embodiment of the compounds of group C, R[0350] 3 is C1-C10 alkyl; C1-C10alkyl-O-C1-C5alkyl; hydroxy; wherein alkyl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
  • In a further embodiment of the compounds of group C, R[0351] 3 is C1-C10 alkyl optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
  • In a further embodiment of the compounds of group C, R[0352] 3 is C1-C10 alkyl.
  • In a further embodiment of the compounds of group C, R[0353] 3 is methyl, ethyl, or isopropyl
  • In a further embodiment of the compounds of group A, B and C, R[0354] 4 is C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R8 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0355] 4 is C1-C10 alkyl; C2-C10 alkenyl; or C2-C10 alkynyl; wherein each alkyl, alkenyl, or alkynyl is optionally substituted with one or more R8 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0356] 4 is C1-C10 alkyl optionally substituted with one or more R8 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0357] 4 is C1-C10 alkyl.
  • In a further embodiment of the compounds of group A, B and C, R[0358] 4 is methyl.
  • In a further embodiment of the compounds of group A, B and C, R[0359] 5 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; aryl; heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R14 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0360] 5 is C1-C10 alkyl or aryl; wherein each alkyl or aryl is optionally substituted with one or more R14 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0361] 6 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; or aryl; wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, or aryl is optionally substituted with one or more R15 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0362] 6 is H; C1-C10 alkyl; or C2-C10 alkenyl; wherein each each alkyl or alkenyl is optionally substituted with one or more R15 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0363] 6 is H or C1-C10 alkyl optionally substituted with one or more R15 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0364] 6 is H.
  • In a further embodiment of the compounds of group A, B and C, R[0365] 6 is C1-C10 alkyl optionally substituted with one or more R15 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0366] 6 is C1-C10 alkyl.
  • In a further embodiment of the compounds of group A, B and C, R[0367] 6 is methyl.
  • In a further embodiment of the compounds of group A, B and C, R[0368] 7 is H; C1-C10 alkyl; C2-C10 alkenyl; or C2-C10 alkynyl, wherein each each alkyl, alkenyl, or alkynyl is optionally substituted with one or more R16 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0369] 7 is C1-C10 alkyl optionally substituted with one or more R16 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0370] 7 is C1-C10 alkyl.
  • In a further embodiment of the compounds of group A, B and C, R[0371] 8 is —OCH3.
  • In a further embodiment of the compounds of group A, B and C, R[0372] 9 is aryl.
  • In a further embodiment of the compounds of group A, B and C, R[0373] 11 is C1-C10 alkyl; aryl; cyano; halogen; wherein each alkyl or aryl is optionally substituted with one or more R8 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0374] 11 is halogen.
  • In a further embodiment of the compounds of group A, B and C, R[0375] 12 is C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; wherein each alkyl, alkenyl, alkynyl, aryl, heteroaryl is optionally substituted with one or more R8 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0376] 12 is aryl; heteroaryl; or hydroxy; wherein each aryl and heteroaryl is optionally substituted with one or more R8 independently.
  • In a further embodiment of the compounds of group A, B and C, R[0377] 12 is phenyl, pyridyl, or pyrrolidinyl.
  • In a further embodiment of the compounds of group A, B and C, R[0378] 12 is hydroxy.
  • In a further embodiment of the compounds of group A, B and C, R[0379] 14 is halogen.
  • A further aspect of the invention is a pharmaceutical composition comprising, as an active ingredient, at least one compound of the invention or a pharmaceutically acceptable salt or prodrug or hydrate thereof together with a pharmaceutically acceptable carrier or diluent. [0380]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV. [0381]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of metabolic disorders. [0382]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for blood glucose lowering. [0383]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of Type 2 diabetes. [0384]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of impaired glucose tolerance (IGT). [0385]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of impaired fasting glucose (IFG). [0386]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for prevention of hyperglycemia. [0387]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for delaying the progression of impaired glucose tolerance (IGT) to Type 2 diabetes. [0388]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for delaying the progression of non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes [0389]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for increasing the number and/or the size of beta cells in a mammalian subject. [0390]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of beta cell degeneration, in particular apoptosis of beta cells. [0391]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of disorders of food intake. [0392]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of obesity. [0393]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for appetite regulation or induction of satiety. [0394]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for the treatment of dyslipidemia. [0395]
  • A further aspect of the invention is the use of a compound of the invention for the manufacture of a medicament for treatment of functional dyspepsia, in particular irritable bowel syndrome. [0396]
  • A further aspect of the invention is a method for the treatment of diseases or disorders associated with proteins that are subject to inactivation by DPP-IV, the method comprising administering to a subject in need thereof an effective amount of a compound of the invention. [0397]
  • A further aspect of the invention is methods of treating the above mentioned diseases, the method comprising administering to a subject in need thereof an effective amount of a compound of the invention. [0398]
  • The compounds of the present invention may be prepared in the form of pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids. Examples of such salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like. Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan. [0399]
  • Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compounds are able to form. [0400]
  • The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent. [0401]
  • The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan. [0402]
  • It is to be understood that the invention extends to all of the stereo isomeric forms of the claimed compounds, as well as the racemates. [0403]
  • In the compounds of formula II, the bonds in the B-ring may be unsaturated, such that the B-ring is a five-membered or a six-membered carbocyclic or heterocyclic ring, which is fully unsaturated. [0404]
  • In a preferred embodiment of the compounds of formula II, D[0405] 3, D4 and at least one D5 are present, and D1, D2, D3, D4, and each D5 may independently be a carbon, nitrogen, oxygen, or a sulfur atom, or C═O, or C═S, and the bonds in the B-ring are unsaturated, such that the B-ring is a five-membered or a six-membered carbocyclic or heterocyclic ring, which is fully unsaturated.
  • When a D-ring is present in the compounds of formula II, the bonds in the D-ring are preferably unsaturated, such that the D-ring may be a five-membered or a six-membered carbocyclic or heterocyclic ring, which is fully unsaturated. [0406]
  • In the compounds of formula II, each n[0407] 1, n2, may be one or two, independently n3 is one, and n4 is two,
  • D[0408] 1 and D2 may be carbon atoms, D4 and one of the D5 may be nitrogen atoms, and D3 and the other D5 may be C═O, or C═S,
  • the bonds in the B-ring may be unsaturated, such that the B-ring is a five-membered carbocyclic or heterocyclic ring, which is fully unsaturated. [0409]
  • In particular, in the compounds of formula II, n[0410] 1 is two and each of n2, n3, n4 is one or two, independently.
  • In a specific embodiment of the compound of formula II, [0411]
  • the B-ring is a benzene ring [0412]
  • each n[0413] 1, n2, is one or two, independently,
  • D[0414] 3, D4, and D5 are absent, such that D1 and D2 may each be optionally substituted with one R2, independently.
  • Pharmaceutical Compositions [0415]
  • In another aspect, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one compound of the invention which inhibits the enzymatic activity of DPP-IV or a pharmaceutically acceptable salt or prodrug or hydrate thereof together with a pharmaceutically acceptable carrier or diluent. Pharmaceutical compositions containing a compound of the invention of the present invention may be prepared by conventional techniques, e.g. as described in [0416] Remington: The Science and Practise of Pharmacy, 19th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
  • Typical compositions include a compound of the invention which inhibits the enzymatic activity of DPP-IV or a pharmaceutically acceptable basic addition salt or prodrug or hydrate thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatine, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art. [0417]
  • The pharmaceutical compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds. [0418]
  • The route of administration may be any route, which effectively transports the active compound of the invention which inhibits the enzymatic activity of DPP-IV to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred. [0419]
  • If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution. [0420]
  • For nasal administration, the preparation may contain a compound of the invention which inhibits the enzymatic activity of DPP-IV, dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes. [0421]
  • For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil. [0422]
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed. [0423]
  • A typical tablet which may be prepared by conventional tabletting techniques may contain: [0424]
  • Core [0425]
    Core:
    Active compound (as free compound or salt thereof) 250 mg 
    Colloidal silicon dioxide (Aerosil) ® 1.5 mg
    Cellulose, microcryst. (Avicel) ®  70 mg
    Modified cellulose gum (Ac-Di-Sol) ® 7.5 mg
    Magnesium stearate Ad.
    Coating:
    HPMC approx.   9 mg
    *Mywacett 9-40 T approx. 0.9 mg
  • The compounds of formula I and formula II may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of the various diseases as mentioned above, e.g. metabolic disorders, Type 2 diabetes, hyperglycemia, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), beta cell degeneration, apoptosis of beta cells, disorders of food intake, obesity, dyslipidemia, and functional dyspepsia, in particular irritable bowel syndrome. In particular, the compounds of formula I or formula II are contemplated to be useful for the prevention or treatment of Type 2 diabetes. Furthermore, the compounds of formula I or formula II may be useful for blood glucose lowering, prevention of hyperglycemia, delaying the progression of impaired glucose tolerance to Type 2 diabetes, delaying the progression of non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes, increasing the number and/or size of beta cells in a mammalian subject, or appetite regulation or induction of satiety. The mammal to be treated with a compound of formula I or formula II is preferably a human, but may also be an animal, both a domesticated animal, e.g. household pet, and non-domesticated animal such as wildlife. [0426]
  • The compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, per day may be used. A most preferable dosage is about 0.5 mg to about 250 mg per day. In choosing a regimen for patients it may frequently be necessary to begin with a higher dosage and when the condition is under control to reduce the dosage. The exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge. [0427]
  • Generally, the compounds of the present invention are dispensed in unit dosage form comprising from about 0.05 to about 1000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage. [0428]
  • Usually, dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 0.05 mg to about 1000 mg, preferably from about 0.5 mg to about 250 mg of the compounds admixed with a pharmaceutically acceptable carrier or diluent. [0429]
  • The invention also encompasses prodrugs of a compound of the invention which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of a compound of the invention which are readily convertible in vivo into a compound af the invention. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985. [0430]
  • The invention also encompasses active metabolites of a compound of the invention. [0431]
  • The preparation of the compounds of formula I can be done in many ways. The starting materials are either known compounds or compounds which may be prepared in analogy with the preparation of similar known compounds. A particularly useful synthesis is outlined below. [0432]
  • Combination Treatments [0433]
  • The invention furthermore relates to the use of a compound according to the present invention for the preparation of a medicament for use in the treatment of diabetes in a regimen which additionally comprises treatment with another antidiabetic agent. [0434]
  • In the present context the expression “antidiabetic agent” includes compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism. [0435]
  • In one embodiment of this invention, the antidiabetic agent is insulin or GLP-1 or any analogue or derivative thereof. [0436]
  • In another embodiment the antidiabetic agent is a hypoglycaemic agent, preferably an oral hypoglycaemic agent. [0437]
  • Oral hypoglycaemic agents are preferably selected from the group consisting of sulfonylureas, non-sulphonylurea insulin secretagogues, biguanides, thiazolidinediones, alpha glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potasium channel openers, insulin sensitizers, hepatic enzyme inhibitors, glucose uptake modulators, compounds modifying the lipid metabolism, compounds lowering food intake, and agents acting on the ATP-dependent potassium channel of the 1-cells. [0438]
  • Among the sulfonylureas, tolbutamide, glibenclamide, glipizide and gliclazide are preferred. [0439]
  • Among the non-sulphonylurea insulin secretagogues, repaglinide and nateglinide are preferred. [0440]
  • Among the biguanides, metformin is preferred. [0441]
  • Among the thiazolidinediones, troglitazone, rosiglitazone and ciglitazone are preferred. [0442]
  • Among the glucosidase inhibitors, acarbose is preferred. [0443]
  • Among the agents acting on the ATP-dependent potassium channel of the β-cells the following are preferred: glibenclamide, glipizide, gliclazide, repaglinide. [0444]
  • Examples from the literature of known compounds which are included in formula II are listed in Table 1 along with their Beilstein and CAS registry numbers. The synthesis methods disclosed in these references for producing compounds of general formula II are incorporated herein by reference. [0445]
    TABLE 1
    Beilstein registry CAS registry
    Structure number number
    Figure US20020161001A1-20021031-C00006
         		521102 100861-48-1 
    Figure US20020161001A1-20021031-C00007
         		1543395 77597-74-1
    Figure US20020161001A1-20021031-C00008
         		1685814 77597-48-9
    Figure US20020161001A1-20021031-C00009
         		1687023 77597-75-2
    Figure US20020161001A1-20021031-C00010
         		4189427 63854-31-9
    Figure US20020161001A1-20021031-C00011
         		4865281 119695-81-7 
    Figure US20020161001A1-20021031-C00012
         		4865461 119695-82-8 
    Figure US20020161001A1-20021031-C00013
         		5667444 87394-50-1
    Figure US20020161001A1-20021031-C00014
         		5745673 87394-64-7
    Figure US20020161001A1-20021031-C00015
         		5749933 87394-63-6
    Figure US20020161001A1-20021031-C00016
         		6510974 104813-92-5 
    Figure US20020161001A1-20021031-C00017
         		6811251
    Figure US20020161001A1-20021031-C00018
         		6924778
    Figure US20020161001A1-20021031-C00019
         		7815919
    Figure US20020161001A1-20021031-C00020
         		7835655
    Figure US20020161001A1-20021031-C00021
         		7884424
    Figure US20020161001A1-20021031-C00022
         		1174841 24961-80-6
    Figure US20020161001A1-20021031-C00023
         		1235399 20367-10-6
    Figure US20020161001A1-20021031-C00024
         		4698427 110963-63-8 
    Figure US20020161001A1-20021031-C00025
         		5784284
    Figure US20020161001A1-20021031-C00026
         		6066512 87233-69-0
    Figure US20020161001A1-20021031-C00027
         		7644451
    Figure US20020161001A1-20021031-C00028
         		7651816
    Figure US20020161001A1-20021031-C00029
         		7653876
    Figure US20020161001A1-20021031-C00030
         		7655222
    Figure US20020161001A1-20021031-C00031
         		7655225
    Figure US20020161001A1-20021031-C00032
         		7656178
    Figure US20020161001A1-20021031-C00033
         		7657431
    Figure US20020161001A1-20021031-C00034
         		7658569
    Figure US20020161001A1-20021031-C00035
         		7659390
    Figure US20020161001A1-20021031-C00036
         		7675354
  • Examples from the literature of the B-D ring systems of compounds of formula II shown here with only methyl or amino substituents for simplicity, includes the compounds shown in Table 2. The synthesis methods disclosed in the corresponding references for obtaining these and structurally similar compounds are incorporated herein by reference. These compounds will enable the skilled person to produce derived compounds within the scope of formula II by utilizing common general knowledge and/or the synthesis methods disclosed above. [0446]
    TABLE 2
    Structure Beilstein Number CAS number
    Figure US20020161001A1-20021031-C00037
         		1238 74195-76-9
    Figure US20020161001A1-20021031-C00038
         		4194 69557-55-7
    Figure US20020161001A1-20021031-C00039
         		5023
    Figure US20020161001A1-20021031-C00040
         		5155 101257-89-0 
    Figure US20020161001A1-20021031-C00041
         		116537 55199-24-1
    Figure US20020161001A1-20021031-C00042
         		116538 35355-36-3
    Figure US20020161001A1-20021031-C00043
         		122537
    Figure US20020161001A1-20021031-C00044
         		122538
    Figure US20020161001A1-20021031-C00045
         		122542
    Figure US20020161001A1-20021031-C00046
         		127514 109510-86-3 
    Figure US20020161001A1-20021031-C00047
         		506507 24659-45-8
    Figure US20020161001A1-20021031-C00048
         		509993 70786-21-9
    Figure US20020161001A1-20021031-C00049
         		510908
    Figure US20020161001A1-20021031-C00050
         		511008 35899-34-4
    Figure US20020161001A1-20021031-C00051
         		513137  6726-50-7
    Figure US20020161001A1-20021031-C00052
         		880387 19949-03-2
    Figure US20020161001A1-20021031-C00053
         		908493
    Figure US20020161001A1-20021031-C00054
         		909190 59558-44-0
    Figure US20020161001A1-20021031-C00055
         		972126 71309-37-0
    Figure US20020161001A1-20021031-C00056
         		972323 56857-06-8
    Figure US20020161001A1-20021031-C00057
         		972466 23576-87-6
    Figure US20020161001A1-20021031-C00058
         		973539 57772-01-7
    Figure US20020161001A1-20021031-C00059
         		975944
    Figure US20020161001A1-20021031-C00060
         		1072661  1194-70-3
    Figure US20020161001A1-20021031-C00061
         		1072837  1123-57-5
    Figure US20020161001A1-20021031-C00062
         		1101453 45859-46-9
    Figure US20020161001A1-20021031-C00063
         		1105223 61262-26-8
    Figure US20020161001A1-20021031-C00064
         		1105319 61262-27-9
    Figure US20020161001A1-20021031-C00065
         		1210589 56857-07-9
    Figure US20020161001A1-20021031-C00066
         		1281990 37610-98-3
    Figure US20020161001A1-20021031-C00067
         		1635988 38828-73-8
    Figure US20020161001A1-20021031-C00068
         		1636056 27866-47-3
    Figure US20020161001A1-20021031-C00069
         		1919015  33430-55-6;  33430-56-7;  33430-87-4;  33507-44-7;  56579-34-1;  56579-40-9; 56579-41-0
    Figure US20020161001A1-20021031-C00070
         		2038630 35408-32-3
    Figure US20020161001A1-20021031-C00071
         		2235602 53356-67-5
    Figure US20020161001A1-20021031-C00072
         		2239113 23288-07-5
    Figure US20020161001A1-20021031-C00073
         		2498411
    Figure US20020161001A1-20021031-C00074
         		2498412
    Figure US20020161001A1-20021031-C00075
         		2553303  1685-83-2
    Figure US20020161001A1-20021031-C00076
         		3541426 123810-45-7 
    Figure US20020161001A1-20021031-C00077
         		4384604 83458-55-3
    Figure US20020161001A1-20021031-C00078
         		4668109 73627-19-7
    Figure US20020161001A1-20021031-C00079
         		4966975 81795-09-7
    Figure US20020161001A1-20021031-C00080
         		4967113 81795-08-6
    Figure US20020161001A1-20021031-C00081
         		4967423 97457-29-9
    Figure US20020161001A1-20021031-C00082
         		5239811 129441-87-0; 126575-73-3 
    Figure US20020161001A1-20021031-C00083
         		5239812 126441-87-0; 126575-73-3 
    Figure US20020161001A1-20021031-C00084
         		5248212 81795-10-0
    Figure US20020161001A1-20021031-C00085
         		5253837
    Figure US20020161001A1-20021031-C00086
         		5499944 107970-21-8 
    Figure US20020161001A1-20021031-C00087
         		6134939
    Figure US20020161001A1-20021031-C00088
         		6193509
    Figure US20020161001A1-20021031-C00089
         		6474743
    Figure US20020161001A1-20021031-C00090
         		6474744
    Figure US20020161001A1-20021031-C00091
         		7421534
    Figure US20020161001A1-20021031-C00092
         		7914160
  • Methods for Measuring the Activity of Compounds Which Inhibit the Enzymatic Activity of CD26/DPP-IV [0447]
  • Summary [0448]
  • Chemical compounds are tested for their ability to inhibit the enzyme activity of purified CD26/DPP-IV. Briefly, the activity of CD26/DPP-IV is measured in vitro by its ability to cleave the synthetic substrate Gly-Pro-p-nitroanilide (Gly-Pro-pNA). Cleavage of Gly-Pro-pNA by DPP-IV liberates the product p-nitroanilide (pNA), whose rate of appearance is directly proportional to the enzyme activity. Inhibition of the enzyme activity by specific enzyme inhibitors slows down the generation of pNA. Stronger interaction between an inhibitor and the enzyme results in a slower rate of generation of pNA. Thus, the degree of inhibition of the rate of accumulation of pNA is a direct measure of the strength of enzyme inhibition. The accumulation of pNA is measured spectrophotometrically. The inhibition constant, Ki, for each compound is determined by incubating fixed amounts of enzyme with several different concentrations of inhibitor and substrate. [0449]
  • Materials [0450]
  • The following reagents and cells are commercially available: [0451]
  • Porcine CD26/DPP-IV (Sigma D-7052), Gly-Pro-pNA (Sigma G0513). [0452]
  • Assay buffer: 50 mM Tris pH7.4, 150 mM NaCl, 0.1% Triton X-100. [0453]
  • Gly-Pro-pNA cleavage-assay for CD26 [0454]
  • The activity of purified CD26/DPP-IV is assayed in reactions containing: [0455]
  • 70 μl assay buffer [0456]
  • 10 μl inhibitor or buffer [0457]
  • 10 μl substrate (Gly-Pro-pNA from a 0.1 M stock solution in water) or buffer [0458]
  • 10 μl enzyme or buffer [0459]
  • Reactions containing identical amounts of enzyme, but varying concentrations of inhibitor and substrate, or buffer as control, are set up in parallel in individual wells of a 96-well ELISA plate. The plate is incubated at 25° C. and absorbance is read at 405 nm after 60 min incubation. The inhibitor constants are calculated by nonlinear regression hyperbolic fit and the result is expressed as inhibition constant (Ki) in nM. [0460]
  • Diabetes Model [0461]
  • The Zucker Diabetic Fatty (ZDF) rat model can be used to investigate the effects of the compounds of the invention on both the treatment and prevention of diabetes as rats of this sub-strain are initially pre-diabetic although develop severe type 2 diabetes characterised by increased HbA1c levels over a period of 6 weeks. The same strain can be used to predict the clinical efficacy of other anti-diabetic drug types. For example, the model predicts the potency and limited clinical efficacy of thiazolidinedione insulin sensitiser compounds.[0462]
    • EXAMPLES
  • A further detailed description of the invention is given with reference to the following examples. [0463]
  • Preparative HPLC (Method A1) [0464]
  • Column: Waters Radial compression column Prep NovaPak c18 25×100, plus a Waters Prep NovaPak HR c18 25×10 precolumn, in a Waters PrepLC 25×100 compression module housing. Buffer: linear gradient 5-95% in 15 min, MeCN, 0.1% TFA, flow rate of 15 ml/min. The pooled fractions are either evaporated to dryness in vacuo, or evaporated in vacuo until the MeCN is removed, and then frozen and freeze dried. [0465]
  • Preparative HPLC (Method A2) [0466]
  • Column: 1.9×15 cm Waters XTerra RP-18. Buffer: linear gradient 5-95% in 15 min, MeCN, 0.1% TFA, flow rate of 15 ml/min. The pooled fractions are either evaporated to dryness in vacuo, or evaporated in vacuo until the MeCN is removed, and then frozen and freeze dried. [0467]
  • Preparative HPLC (Method A3) [0468]
  • Column: Supelcosil ABZ+Plus, 25 cm×10 mm, 5 μm. Solvent A: 0.1% TFA/Water, solvent B: MeCN. Eluent composition: 5 min. 100% A, linear gradient 0-100% B in 7 min, 100% B in 2 min. Flow rate 5 ml/min. The column is allowed to equilibrate for 4 min in 100% A before the next run. [0469]
  • HPLC-MS (Method B) [0470]
  • Column: Waters Xterra MS C-18×3 mm id. Buffer: Linear gradient 10% -100% in 7.5 min, MeCN, 0.01% TFA, flow rate 1.0 ml/min. Detection 210 nm (analog output from diode array detector), MS-detection ionisation mode API-ES, scan 100-1000 amu step 0.1 amu. [0471]
  • HPLC-MS (Method C) [0472]
  • The following instrumentation was used: [0473]
  • Sciex API 100 Single quadropole mass spectrometer [0474]
  • Perkin Elmer Series 200 Quard pump [0475]
  • Perkin Elmer Series 200 autosampler [0476]
  • Applied Biosystems 785A UV detector [0477]
  • Sedex 55 evaporative light scattering detector [0478]
  • A Valco column switch with a Valco actuator controlled by timed events from the pump. [0479]
  • The Sciex Sample control software running on a Macintosh PowerPC 7200 computer was used for the instrument control and data acquisition. [0480]
  • The HPLC pump was connected to four eluent reservoirs containing: [0481]
  • A: Acetonitrile [0482]
  • B: Water [0483]
  • C: 0.5% TFA in water [0484]
  • D: 0.02 M ammonium acetate [0485]
  • The requirements for samples are that they contain approximately 500 μg/ml of the compound to be analysed in an acceptable solvent such as methanol, ethanol, acetonitrile, THF, water and mixtures thereof. (High concentrations of strongly eluting solvents will interfere with the chromatography at low acetonitrile concentrations.) [0486]
  • The analysis was performed at room temperature by injecting 20 μL of the sample solution on the column, which was eluted with a gradient of acetonitrile in either 0.05% TFA or 0.002 M ammonium acetate. Depending on the analysis method varying elution conditions were used. [0487]
  • The eluate from the column was passed through a flow splitting T-connector, which passed approximately 20 μL/min (1/50) through approx. 1 m. 75μ fused silica capillary to the API interface of API 100 spectrometer. [0488]
  • The remaining 1.48 ml/min (49/50) was passed through the UV detector and to the ELS detector. [0489]
  • During the LC-analysis the detection data were acquired concurrently from the mass spectrometer, the UV detector and the ELS detector. [0490]
  • The LC conditions, detector settings and mass spectrometer settings used for the different methods are given in the following tables. [0491]
    Column Waters Symmetry C18 3 mm × 150 mm
    Gradient 5%-90% acetonitrile in 0.05% TFA linearly during 15 min at
    1 ml/min
    Detection UV: 214 nm ELS: 40° C.
    MS Experiment: Start: 100 amu Stop: 800 amuStep: 0.2 amu
    Dwell: 0.571 msec
    Method: Scan 284 times = 9.5 mm
  • Analytical HPLC (Method D) [0492]
  • Column 2.4×20 cm RP18. Buffer pH=3.0 (H[0493] 3PO4), Acetonitrile. Flow rate 1.0 ml/min. UV detection. Merck Hitachi system.
    • General Piperazine Synthesis Procedure I
  • The procedure is described in [0494] Synthesis; 3; 1984; 271-274; Synthesis; 12; 1981; 969-971. Synthesis; 10; 1982; 861-864. Synthesis; 4; 1991; 318-319
    Figure US20020161001A1-20021031-C00093
  • Step A: Preparation of Oxazolidine-2,5-dione derivatives [0495]
  • The amino acid (25.6 mol) was slurried in THF (100 ml) phosgene (20% in toluene) (3.05 g; 30.8 mmol) was added. The reaction mixture was stirred at room temperature for 15 hours. The reaction mixture was evaporated in vacuo. The title compound precipitated as white crystals. The product was used without any further purification. [0496]
  • Step B: Preparation of (2-Amino-propionylamino) Acetic Acid Methyl Ester Derivatives [0497]
  • The above oxazolidine-2,5-dione derivative (27.1 mmol) dissolved in THF (50 ml) was added a slurry of glycine methyl ester hydrochloride (3.75 g; 29.9 mmol) and TEA (7.4 g; 73.3 mmol) in DCM (50 ml) at 0° C. The reaction mixture was allowed to warm up to room temperature and was stirred for 15 hours. The mixture was filtered (TEA,HCl) and the reminisce was evaporated in vacuo giving an oil. The product was used without any further purification. [0498]
  • Step C: Preparation of Piperazine-2,5-dione Derivatives [0499]
  • The above (2-Amino-propionylamino) acetic acid methyl ester derivative (28.6 mmol) was slurred in xylene (200 ml) and refluxed (140° C.) for 96 hours. A crude blackish crystalline material was filtered of. The crystals was recrystallised from methanol and charcoal giving the title compound as white crystals. [0500]
  • Step D: Preparation of Piperazine Derivatives [0501]
  • The above piperazine-2,5-dione derivative (1.1 mmol) was dissolved in THF (100 ml). LiAlH[0502] 4 was added in small portions under N2. The reaction mixture was stirred for 15 hours at 70° C. Water was added dropwise until the mixture was white. K2CO3 was added until the mixture had a filterable consistence. The mixture was filtered evaporated in vacuo giving the title compound as an oil.
    • General Piperazine Synthesis Procedure II
  • Step E and F are described in [0503] J.Org.Chem. 50 (24); 1985; 4796-4799 while step D is as described above.
    Figure US20020161001A1-20021031-C00094
  • Step E: Preparation of t-Boc-dipeptide Esters [0504]
  • The t-Boc-amino acid (9.4 mmol) was dissolved in dry DCM (25 ml) and 1-hydroxybenzotriazol (9.6 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochoride (9.9 mmol) were added at 0-5° C. Stirring was continued for ½ hour after which the amino acid methyl ester hydrochloride (10.3 mmol) and TEA (10.7 mmol) were added at 0-5° C. The reaction mixture was stirred at room temperature overnight. The mixture was poured into 0.5 M potassium hydrogensulphate (50 ml) and filtered. The organic phase was isolated and washed with 10% aqueous sodium hydrogencarbonate (2×20 ml) and brine (1×20 ml), dried over magnesium sulphate and evaporated in vauco. The product was used without further purification. [0505]
  • Step F: Preparation of 2,5-diketopiperazines [0506]
  • The t-Boc-dipeptide methyl ester (11.6 mmol) was dissolved in formic acid (60 ml) and stirred at room temperature for 2½ hours. The solvent was removed at 35° C. under high vacuum and the crude dipeptide ester formate was dissolved in a mixture of dry sec-butyl alcohol (24 ml) and dry toluene (12 ml). The solution was refluxed for 2 hours. After approx. one hour the diketopiperazine start to crystallize out of the hot reaction. The reaction mixture was cooled to 0-5° C. and the white crystals of diketopiperazine was isolated by filtration. [0507]
  • Abbreviations [0508]
    DCM Dichloromethane
    DIEA Diisopropylethylamine
    DMF Dimethylformamide
    DMSO Dimethyl sulfoxide
    HOAc Acetic acid
    MeCN Acetonitrile
    TFA Trifluoroacetic acid
    THF Tetrahydrofurane
    TMG Tetramethylguanidine
  • General Procedure (A) [0509]
    Figure US20020161001A1-20021031-C00095
  • Step A [0510]
  • 8-Chloro-1,3-dimethyl-3,7-dihydro-purine-2,6-dione (Avocado, UK) (0.2 g; 0.93 mmol) and the arylmethylhalogenide (0.93 mmol) K[0511] 2CO3 (0.257 g; 18.6 mmol) and DMF (5 ml) is mixed in a scintillations vessel (20 ml). The vessels are carefully sealed and the reaction mixtures are shaken for 121 hours at 100 C.°. After cooling, brine (5 ml) and ethyl acetate (5 ml) is added. The reaction mixtures are shaken for 10 hours. The ethyl acetate phase is decanted to a new scintillations vessel. The water/DMF-phase is then extracted with DCM (5 ml). The DCM and ethyl acetate phase are combined and evaporated in a speedvac. The residue is used without any purification in the next step.
  • Step B [0512]
  • 8-Chloro-7-(arylmethyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione derivative (50 mg, ˜0.15 mmol) is dissolved in methoxyethanol (1 ml) in a 4 ml scintillation vessel. The piperazine derivative (0.235 mmol), and TEA (32 mg; 43 μL; 0.31 mmol) are added. The vessels are sealed carefully and shaken for 7 days at 100 C.°. The reaction mixtures are evaporated in a speedvac. Each vessel is added methanol (1 ml), and 1N HCl (0.5 ml), shaken for 10 hours and evaporated in a speedvac. The samples are purified by prep. HPLC (Method A1). [0513]
  • The purified compounds are analysed by LC-MS. [0514]
  • General Procedure (B) [0515]
    Figure US20020161001A1-20021031-C00096
  • R[0516] 1, R3, R6, R7, X and n are defined as in formula I.
  • Step A [0517]
  • The starting material 3-benzyl-8-bromo-3,7-dihydro-purine-2,6-dione or 3-methyl-8-bromo-3,7-dihydro-purine-2,6-dione (16 umol) is dissolved in a mixture of DMF and DIEA (3% DIEA, 250 μL). Substituted benzyl bromide or other alkylating agents (16.8 umol, 1.05 equiv) are dissolved in DMF (100 μL) and added. The mixture is heated to 65° C. for 2 h. [0518]
  • Step B [0519]
  • Alkylation reagent R[0520] 6-X (32 μmol) is dissolved in DMF (100 μl) and added to the above reaction mixture, followed by a solution of TMG in DMF (1.16 ml TMG diluted to 5.8 ml, 48 ul). The mixture is kept at 65° C. for 4 h.
  • Step C [0521]
  • Diamine (200 umol) is dissolved in a mixture of DMF and DIEA (3% DIEA, 200 μL) and added to the above reaction mixture. The reaction is kept at 65° C. for 1-4 d. Samples are neutralized using HOAc (20 μl). The solvent is evaporated and the residue is dissolved in DMSO/H[0522] 2O (4:1, 500 μl) and purified by HPLC (Method A3).
  • General Procedure (C) [0523]
  • Step A [0524]
  • The first reaction step is identical to Step A in general procedure (A) [0525]
  • Step B [0526]
  • 8-Chloro-7-(arylmethyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione derivative (1 eq.), piperazine (3 eq.) and TEA (5 eq) is heated in an appropriate solvent in a closed vessel in a micro wave oven (CEM MARSX microwave instrument. Magnetron frequency: 2455 MHz. Power Output: 1200 Watt.) at 150° C. for 4 hours. The reaction mixture is cooled and evaporated in vacuo. The remaining oil is purified on a silica gel column with DCM/MeOH (3:1) as eluent, giving the title compound as an oil. The oil may be dissolved in DCM to afford the hydrochloride salt upon addition of hydrochloride in ether. Alternatively, the samples may be purified by prep. HPLC (Method A2). The purified compounds are analysed by LC-MS. [0527]
  • All reactions are performed in closed vessels: XP 1500 Plus Vessel set; at a given temperature in an appropriate solvent. Normally solvents like MeOH; EtOH, iPrOH; H2O; DMF and DMSO are used. [0528]
  • General Procedure (D) [0529]
  • Step A [0530]
  • The first reaction step is identical to Step A in general procedure (A) [0531]
  • Step B [0532]
  • 8-Chloro-7-(arylmethyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione derivative (1.64 mmol), amine (2.39 mmol) and potassium carbonate (2.4 mmol) was heated in DMF (30 ml) at 100° C. for 5 hours. The reaction mixture was cooled to room temperature and filtered. The filtrate was evaporated to dryness in vacuo and the residue was purified on a silica gel column (Eluent: Ethyl acetate/Methanol/Triethylamine (90:10:2)) giving the pure base. The hydrochloride salt may be prepared by dissolving the base in isopropanol and adding hydrogen chloride in diethyl ether to the solution. [0533]
  • General Procedure (E): Preparation of 6-substituted-[1,4]-diazepanes [0534]
    Figure US20020161001A1-20021031-C00097
  • 1,4-Dibenzyl-[1,4]diazepane-5,7-dione is converted to the Na-salt in THF with NaH as base, and reacted with the R[0535] 3—X alkylating reagent e.g. benzyl bromide, at room temperature. The product e.g. 1,4,6-Tribenzyl-[1,4]diazepane-5,7-dione is reduced to the 1,4,6-Tribenzyl-[1,4]diazepane by treatment with LiAlH4 in THF at elevated temperature. The N-benzyl groups are removed by catalytic hydrogenation in EtOH:AcOH (1:1), using Pd/C as catalyst.
    • Example 1 7-Benzyl-8-(6-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. TFA
  • [0536]
    Figure US20020161001A1-20021031-C00098
  • Step A: Preparation of 1,4-dibenzyl-[1,4]diazepane-6-carboxylic Acid. Na-salt (1A) [0537]
  • N,N′-dibenzylethylenediamine (4.9 ml, 20.8 mmol) was dissolved in toluene (200 ml), triethylamine (8.94 ml, 64.5 mmol), and methanol (20 ml) and 3-bromo-2-bromomethylpropionic acid (5.12 g, 20.8 mmol) was added. The reaction mixture was heated to reflux for 24 hours. The solvents were evaporated and the remaining was redissolved in water (150 ml) and ethyl acetate (150 ml). The aqueous layer was acidified with 6N hydrochloric acid until pH=2, and the layers were separated. The aqueous layer was washed with ethyl acetate and then 10% aqueous sodium hydroxide was added until pH=12. The aqueous layer was washed with 4×150 ml of ethyl acetate, and then evaporated to dryness. The remaining was suspended in ethyl acetate (200 ml) and dry methanol (20 ml) and salts was filtered off. The mother liquor was evaporated and purified by chromatography on silica, using 10% methanol in dichloromethane as the eluent. Fractions containing the product were evaporated, to afford 5.09 g of 1A as an yellow foam in 70% yield. [0538]
  • [0539] 1H-NMR (CDCl3): δ 7.31 (10H, m); 3.78 (4H, m); 3.18 (4H, m); 2.81 (3H, m); 2.58 (2H, m).
  • HPLC-MS (Method B): m/z=325 (M+1); R[0540] t=1.55 min.
  • Step B: Preparation of (1,4-dibenzyl-[1,4]diazepan-6-yl)methanol (1B) [0541]
  • The sodium salt of 1,4-dibenzyl-[1,4]diazepane-6-carboxylic acid (1A) (2.36 g, 6.81 mmol) was dissolved in dry tetrahydrofuran (50 ml) under a nitrogen atmosphere and lithium aluminium hydride (0.50 g, 13.6 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours and then quenched with water until effervescence ceases. Ethyl acetate (200 ml) and solid potassium carbonate was added until a white suspension appeared, and the mixture was allowed to stir for half an hour. The suspension was filtered through celite, which was washed with 3×50 ml of ethyl acetate. Water (200 ml) was added and the aqueous layer was extracted with 3×200 ml of ethyl acetate. The combined organic layers were washed with brine and dried over sodium sulfate. The solvent was evaporated to afford 2.06 g of 1B as an yellow oil in 97% yield. [0542]
  • [0543] 1H-NMR (CDCl3): δ 7.28 (10H, m); 3.61 (4H, s); 3.55 (2H, d); 2.99 (2H, dd); 2.73 (2H, dd); 2.57 (4H, m); 1.93 (1H, m).
  • HPLC-MS (Method B): m/z=311 (M+1); R[0544] t=1.24 min.
  • Step C: Preparation of ([1,4]diazepan-6-yl)methanol (1C) [0545]
  • (1,4-Dibenzyl-[1,4]diazepan-6-yl)methanol (1B) (1.02 g, 3.28 mmol) was dissolved in ethanol (50 ml) and acetic acid (8 ml) and palladium, 10 wt. % on activated carbon (0.2 g) was added. The mixture was hydrogenated on a Parr apparatus at 45 psi. for 6 days, and filtered twice. The solvents were evaporated and the crude product was dissolved in water (2 ml) and saturated potassium carbonate was added until pH=13. The aqueous layer was washed with 4×10 ml of ethyl acetate, and water was evaporated. The crude product was purified by preparative HPLC (method A1; R[0546] t=2.27 min.) to afford 5.3 g of 1C including potassium carbonate salt.
  • HPLC-MS (Method B): m/z=131 (M+1); R[0547] t=0.33 min.
  • Step D: Preparation of 7-benzyl-8-(6-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. TFA (1) [0548]
  • ([1,4]Diazepan-6-yl)methanol (1C) including potassium carbonate salts (ca 1 mmol) was suspended in dry DMF (200 ml) and 7-benzyl-8-chloro-1,3-dimethyl-3,7-dihydro-purine-2,6-dione (199.9 mg, 0.656 mmol) and potassium carbonate (453 mg, 3.28 mmol) were added. The reaction mixture was stirred at room temperature for 24 hours, heated to 60° C. for 3 hours, heated to 95° C. for 5 hours and heated to 120° C. for 2 hours. The suspension was allowed to cool to room temperature and white salts were filtered off. The filtrate was evaporated and purified by chromatography on silica, using 5% methanol in dichloromethane as the eluent. Fractions containing the product were evaporated and purified by preparative HPLC (method A2; R[0549] t=2.52 min.) to afford 8 mg of the title compound as an yellow oil in 1% yield.
  • [0550] 1H-NMR (MeOH-d4): δ 7.30 (3H, m); 7.14 (2H, d); 5.53 (2H, s); 3.80-3.05 (16H, m); 2.09 (1H, m). HPLC-MS (Method B): m/z=399 (M+1); Rt=1.75 min.
    • Example 2 7-Benzyl-8-(6-hydroxy-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. TFA
  • [0551]
    Figure US20020161001A1-20021031-C00099
  • Step A: Preparation of 1,4-dibenzyl-[1,4]diazepan-6-ol (2A) [0552]
  • N,N′-dibenzylethylenediamine (4.9 ml, 20.8 mmol) was dissolved in toluene (200 ml), triethylamine (8.94 ml, 64.5 mmol), and 1,3-dibromo-2-propanol (4.53 g, 20.8 mmol) was added. The reaction mixture was heated to reflux for 4 days. The solvents were evaporated and the remaining was redissolved in water (150 ml) and ethyl acetate (150 ml). The aqueous layer was acidified with 6N hydrochloric acid until pH=2, and the layers were separated. The aqueous layer was washed with 3×100 ml of ethyl acetate and the combined organic material was dried with sodium sulphate, filtered and the solvent was evaporated. The crude product was purified by chromatography on silica, using 5% methanol in dichloromethane as the eluent. Fractions containing the product were evaporated, to afford 3.59 g of 2A as an yellow oil in 59% yield. [0553]
  • [0554] 1H-NMR (MeOH-d4): δ 7.30 (10H, m); 3.81 (1H, m); 3.67 (4H, s); 2.90 (2H, dd); 2.74-2.60 (6H, m). HPLC-MS (Method B): m/z=297 (M+1); Rt=1.49 min.
  • Step B: Preparation of [1,4]diazepan-6-ol. HOAc (2B) [0555]
  • 1,4-Dibenzyl-[1,4]diazepan-6-ol (2A) (873 mg, 2.95 mmol) was hydrogenated for 21 days as described in example 1, step C. The reaction mixture was filtered twice, and the solvents were evaporated to afford 420 mg of 2B, as yellow crystals in 60% yield. [0556]
  • [0557] 1H-NMR (MeOH-d4): δ 4.07 (1H, m); 3.61 (1H, m); 3.27-2.98 (8H, m); 1.92 (6H, s). HPLC-MS (Method B): m/z=117 (M+1); Rt=0.36 min.
  • Step C: Preparation of 7-Benzyl-8-(6-hydroxy-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. TFA (2) [0558]
  • [1,4]Diazepan-6-ol acetate (2B) (116 mg, 0.49 mmol) and 7-benzyl-8-chloro-1,3-dimethyl-3,7-dihydropurine-2,6-dione (100 mg, 0.33 mmol) were dissolved in 2-propanol (20 ml) and triethylamine (0.68 ml, 4.9 mmol) and the mixture was subjected to micro waves (150° C., 6 bar, 300 W, 8 hours). The solvents were evaporated and the remaining was redissolved in dichloromethane (20 ml) and water (20 ml). The aqueous layer was acidified with potassium hydrogen sulfate until pH=2. The aqueous layer was separated and aqueous sodium hydroxide was added until pH=12. The aqueous layer was extracted with 3×50 ml of dichloromethane, and the combined organic material were added excess trifluoroacetic acid, and evaporated, to afford 123 mg of the title compound as a brown oil in 75% yield. [0559]
  • [0560] 1H-NMR (MeOH-d4): δ 7.31 (3H, m); 7.14 (2H, m); 5.59 (2H, s); 4.23 (1H, m); 3.27-4.02 (14H, m). HPLC-MS (Method B): m/z=385 (M+1); Rt=1.52 min.
    • Example 3 7-Benzyl-8-(3-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. TFA
  • [0561]
    Figure US20020161001A1-20021031-C00100
  • Step A: Preparation of 1,4-dibenzyl-[1,4]diazepane-2-carboxylic Acid Methyl Ester (3A) [0562]
  • N,N′-Dibenzylpropane-1,3-diamine (Sandstroem, J. et al, Tetrahedron; EN; 34; 1978; 371-378) (2.0 g, 7.86 mmol), methyl 2,3-dibromopropionate (1.28 ml, 7.86 mmol), and potassium carbonate (2.17 g, 15.72 mmol) were dissolved in dry dimethylformamide (125 ml) and methanol (20 ml) and the mixture was heated to reflux for 6 days. The reaction mixture was allowed to cool to room temperature and water (200 ml) and ethyl acetate (200 ml) were added. The aqueous layer was extracted with 2×200 ml of ethyl acetate, and the combined organic layers were dried with sodium sulfate, filtered and the solvent was evaporated. The crude product was purified by chromatography on silica, using a mixture of ethyl acetate and heptane 1:6 as the eluent. Fractions containing the product were evaporated, to afford 180 mg of 3A as an clear oil in 7% yield. [0563]
  • [0564] 1H-NMR (CDCl3): δ 7.29 (10H, m); 3.71 (3H, s); 3.62 (4H, s); 3.33-2.51 (7H, m); 1.74 (2H, m). HPLC-MS (Method B): m/z=339 (M+1); Rt=2.76 min.
  • Step B: Preparation of (1,4-dibenzyl-[1,4]diazepan-2-yl)-methanol (3B) [0565]
  • 1,4-Dibenzyl-[1,4]diazepane-2-carboxylic acid methyl ester (3A) (180 mg, 0.53 mmol) was reduced and purified by the method described in example 1, step B, to afford 169 mg of 3B as an yellow oil in 100% yield. [0566]
  • [0567] 1H-NMR (CDCl3): δ 7.31 (10H, m); 3.87 (2H, dd); 3.62 (2H, s); 3.43 (2H, d); 3.03-2.43 (7H, m); 1.74 (2H, m). HPLC-MS (Method B): m/z=311 (M+1); Rt=1.54 min.
  • Step C: Preparation of ([1,4]diazepan-2-yl)methanol. HOAc (3C) [0568]
  • (1,4-Dibenzyl-[1,4]diazepan-2-yl)methanol was hydrogenated for 20 days as described in example 1, step C. The reaction mixture was filtered twice, and the solvents were evaporated. The crude product was crystallized from dry dichloromethane and diethyl ether to afford 62 mg of 3C, as white crystals in 46% yield. [0569]
  • [0570] 1H-NMR (MeOH-d4): δ 3.65-2.80 (9H, m); 1.93 (9H, s); 1.27 (2H, m). HPLC-MS (Method B): m/z=131 (M+1); Rt=0.29 min.
  • Step D: Preparation of 7-benzyl-8-(3-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. TFA (3) [0571]
  • ([1,4]Diazepan-2-yl)methanol acetate (3C) (62 mg, 0.25 mmol) and 7-benzyl-8-chloro-1,3-dimethyl-3,7-dihydropurine-2,6-dione (50.3 mg, 0.17 mmol) was subjected to micro waves (150° C., 11 bar, 300 W, 12 hours) as described in example 2, step C. The solvents were evaporated and the crude product was purified by preparative HPLC (method A2; R[0572] t=6.90 min.) to afford 8 mg of the title compound as an yellow oil in 12% yield.
  • HPLC-MS (Method B): m/z=399 (M+1); R[0573] t=1.78 min.
    • Example 4 (General Procedure (A)) 7-Benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0574]
    Figure US20020161001A1-20021031-C00101
  • Step A: Preparation of 7-benzyl-8-chloro-1,3-dimethyl-3,7-dihydro-purine-2,6-dione (4A) [0575]
  • 8-Chloro-1,3-dimethyl-3,7-dihydro-purine-2,6-dione (2.0 g, 9.3 mmol) was dissolved in DMF (50 ml) K[0576] 2CO3 (2.57 g, 18.6 mmol) and benzyl bromide (1.75 g, 10.3 mmol) were added and the reaction mixture was stirred for 15 hours at room temperature. The reaction mixture was evaporated in vacuo the residue was dissolved in DCM:H2O (1:1) (100 ml) the water phase was extracted with DCM (50 ml) the combined organic phase was dried with MgSO4 filtered and evaporation gave 4A as a white crystalline compound. Yield: 2.92 g. Mp: 145.7-147.1° C.
  • [0577] 1H-NMR (CDCl3): δ 7.2-7.4 (m, 5H); 5.15 (s, 2H); 3.55 (s, 3H); 3.4 (s, 3H).
  • [0578] 13C-NMR (CDCl3): δ 154.8. 151.6; 147.7; 139.1; 135.3; 129.3; 128.9; 128.4; 108.1; 49.6; 30.2; 28.5.HPLC-MS (Method B): M+1=305; Rt=1.9 min.
  • HPLC (Method D; MeCN: buffer 1:1) R[0579] t=7.19 min; purity>99%.
  • Step B: Preparation of 4-(7-Benzyl-1,3-dimethyl-2,6-dioxo-2,3,4,5-tetrahydro-1H-purine-8-yl)-piperazine-1-carboxylic acid tert-butylate (4B) [0580]
  • 7-Benzyl-8-chloro-1,3-dimethyl-3,7-dihydro-purine-2,6-dione (4A) (1.0 g, 3.3 mmol) was dissolved in ethanol (30 ml) piperazine-1-carboxylic acid tert-butylate (0.73 g, 3.9 mmol) and TEA (0.66 g, 0.1 ml, 6.6 mmol) were added and the reaction mixture was heated for 72 hours at 120 C.° in a sealed vessel. The reaction mixture was evaporated and the remaining oil was purified on a silica gel column using (DCM, MeOH) (39:1) as eluent giving 0.93 g of 4B as a yellow oil. Yield: 62%. [0581]
  • HPLC (Method D; MeCN: buffer 1:1) R[0582] t=13.15 min; purity>96%.
  • R[0583] t=13.15 min. >96% purity (Method D: MeCN: buffer (1:1) pH=3 H3PO4)
  • [0584] 1H-NMR (CDCl3): δ 7.2-7.3 (m, 5H); 5.4 (s, 2H); 3.5 (s, 3H); 3.45 (m, 4H); 3.35 (s, 3H); 3.1 (m, 4H); 1.5 (s, 9H).
  • [0585] 13C-NMR (CDCl3): δ 155.0; 156.4; 151.9; 154.8; 147.8; 136.9; 129.1; 128.8; 128.2; 127.1; 105.3; 80.4; 50.6; 48.9; 43.3 (broad); 30.0; 28.7; 28.1.
  • Step C: Preparation of 4-(7-Benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA (4) [0586]
  • 4-(7-Benzyl-1,3-dimethyl-2,6-dioxo-2,3,4,5-tetrahydro-1H-purine-8-yl)-piperazine-1-carboxylic acid tert-butylate (4B) (188 mg, 0.41 mmol) was dissolved in TFA (10 ml). The reaction mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo. The remaining oil was crystallised from acetone/ether. The title compound was isolated as the white TFA salt 170 mg. Yield: 89%. Mp: 217-19C.° decomposes. [0587]
  • HPLC (Method D; MeCN: buffer 1:1) R[0588] t=2.98 min; purity >99%.
  • [0589] 1H-NMR (CDCl3): δ 7.15-7.4 (m, 5H); 5.4 (s, 2H); 3.45 (s, 3H); 3.4 (broad d, 2H); 3.15 (broad d, 2H); 3.05 (s, 3H). HPLC-MS (Method B): m/z=355 (M+1); Rt=1.699 min; TIC area=100%
    • Example 5 (General Procedure (A)) 1,3-Dimethyl-7-(4-methylbenzyl)-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. HCl
  • [0590]
    Figure US20020161001A1-20021031-C00102
  • HPLC-MS (Method C) m/z=369 (M+1); R[0591] t=1.319 min.
    • Example 6 (General Procedure (A)) 3-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzonitrile. TFA
  • [0592]
    Figure US20020161001A1-20021031-C00103
  • HPLC-MS (Method C) m/z=380 (M+1); R[0593] t=1.22 min.
    • Example 7 (General Procedure (A)) 2-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzonitrile. TFA
  • [0594]
    Figure US20020161001A1-20021031-C00104
  • HPLC-MS (Method C) m/z=380 (M+1); R[0595] t=1.18 min.
    • Example 8 (General Procedure (A))
  • 1,3-Dimethyl-7-(1-phenylethyl)-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA [0596]
    Figure US20020161001A1-20021031-C00105
  • HPLC-MS (Method C) m/z 369 (M+1); R[0597] t=2.47 min
    • Example 9 (General Procedure (A)) 7-(2-Iodobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0598]
    Figure US20020161001A1-20021031-C00106
  • HPLC-MS (Method C) m/z=481 (M+1); R[0599] t=1.43 min.
    • Example 10 (General Procedure (A))
  • 1,3-Dimethyl-8-piperazin-1-yl-7-(2-trifluoromethylbenzyl)-3,7-dihydropurine-2,6-dione. TFA [0600]
    Figure US20020161001A1-20021031-C00107
  • HPLC-MS (Method C) m/z=423 (M+1); R[0601] t=1.44 min.
    • Example 11 (General Procedure (A)) 1,3-Dimethyl-7-naphthalen-1-ylmethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0602]
    Figure US20020161001A1-20021031-C00108
  • HPLC-MS (Method C) m/z=405 (M+1); R[0603] t=1.55 min.
    • Example 12 (General Procedure (A)) 1,3-Dimethyl-7-naphthalen-2-ylmethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0604]
    Figure US20020161001A1-20021031-C00109
  • HPLC-MS (Method C) m/z=405 (M+1); R[0605] t=1.51 min.
    • Example 13 (General Procedure (A)) 7-(3-Bromobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0606]
    Figure US20020161001A1-20021031-C00110
  • HPLC-MS (Method C) m/z=434 (M+1); R[0607] t=1.33 min.
    • Example 14 (General Procedure (A)) 7-Benzyl-8-(3-isopropylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. HCl
  • [0608]
    Figure US20020161001A1-20021031-C00111
  • The piperazine moiety was prepared according to the general procedure for preparation of piperazine derivatives. [0609]
  • [0610] 1H-NMR (CDCl3): δ 7.1-7.4 (m; 5H); 5.4 (s; 2H); 3.55 (s; 3H); 3.35 (s; 3H); 3.3 (s br; 1H); 2.9-3.05 (m; 3H); 2.65 (t; 1H); 2.45 (dt, 1H); 2.1 (s br; 1H); 1.5 (p; 1H); 0.9 (d; 3H); 0.75 (d; 3H). 13C-NMR (CDCl3): δ 157.17; 154.98; 152.12; 148.16; 137.12; 129.15; 128.07; 126.94; 105.33; 60.88; 54.64; 51.04; 49.06; 45.90; 31.42; 30.12; 28.17; 19.21; 19.03.
    • Example 15 (General Procedure (C)) 7-Benzyl-8-[1,4]diazepan-1-yl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0611]
    Figure US20020161001A1-20021031-C00112
  • HPLC-MS (Method B): m/z=369; R[0612] t=1.75 min. TIC area=100%
    • Example 16 (General Procedure (C)) 1,3-Dimethyl-7-(2-oxo-2-pyrrolidin-1-yl-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. HCl
  • [0613]
    Figure US20020161001A1-20021031-C00113
  • HPLC-MS (Method B): m/z=376; R[0614] t=2.86 min.+0.47 min; Area: 47+53%
    • Example 17 (General Procedure (C)) 2-(8-[1,4]Diazepan-1-yl-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile. HCl
  • [0615]
    Figure US20020161001A1-20021031-C00114
  • Step A [0616]
  • 2-(8-Chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ylmethyl) benzonitrile (0.5 g, 1.5 mmol) and homopiperazine (0.45 g, 4.5 mmol) and TEA (0.77 ml; 7.5 mmol) was heated in 2-propanol in a closed vessel in a micro wave oven at 150° C. for 4 hours. The reaction mixture was evaporated in vacuo. The remaining oil was purified on a silica gel column with DCM/MeOH (3:1) as eluent, giving the title compound as an oil. The oil was dissolved in DCM (3 ml) and hydrochloride in ether was added. Yield 632 mg white crystals. Mp: 160.8-162.3° C. [0617]
  • [0618] 1H-NMR (MeOH-d4): δ 7.75 (dd; 1H); 7.65 (dt; 1H); 7.4 (t; 1H); 7.1 (d; 1H); 5.65 (s; 2H); 3.55-3.65 (s; 2H); 3.5 (s; 3H); 3.2 (s; 3H); 3.1 (t; 2H); 2.9 (t; 2H); 1.9 (t,t; 2H).
    • Example 18 (General Procedure (C)) 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione. HCl
  • [0619]
    Figure US20020161001A1-20021031-C00115
  • [0620] 1H-NMR (CDCl3): δ 7.85 (d; 1H); 7.25 (t; 1H); 6.95 (t; 1H); 5.45 (s; 2H); 3.55 (s; 3H); 3.35-3.5 (m; 2H); 3.35 (s; 3H); 2.7-3.1 (m; 6H); 1.75 (m; 2H).
    • Example 19 (General Procedure (A)) 7-(2-Difluoromethoxy-benzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0621]
    Figure US20020161001A1-20021031-C00116
  • HPLC-MS (Method B): m/z=421; R[0622] t=3.72 min. area:100%
    • Example 20 (General Procedure (A)) 7-(2,3-Dimethoxy-benzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0623]
    Figure US20020161001A1-20021031-C00117
  • HPLC-MS (Method B): m/z=415; R[0624] t=3.65 min. area: 100%.
    • Example 21 (General Procedure (A)) 1,3-Dimethyl-8-piperazin-1-yl-7-(2-trifluoromethoxy-benzyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0625]
    Figure US20020161001A1-20021031-C00118
  • HPLC-MS (Method B): m/z=439; R[0626] t=2.75min. area 99%
    • Example 22 (General Procedure (A)) 1,3-Dimethyl-8-piperazin-1-yl-7-(2-trifluoromethylsulfanyl-benzyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0627]
    Figure US20020161001A1-20021031-C00119
  • HPLC-MS (Method B): m/z=455; R[0628] t=4.17 min. area 99%
    • Example 23 (General Procedure (A)) 4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydro-purin-7-yl)-butyronitrile. TFA
  • [0629]
    Figure US20020161001A1-20021031-C00120
  • HPLC-MS (Method B): m/z=332; R[0630] t=2.45 min. area 99.7%
    • Example 24 (General Procedure (A)) (R)-7-Benzyl-8-(3-isopropylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. TFA
  • [0631]
    Figure US20020161001A1-20021031-C00121
  • The piperazine moiety was prepared according to the general procedure for preparation of piperazine derivatives. [0632]
  • [0633] 1H-NMR (CDCl3): δ 7.2-7.35 (m; 3H) 7.15 (dd; 2H); 5.4 (s; 2H); 3.6 (s; 3H); 3.35 (s; 3H); 3.3 (m; 5H); 3.1 (m; 2H); 1.8 (p; 1H); 0.9 (d; 3H); 0.75 (d; 3H). HPLC-MS (Method B): m/z=397 (M+1); Rt=2.06 min.
    • Example 25 (General Procedure (A)) (S)-7-Benzyl-8-(3-isopropylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. TFA
  • [0634]
    Figure US20020161001A1-20021031-C00122
  • [0635] 1H-NMR (CDCl3): δ 11.4 (broad s; 2.5H); 7.25-7.4 (m; 3H); 7.15 (dd; 2H); 5.4 (s; 2H); 3.6 (s; 3H); 3.25-3.5 (m; 7H); 3.0-3.2 (m; 2H); 1.8 (p; 1H); 0.85 (d; 3H); 0.7 (d; 3H). HPLC-MS (Method B): m/z=397 (M+1); Rt=2.09 min.
    • Example 26 (General Procedure (A)) 7-Benzyl-8-(6,9-diazaspiro[4.5]dec-9-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. TFA
  • [0636]
    Figure US20020161001A1-20021031-C00123
  • The piperazine moiety was prepared according to the general procedure for preparation of piperazine derivatives. [0637]
  • [0638] 1H-NMR (CDCl3): δ 10.0 (broad s; 2H); 8.9 (broad s, 2H); 7.25-7.4 (m, 3H); 7.1 (d, 2H); 5.4 (s; 2H); 3.55 (s; 3H); 3.35-3.4 (m; 5H); 3.1-3.3 (m; 4H); 1.6-1.85 (m; 6H); 1.3 (m; 2H).
  • HPLC-MS (Method B): m/z=409 (M+1); R[0639] t=2.11 min.
    • Example 27 (General Procedure (A)) 7-Benzyl-8-(piperazin-3-spiro-3′-bicyclo[2,2,1]heptane-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione. TFA
  • [0640]
    Figure US20020161001A1-20021031-C00124
  • The piperazine moiety was prepared according to the general procedure for preparation of piperazine derivatives. [0641]
  • [0642] 1H-NMR (CDCl3): δ 11.1 (broad s; 1H); 8.9 (broad s; 1H); 7.25-7.4 (m; 3H); 7.1 (dd; 2H); 5.45 (s; 2H); 3.5 (s; 3H); 3.15-3.4 (m; 9H); 2.2-2.3 (d; 2H); 1.1-1.6 (m; 7H); 0.9 (d; 1H).
  • HPLC-MS (Method B): m/z=435 (M+1); R[0643] t=2.34 min.
    • Example 28 (General Procedure (A)) 8-[1,4]Diazepan-1-yl-7-(2-methoxy-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0644]
    Figure US20020161001A1-20021031-C00125
  • HPLC-MS (Method B): m/z=399; R[0645] t=1.93 min. UV area=98.63%
    • Example 29 (General Procedure (A)) 8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-naphthalen-1-ylmethyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0646]
    Figure US20020161001A1-20021031-C00126
  • HPLC-MS (Method B): m/z=419; R[0647] t=2.26 min. UV area=99.7%.
    • Example 30 (General Procedure (A)) 8-[1,4]Diazepan-1-yl-7-(2-fluoro-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0648]
    Figure US20020161001A1-20021031-C00127
  • HPLC-MS (Method B): m/z=387; R[0649] t=1.86 min. UV area=94.4%.
    • Example 31 (General Procedure (A)) 8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-methyl-benzyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0650]
    Figure US20020161001A1-20021031-C00128
  • HPLC-MS (Method B): m/z=383 (M+1); R[0651] t=1.99 min. UV area=97.68%.
    • Example 32 (General Procedure (A)) 7-(2-Chloro-benzyl)-8-[1,4]diazepan-1-yl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0652]
    Figure US20020161001A1-20021031-C00129
  • HPLC-MS (Method B): m/z=403; 405; 406; (M+1); R[0653] t=1.97 min. UV area=98.93.
    • Example 33 (General Procedure (A)) 7-(2-Bromo-benzyl)-8-[1,4]diazepan-1-yl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0654]
    Figure US20020161001A1-20021031-C00130
  • HPLC-MS (Method B): m/z=447; 450; (M+1); R[0655] t=2.09 min. UV area=98.51.
    • Example 34 (General Procedure (A)) 8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-trifluoromethyl-benzyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0656]
    Figure US20020161001A1-20021031-C00131
  • HPLC-MS (Method B): m/z=437 (M+1); R[0657] t=2.20 min. UV area=99.50%.
    • Example 35 (General Procedure (A)) 8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-nitro-benzyl)-3,7-dihydro-purine-2,6-dione. HCl
  • [0658]
    Figure US20020161001A1-20021031-C00132
  • HPLC-MS (Method B): m/z=437 (M+23); R[0659] t=2.23 min. UV area=100%.
    • Example 36 (General Procedure (B)) 3-Benzyl-8-piperazin-1-yl-7-(2-trifluoromethyl-benzyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0660]
    Figure US20020161001A1-20021031-C00133
  • [0661] 1H-NMR (DMSO-d6): δ 11.12 (s, 1H); 8.83 (s, 1H); 7.86-7.71 (d, 2H); 7.71-7.45 (m, 2H); 7.45-7.23 (m, 5 H); 7.08-6.98 (d, 1 H); 5.48 (s, 1H); 5.10 (s, 1H); 3.34-3.01 (m, 4H)
    • Example 37 (General Procedure (B)) 3,7-Dibenzyl-1-(2-hydroxy-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0662]
    Figure US20020161001A1-20021031-C00134
  • [0663] 1H-NMR (DMSO-d6): δ 8.86 (s br, 2H); 7.40-7.18 (m, 10H); 5.41 (s, 2H); 5.13 (s, 2H); 3.93 (t,2H); 3.45 (t,2H); 3.31 (s br, 4H); 3.19 (s br,4H).
    • Example 38 (General Procedure (B)) 3-Benzyl-7-phenethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0664]
    Figure US20020161001A1-20021031-C00135
  • [0665] 1H-NMR (DMSO-d6): δ 11.11 (s, 1H); 8.79 (s br, 2H); 7.40-7.05 (m, 10H); 5.02 (s, 2H); 4.30 (t, 2H); 3.09 (s br, 8H); 3.03 (t, 2H).
    • Example 39 (General Procedure (B)) 3,7-Dibenzyl-8-[1,4]diazepan-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0666]
    Figure US20020161001A1-20021031-C00136
  • [0667] 1H-NMR (DMSO-d6): δ 7.67-6.92 (m, 10H); 5.42 (s.2H); 5.04 (s, 2H); 3.89-3.35 (m, 5H); 2.96-2.35 (m, 5H); 1.68 (s, 2H). HPLC-MS m/z=431
    • Example 40 (General Procedure (B)) 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0668]
    Figure US20020161001A1-20021031-C00137
  • [0669] 1H-NMR (DMSO-d6): δ 10.89 (s, 1H); 9.19 (s, 2H); 7.46-7.00 (m, 5H) 5.42 (s, 2H) 3.67 (s br,2H); 3.53-3.40 (m, 2H); 3.32 (s, 3H); 3.23 (s br,2H); 3.14 (s, 2H); 2.00 (m, 2H) HPLC-MS m/z=355
    • Example 41 (General Procedure (B)) 3,7-Dibenzyl-8-[1,4]diazepan-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0670]
    Figure US20020161001A1-20021031-C00138
  • [0671] 1H-NMR (DMSO-d6): δ 8.67 (s br,2H); 7.45-7.06 (m, 10H); 5.46 (s, 2H) 5.12 (s, 2H) 3.79 (t,2H); 3.67 (m, 2H); 3.50 (m, 2H); 3.27 (s br,2H) 3.16 (s br, 2H); 1.98 (m, 2H); 1.52 (m, 2H); 0.81 (t,3H).
    • Example 42 (General Procedure (B)) 3,7-Dibenzyl-8-[1,4]diazepan-1-yl-1-(2-hydroxy-ethyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0672]
    Figure US20020161001A1-20021031-C00139
  • [0673] 1H-NMR (DMSO-d6): δ 8.79 (s, 2H); 7.41-7,22 (m, 8H); 7.20-7.07 (m, 2H); 5.47 (s, 2H); 5.12 (s, 2H); 4.00-3.86 (t, 2H); 3.73-3.61 (m, 2 H); 3.54-3.40 (m, 4H) 3.27 (s, 2H); 3,15 (s, 2H) 1.98 (s, 2H)
    • Example 43 (General Procedure (B)) 2-(3,7-Dibenzyl-8-[1,4]diazepan-1-yl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-N,N-diethyl-acetamide
  • [0674]
    Figure US20020161001A1-20021031-C00140
  • [0675] 1H-NMR (DMSO-d6): δ 8.67 (s br,2H); 7.41-7.20 (m, 8H); 7.16-7.03 (m, 2H); 5.47 (s, 2H); 5.13 (s, 2H); 4.64 (s, 2H); 3.69 (s br, 2H); 3.51 (t.2H) 3.44-3.10 (m, 7H); 2.67 (s, 1H); 1.98 (s br, 2H); 1.16 (t, 3H) 0.99 (t, 3H)
    • Example 44 (General Procedure (B)) 1,3,7-Tribenzyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0676]
    Figure US20020161001A1-20021031-C00141
  • [0677] 1H-NMR (DMSO-d6): δ 8.83 (s br, 2H); 7.48-7.16 (m, 15H); 5.40 (s, 2H); 5.14 (s, 2H); 5.02 (s, 2H); 3.20 (s br, 4H).
    • Example 45 (General Procedure (B)) 1,3,7-Tribenzyl-8-[1,4]diazepan-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0678]
    Figure US20020161001A1-20021031-C00142
  • [0679] 1H-NMR (DMSO-d6): δ 8.76 (s br, 2H); 7.58-7.04 (m, 15H); 5.48 (s, 2H) 5.13 (s, 2H); 5.03 (s, 2H); 3.70 (s br,2H); 3.52 (t,2H); 3.29 (s br, 2H); 3.17 (s br,2H); 1.99 (s br, 2H)
    • Example 46 (General Procedure (A)) (S)-7-Benzyl-8-(3-benzyloxymethylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
  • [0680]
    Figure US20020161001A1-20021031-C00143
  • The piperazine moiety was prepared according to the general procedure for preparation of piperazine derivatives. [0681]
  • [0682] 1H-NMR (CDCl3): δ 7.1-7.45 (m; 5H); 5.35 (s br; 2H); 4.5 (s; 2H); 3.5 (s; 3H); 3.35 (s; 3H); 3.2-3.0 (m; 3H); 2.7-3.1 (m; 5H); 2.25 (s br; 1H). 13C-NMR (CDCl3): δ 156.92; 155.07; 152.11; 148.12; 138.22; 137.08; 129.16; 128.85; 128.22; 128.19; 128.15; 127.21; 105.35; 73.89; 72.07; 54.65; 53.89; 53.30; 51.41; 49.11; 45.14; 30.14; 28.22.
    • Example 47 (General Procedure (B)) 3,7-Dibenzyl-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0683]
    Figure US20020161001A1-20021031-C00144
  • [0684] 1H-NMR (DMSO-d6): δ 8.95 (s br, 2H); 7.40-7.20 m, 10 H); 5.40 (s, 2H); 5.13 (s, 2H); 3.79 (t, 2H); 3.32 (m, 4H); 3.20 (m, 4H); 1.50 (sextet, 2H); 0.81 (t, 3H). HPLC-MS (Method C): m/z=459 (M+1); Rt=4.62 min
    • Example 48 (General Procedure (B)) 3,7-Dibenzyl-8-[1,4]diazepan-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0685]
    Figure US20020161001A1-20021031-C00145
  • HPLC-MS (Method C): m/z=473 (M+1); R[0686] t=4.72 min
    • Example 49 (General Procedure (B)) 3,7-Dibenzyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0687]
    Figure US20020161001A1-20021031-C00146
  • [0688] 1H-NMR (DMSO-d6): δ 11.05 (s, 1H); 8.72 (s, br 2H); 7.40-7.20 (m, 10H); 5.37 (s, 2H); 5.07 (s, 2H). HPLC-MS (Method C): m/z=417 (M+1); Rt=3.69 min
    • Example 50 (General Procedure (B)) 3,7-Dibenzyl-8-[1,4]diazepan-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0689]
    Figure US20020161001A1-20021031-C00147
  • DMSO d6 d=10.90 (s, 1H); 8.65 (s br, 2H); 7.40-7.20 (m, 8H); 7.14 (d, 2H); 5.43 (s, 2H); 5.06 (s, 2H); 3.65 (m, 2H); 3.48 (m, 2H); 3.26 (m, 2H); 3.16 (s br, 2H); 1.97 (m, 2H) [0690]
  • HPLC-MS (Method C): m/z=431 (M+1); R[0691] t=3.83 min
    • Example 51 (General Procedure (B)) 2-(3-Benzyl-2,6-dioxo-8-piperazin-1-yl-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
  • [0692]
    Figure US20020161001A1-20021031-C00148
  • [0693] 1H-NMR (DMSO-d6): δ 8.73 (s br, 2H); 7.88 (d, 1H); 7.64 (t, 1H); 7.49 (t, 1H); 7.42-7.25 (m, 5H); 7.15 (d, 1H); 5.56 (s, 2H); 3.73 (t, 2H); 1.46 (q, 2H); 0.77 (t, 3H). HPLC-MS (Method C): m/z=484 (M+1); Rt=4.56 min
    • Example 52 (General Procedure (B)) 2-(3-Benzyl-8-[1,4]diazepan-1-yl-2,6-dioxo-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
  • [0694]
    Figure US20020161001A1-20021031-C00149
  • [0695] 1H-NMR (DMSO-d6): δ 8.66 (s br, 2H); 7.89 (d, 1H); 7.65 (t, 1H); 7.52 (t, 1H); 7.42-7.10 (m, 5H); 7.12 (d, 1H); 5.59 (s, 2H); 5.14 (s, 2H); 3.78-3.65 (m, 4H); 3.48 (t, 2H); 3.31 (s br, 2H); 3.19 (s br, 2H); 2.00 (m 2H); 1.45 (q, 2H); 0.77 (t, 3H).
    • Example 53 (General Procedure (B)) 2-(3-Benzyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
  • [0696]
    Figure US20020161001A1-20021031-C00150
  • [0697] 1H-NMR (DMSO-d6): δ 11.02 (s, 1H); 8.73 (s br 2H); 7.88 (d, 1H); 7.66 (t, 1H); 7.50 (t, H); 7.40-7.25 (m, 5H); 7.16 (d, 1H); 5.53 (s, 2H); 5.08 (s, 2H); 3.38 (s br, 4H); 3.20 (s br, 4H)
    • Example 54 (General Procedure (B)) 2-(3-Benzyl-8-[1,4]diazepan-1-yl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
  • [0698]
    Figure US20020161001A1-20021031-C00151
  • [0699] 1H-NMR (DMSO-d6): δ 10.90 (s, 1H); 8.67 (s br, 1H); 7.89 (d, 1H); 7.67 (t, 1H); 7.51 (t, 1H); 7.44-7.25 (m, 5H); 7.12 (d, 1H); 5.56 (s, 2H); 5.07 (s, 2H); 3.68 (m, 2H); 3.46 (m, 2H); 3.36 (s br, 2H); 3.19 (s br, 2H); 1.89 (m, 2H).
    • Example 55 (General Procedure (B)) 3-Benzyl-7-(2-iodo-benzyl)-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0700]
    Figure US20020161001A1-20021031-C00152
  • [0701] 1H-NMR (DMSO-d6): δ 8.71 (s br, 2H); 7.93 (d 1H); 7.42-7.25 (m, 6H); 7.09 (d, 1H); 6.8 (d, 1H); 5.28 (s, 2H); 5.17 (s, 2H); 3.75 (t, 2H); 3.16 (s br 4H); 1.48 (q, 2H); 0.79 (t, 3H).
    • Example 56 (General Procedure (B)) 3-Benzyl-8-[1,4]diazepan-1-yl-7-(2-iodo-benzyl)-1-propyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0702]
    Figure US20020161001A1-20021031-C00153
  • [0703] 1H-NMR (DMSO-d6): δ 8.64 (s br, 2H); 7.93 (d, 1H); 7.44-7.25 (m, 6H); 7.09 (t, 1H); 6.76 (d, 1H); 5.29 (s, 2H); 5.16 (s, 2H); 3.75 (t, 2H); 3.67 (m, 2H); 3.41 (m, 2H); 3.16 (m, 2H); 1.95 (m, 2H); 1.49 (q, 2H); 0.80 (t, 3H). HPLC-MS (Method C): m/z=599 (M+1); Rt=4.96 min
    • Example 57 (General Procedure (B)) 3-Benzyl-7-(2-iodo-benzyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0704]
    Figure US20020161001A1-20021031-C00154
  • [0705] 1H-NMR (DMSO-d6): δ 11.03 (s, 1H); 8.71 (s br, 1H); 7.92 (d, 1H); 7.42-7.28 (m, 6H); 7.08 (d, 1H); 6.81 (d, 1H); 5.26 (s, 2H); 5.10 (s, 2H); 3.15 (s br 4H).
    • Example 58 (General Procedure (B)) 3-Benzyl-8-[1,4]diazepan-1-yl-7-(2-iodo-benzyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0706]
    Figure US20020161001A1-20021031-C00155
  • [0707] 1H-NMR (DMSO-d6): δ 10.91 (s, 1H); 8.64 (s br, 2H); 7.93 (d, 1H); 7.44-2.25 (m, 6H); 7.09 (d, 1H); 6.75 (d, 1H); 5.27 (s, 2H); 5.09 (s, 2H); 3.65 (m, 2H); 3.39 (m, 1H); 3.30-3.22 (m, 3H); 3.15 (s br 2H); 1.94 (m, 2H).
    • Example 59 7-Benzyl-3-methyl-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0708]
    Figure US20020161001A1-20021031-C00156
  • [0709] 1H-NMR (DMSO-d6): δ 8.77 (s br 2H); 7.37-7.25 (m, 3H); 7.21 (d, 2H); 5.40 (s, 2H); 3.80 (t, 2H); 3.21 (s br 4H); 1.53 (q, 2H); 0.83 (t, 3H).
    • Example 60 (General Procedure (B)) 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-propyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0710]
    Figure US20020161001A1-20021031-C00157
  • [0711] 1H-NMR (DMSO-d6): δ 8.66 (s br, 2H); 7.40-7.25 (m, 3H); 7.12 (d, 2H); 5.46 (s, 2H); 3.80 (t, 2H); 3.66 (m, 2H); 3.50 (m, 2H); 3.28 (m, 2H); 3.17 (s br, 2H); 1.99 (m, 2H); 1.53 (q, 2H); 0.83 (t, 3H).
    • Example 61 (General Procedure (B)) 7-Benzyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0712]
    Figure US20020161001A1-20021031-C00158
  • [0713] 1H-NMR (DMSO-d6): δ 10.97 (s, 1H); 8.66 (s br) 7.40-7.25 (m, 3H); 7.21 (d, 2H); 5.37 (s, 2H).
    • Example 62 (General Procedure (B)) 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0714]
    Figure US20020161001A1-20021031-C00159
  • [0715] 1H-NMR (DMSO-d6): δ 10.84 (s, 1H); 8.61 (s br 2H); 7.40-7.25 (m, 3H); 7.13 (d, 2H); 5.43 (s, 2H); 3.65 (m, 2H); 3.47 (m, 2H); 3.17 (m, 2H); 1.98 (m, 2H).
    • Example 63 (General Procedure (B)) 2-(3-Methyl-2,6-dioxo-8-piperazin-1-yl-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
  • [0716]
    Figure US20020161001A1-20021031-C00160
  • [0717] 1H-NMR (DMSO-d6): δ 8.78 (s br 2H); 7.88 (d,1H); 7.63 (t, 1H); 7.49 (t, 1H); 7.08 (d, 1H); 5.55 (s, 2H); 3.73 (t, 2H); 3.22 (s br, 4H); 1.47 (q, 2H); 0.78 (t, 3H).
    • Example 64 (General Procedure (B)) 2-(8-[1,4]Diazepan-1-yl-3-methyl-2,6-dioxo-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
  • [0718]
    Figure US20020161001A1-20021031-C00161
  • [0719] 1H-NMR (DMSO-d6): δ 8.66 (s br, 2H); 7.89 (d, 1H); 7.65 (t, 1H); 7.50 (t, 1H); 7.06 (d, 1H); 5.58 (s, 2H); 3.73 (t, 2H); 3.69 (m, 2H); 3.47 (m, 2H); 3.42 (s, 3H); 3.21 (m, 2H); 2.00 (m, 2H); 1.48 (sextet, 2H); 0.78 (t, 3H).
    • Example 65 (General Procedure (B)) 2-(8-[1,4]Diazepan-1-yl-3-methyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
  • [0720]
    Figure US20020161001A1-20021031-C00162
  • [0721] 1H-NMR (DMSO-d6): δ 10.84 (s, 1H); 8.94 (s br, 1H); 8.69 (s br, 1H); 7.89 (d, 1H); 7.66 (t, 1H); 7.50 (t, 1H); 7.06 (d, 1H); 5.56 (s, 2H); 3.68 (m, 2H); 3.46 (m, 2H); 3.42 (s, 3H).
    • Example 66 (General Procedure (B)) 7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0722]
    Figure US20020161001A1-20021031-C00163
  • [0723] 1H-NMR (DMSO-d6): δ 8.73 (s br, 2H); 7.92 (d, 1H); 7.33 (t, 1H); 7.07 (t, 1H); 6.70 (d, 1H); 5.28 (s, 2H); 3.75 (t, 2H); 3.44 (s, 3H); 3.17 (s br, 4H); 1.49 (sextet, 2H); 0.80 (t, 3H).
    • Example 67 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-propyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0724]
    Figure US20020161001A1-20021031-C00164
  • [0725] 1H-NMR (DMSO-d6): δ 8.66 (s br, 2H); 7.93 (d, 1H); 7.35 (t, 1H); 7.08 (t, 1H); 6.69 (d, 1H); 5.30 (s, 2H); 3.75 (t, 2H); 3.43 (s, 3H); 3.28 (m, 2H); 3.17 (m, 2H); 1.95 (m, 2H); 1.50 (sextet, 2H); 0.81 (t, 3H).
    • Example 68 (General Procedure (B)) 7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0726]
    Figure US20020161001A1-20021031-C00165
  • [0727] 1H-NMR (DMSO-d6): δ 10.96 (s, 1H); 8.72 (s br); 7.72 (d, 1H); 7.34 (t, 1H); 7.07 (t, 1H); 6.73 (d, 1H); 5.26 (s, 2H); 3.15 (m, 4H).
    • Example 69 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0728]
    Figure US20020161001A1-20021031-C00166
  • [0729] 1H-NMR (DMSO-d6): δ 10.84 (s, 1H); 8.62 (s br, 2H); 7.93 (d, 1H); 7.36 (t, 1H); 7.08 (t, 1H); 6.69 (d,1H); 5.28 (s, 2H); 3.65 (dm, 2H); 3.39 (m, 2H); 3.36 (s, 3H); 3.16 (m, 2H); 1.94 (m, 2H).
    • Example 70 (General Procedure (B)) 3-Benzyl-8-[1,4]diazepan-1-yl-1-(3-hydroxy-propyl)-7-(2-iodo-benzyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0730]
    Figure US20020161001A1-20021031-C00167
  • [0731] 1H-NMR (DMSO-d6): δ (Selected peaks) 8.62 (s br, 2H); 7.88 (d, 1H); 7.40-7.20 (m, 7H); 7.04 (t, 1H); 6.71 (d, 1H); 5.23 (s, 2H); 5.10 (s, 2H);
    • Example 71 (General Procedure (B)) 3-Benzyl-8-[1,4]diazepan-1-yl-1-(2-ethoxy-ethyl)-7-(2-iodo-benzyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0732]
    Figure US20020161001A1-20021031-C00168
  • [0733] 1H-NMR (DMSO-d6): ((Selected peaks) 8.62 (s br, 2H); 7.88 (d, 1H); 7.40-7.20 (m, 7H); 7.04 (t, 1H); 6.71 (d, 1H); 5.24 (s, 2H); 5.101 (s, 2H); 0.93 (t, 3H).
    • Example 72 (General Procedure (B)) 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(3-phenyl-allyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0734]
    Figure US20020161001A1-20021031-C00169
  • [0735] 1H-NMR (DMSO-d6): δ 8.66 (s br, 2H); 7.50-7.20 (m) 7.14 (d, 2H); 6.46 (d, 1H); 6.27 (dt, 1H); 5.47 (s, 2H); 4.61 (d, 2H); 3.67 (m, 2H); 3.50 (m, 2H); 3.43 (s, 3H); 3.17 (m, 2H); 2.00 (m, 2H).
    • Example 73 (General Procedure (B)) 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(3-phenylallyl)-3,7-dihydropurine-2,6-dione. TFA
  • [0736]
    Figure US20020161001A1-20021031-C00170
  • [0737] 1H-NMR (DMSO-d6): δ 8.66 (s br, 2H); 7.50-7.20 (m) 7.14 (d, 2H); 6.46 (d, 1H); 6.27 (dt, 1H); 5.47 (s, 2H); 4.61 (d, 2H); 3.67 (m, 2H); 3.50 (m, 2H); 3.43 (s, 3H); 3.17 (m, 2H); 2.00 (m, 2H).
    • Example 74 (General Procedure (B)) 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(2-oxo-2-phenyl-ethyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0738]
    Figure US20020161001A1-20021031-C00171
  • [0739] 1H-NMR (DMSO-d6): δ 8.62 (s br, 2H); 8.05 (d, 2H); 7.71 (t, 1H); 7.58 (t, 2H); 7.40-7.25 (m, 3H); 7.13 (d, 3H) 5.46 (s, 2H); 5.35 (s, 2H); 3.71 (m, 2H); 3.53 (m, 2H); 3.44 (s, 3H); 3-20 (m, 2H); 2.01 (m, 2H).
    • Example 75 (General Procedure (B)) 2-(7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-ylmethyl)-benzonitrile
  • [0740]
    Figure US20020161001A1-20021031-C00172
  • [0741] 1H-NMR (DMSO-d6): δ 8.66 (s br, 2H); 7.81 (d, 1H); 7.61 (t, 1H); 7.44 (t, 1H); 7.40-7.25 (m, 3H); 7.18 (d, 1H); 7.14 (d, 2H); 5.46 (s, 2H); 5.21 (s, 2H); 3.69 (m, 2H); 3.52 (m, 2H): 3.42 (s, 3H); 3.20 (m, 2H); 2.00 (m, 2H).
    • Example 76 (General Procedure (B)) (7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetonitrile
  • [0742]
    Figure US20020161001A1-20021031-C00173
  • [0743] 1H-NMR (DMSO-d6): δ 8.66 (s br, 2H); 7.40-7.25 (m, 3H); 5.46 (s, 2H); 4.84 (s, 2H); 3.69 (m, 2H); 3.52 (m, 2H); 3.44 (s, 3H); 3.17 (m, 2H); 1.99 (m, 2H).
    • Example 77 (General Procedure (B)) 3-Methyl-7-(2-methyl-thiazol-4-ylmethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0744]
    Figure US20020161001A1-20021031-C00174
  • [0745] 1H-NMR (DMSO-d6): δ 10.99 (s, 1H); 8.88 (s br,2H); 7.31 (s, 1H); 5.36 (s, 2H); 3.42 (m, 4H); 3.32 (s, 3H); 3.22 (s br,4H); 2.60 (s, 3H)
    • Example 78 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-3-methyl-7-(2-methyl-thiazol-4-ylmethyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0746]
    Figure US20020161001A1-20021031-C00175
  • [0747] 1H-NMR (DMSO-d6): δ 10.87 (s, 1H); 8.88 (s br,2H); 7.21 (s, 1H); 5.41 (s, 2H); 3.73 (m, 2H); 3.57 (t,2H); 3.31 (s br,4H); 3.23 (s br,2H); 2.61 (s.3H); 2,51 (m, 1H); 2.04 (m, 2H);
  • HPLC-MS m/z=376 [0748]
    • Example 79 (General Procedure (B)) 3-Methyl-7-(2-oxo-2-phenyl-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0749]
    Figure US20020161001A1-20021031-C00176
  • [0750] 1H-NMR (DMSO-d6): δ 11.00 (s, 1H); 9.89 (s br, 2H); 8.07 (d, 2H); 7.74 (t, H); 7.64 (t,2H); 5.75 (s, 2H); 3.36 (s, 3H); 3.29 (m, 4H); 3.24 (m, 4H). HPLC-MS m/z=369
    • Example 80 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-3-methyl-7-(2-oxo-2-phenyl-ethyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0751]
    Figure US20020161001A1-20021031-C00177
  • [0752] 1H-NMR (DMSO-d6): δ 10.88 (s, 1H); 8.87 (s br, 2H); 8.09-7.60 (m, 5H); 5.80 (s, 2H); 3.67 (t,2H); 3.46 (t,2H); 3.34 (s, 3H); 3.21 (t,2H); 2.01 (m, 2H). HPLC-MS m/z=383
    • Example 81 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-3-methyl-7-phenethyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0753]
    Figure US20020161001A1-20021031-C00178
  • [0754] 1H-NMR (DMSO-d6): δ 10.89 (s, 1H); 8.87 (s br,2H); 7.29-7.12 (m, 5H); 4.29 (t,2H); 3.54 (m, 2H); 3.42 (t,2H); 3.28 (s, 3H); 3.21 (s br, 2H); 3.00 (t,2H) 2.03 (m, 2H). HPLC-MS m/z=369
    • Example 82 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-1-(3-hydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0755]
    Figure US20020161001A1-20021031-C00179
  • [0756] 1H-NMR (DMSO-d6): δ 8.72 (s br, 2H); 7.93 (d, 1H); 7.35 (t, 1H); 7.08 (t, 1H); 6.70 (d, 1H); 5.29 (s, 2H); 3.84 (t, 2H); 3.66 (m, 2H); 3.43 (s, 3H); 3.42-3.33 (m, 4H) 3.27 (m, 2H); 3.15 (m, 2H); 1.94 (m, 2H); 1.62 (q, 2H); HPLC-MS (Method C): m/z=539 (M+1); Rt=3.69 min
    • Example 83 (General Procedure (B)) 1-(3-Hydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0757]
    Figure US20020161001A1-20021031-C00180
  • [0758] 1H-NMR (DMSO-d6): δ 8.80 (s br 2H); 7.92 (d, 1H); 7.33 (t, 1H); 7.07 (t, 1H); 6.71 (d, 1H); 5.27 (s, 2H); 3.83 (t, 2H); 3.44 (s, 3H); 3.37 (t, 2H); 3.29 (m, 2H); 3.16 (m, 2H); 1.62 (q, 2H); HPLC-MS (Method C): m/z=525 (M+1); Rt=3.53 min
    • Example 84 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-1-(2-ethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0759]
    Figure US20020161001A1-20021031-C00181
  • [0760] 1H-NMR (DMSO-d6): δ 8.64 (s br 2H); 7.93 (d, 1H); 7.35 (t, 1H); 7.08 (t, 1H); 6.69 (d, 1H); 5.28 (s, 2H); 3.96 (t, 2H); 3.66 (m, 2H); 3.16 (m, 2H); 3.43 (s, 3H); 1.01 (t, 3H). HPLC-MS (Method C): m/z=553 (M+1); Rt=4.09 min
    • Example 85 (General Procedure (B)) 1-(2-Ethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0761]
    Figure US20020161001A1-20021031-C00182
  • [0762] 1H-NMR (DMSO-d6): δ 8.80 (s br, 2H); 7.92 (d, 1H); 7.32 (t, 1H); 7.07 (t, 1H); 6.70 (d, 1H); 5.27 (s, 2H); 3.96 (t, 1H); 3.48-3.40 (m, 5H); 3.38 (q, 2H); 3.30 (m, 4H); 3.16 (m, 4H); 1.00 (t, 3H). HPLC-MS (Method C): m/z=539 (M+1); Rt=4.03 min
    • Example 86 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(2-phenoxy-ethyl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0763]
    Figure US20020161001A1-20021031-C00183
  • HPLC-MS (Method C): m/z=601 (M+1); R[0764] t=4.73 min
    • Example 87 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1-[2-(2-methoxy-ethoxy)-ethyl]-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0765]
    Figure US20020161001A1-20021031-C00184
  • [0766] 1H-NMR (DMSO-d6): δ 8.70 (s br, 2H); 7.93 (d, 1H); 7.35 (t, 1H); 7.08 (t, 1H); 6.70 (d, 1H); 5.29 (s, 2H); 3.96 (t, 2H); 3.66 (m, 2H); (3.52-3.44 (m, 4H); 3.43 (s, 3H); 3.42-3.37 (m, 2H); 3.36-3.31 (m, 2H); 3.26 (m, 2H); 3.20 (m, 5H); 1.94 (m, 2H). HPLC-MS (Method C): m/z=583 (M+1); Rt=3.96 min
    • Example 88 (General Procedure (B)) 7-(2-Iodo-benzyl)-1-[2-(2-methoxy-ethoxy)-ethyl]-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0767]
    Figure US20020161001A1-20021031-C00185
  • [0768] 1H-NMR (DMSO-d6): δ 8.78 (s br, 2H); 7.93 (d, 1H); 7.33 (t, 1H); 7.07 (t, 1H); 6.70 (t, 1H); 5.27 (s, 2H); 3.96 (t, 2H); 3.52-3.42 (m, 4); 3.44 (s, 3H); 3.38-3.27 (m, 6H); 3.20-3.12 (m, 4H) 3.18 (s, 3H). HPLC-MS (Method C): m/z=569 (M+1); Rt=3.86 min
    • Example 89 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-1-(3,5-dimethoxy-benzyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0769]
    Figure US20020161001A1-20021031-C00186
  • [0770] 1H-NMR (DMSO-d6): δ 8.70 (s br, 2H); 7.91 (d, 1H); 7.34 (t, 1H); 7.07 (t, 1H); 6.74 (d, 1H); 6.34 (m, 1H); 6.32 (m, 2H); 5.30 (s, 2H); 4.91 (s, 2H); 3.69 (m, 2H); 3.66 (s, 6H); 3.44 (s, 3H); 3.42 (m, 2H); 3.28 (m, 2H); 3.17 (m, 2H); 1.95 (m, 2H). HPLC-MS (Method C): m/z=631 (M+1); Rt=4.72 min
    • Example 90 (General Procedure (B)) 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1-(3-methoxy-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0771]
    Figure US20020161001A1-20021031-C00187
  • [0772] 1H-NMR (DMSO-d6): δ 8.70 (s br, 2H); 7.93 (d, 1H); 7.35 (t,1H); 7.18 (t,1H); 7.08 (t, 1H); 6.80-6.70 (m, 4H); 5.30 (s, 2H); 4.95 (s, 2H); 3.68 (s, 3H); 3.44 (s, 3H); 3.42 (m, 2H); 3.28 (m, 2H); 3.16 (m, 2H); 1.95 (m, 2H). HPLC-MS (Method C): m/z=601 (M+1); Rt=4.62 min
    • Example 91 (General Procedure (B)) 7-Biphenyl-2-ylmethyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0773]
    Figure US20020161001A1-20021031-C00188
  • [0774] 1H-NMR (DMSO-d6): δ 10.81 (s, 1H); 8.74 (s br, 2H); 7.5-7.22 (m, 9H); 5.35 (s, 2H); 5.53 (t,2H); 3.29 (s, 3H); 3.26 (m, 2H); 3.15 (s br,2H); 3.06 (s br,2H); 1.82 (m, 2H) HPLC-MS m/z=431
    • Example 92 (General Procedure (B)) 7-(2-Bromo-benzyl)-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0775]
    Figure US20020161001A1-20021031-C00189
  • [0776] 1H-NMR (DMSO-d6): δ 10.89 (s, 1H); 8.8 (s br,2H); 7.74-6.74 (m, 4H); 5.37 (s, 2H); 3.66 (m, 2H); 3.40 (t,2H); 3.35 (s, 3H); 3.26 (s br,2H); 3.16 (s br, 2H); HPLC-MS m/z=435
    • Example 93 (General Procedure (B)) 7-(2-Chloro-benzyl)-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0777]
    Figure US20020161001A1-20021031-C00190
  • [0778] 1H-NMR (DMSO-d6): δ 10.88 (s, 1H); 8.83 (s br, 2H); 7.55-7.47 (m, 1H) 7.42-7.25 (m, 2H) 6.87-6.78 (m 1H); 5.43 (s, 2H); 3.66 (t,2H); 3.41 (t,2H); 3.35 (s, 3H); 3.27 (s br, 2H); 3.16 (s br,2H); 1.95 (m, 2H). HPLC-MS m/z=389
    • Example 94 (General Procedure (C)) 7-Benzyl-8-(3,5-dimethyl-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione. 2HCl
  • [0779]
    Figure US20020161001A1-20021031-C00191
  • HPLC-MS (Method B): m/z=383 (m+1); R[0780] t=1.91 min.
    • Example 95 (General Procedure (A)) 7-(4-Methoxybenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0781]
    Figure US20020161001A1-20021031-C00192
  • HPLC-MS (Method C) m/z=384 (M+1); R[0782] t=1.24 min.
    • Example 96 (General Procedure (A)) (1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-yl)-phenylacetic Acid Methyl Ester. TFA
  • [0783]
    Figure US20020161001A1-20021031-C00193
  • HPLC-MS (Method C): m/z=413 (M+1); R[0784] t=1.31 min.
    • Example 97 (General Procedure (A)) 7-(5-Chloro-2-nitrobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0785]
    Figure US20020161001A1-20021031-C00194
  • HPLC-MS (Method C): m/z=434 (M+1); R[0786] t=2.53 min. Purity=100% (ELS)
    • Example 98 (General Procedure (A)) 4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzonitrile. TFA
  • [0787]
    Figure US20020161001A1-20021031-C00195
  • HPLC-MS (Method C) m/z=380 (M+1); R[0788] t=1.21 min.
    • Example 99 (General Procedure (A)) 7-(4-Methanesulfonylbenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione.
  • [0789]
    Figure US20020161001A1-20021031-C00196
  • HPLC-MS (Method C) m/z=433 (M+1 ); R[0790] t=1.05 min.
    • Example 100 (General Procedure (A)) 7-(2-Fluoro-6-nitrobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0791]
    Figure US20020161001A1-20021031-C00197
  • HPLC-MS (Method C) m/z=418 (M+1); 1.22 min. [0792]
    • Example 101 (General Procedure (A)) 7-(4-Benzyloxybenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0793]
    Figure US20020161001A1-20021031-C00198
  • HPLC-MS (Method C) m/z=461 (M+1); R[0794] t=1.82 min.
    • Example 102 (General Procedure (A)) 7-(2,4-Dichlorobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0795]
    Figure US20020161001A1-20021031-C00199
  • HPLC-MS (Method C) m/z=425 (M+2); R[0796] t=1.57 min. (Chlorine isotope signal)
    • Example 103 (General Procedure (A)) 1,3-Dimethyl-8-piperazin-1-yl-7-(4-trifluoromethylbenzyl)-3,7-dihydropurine-2,6-dione. TFA
  • [0797]
    Figure US20020161001A1-20021031-C00200
  • HPLC-MS (Method C) m/z=423 (M+1); R[0798] t=1.58 min.
    • Example 104 (General Procedure (A)) 7-Biphenyl-4-ylmethyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0799]
    Figure US20020161001A1-20021031-C00201
  • HPLC-MS (Method C) m/z=431 (M+1); R[0800] t=1.76 min
    • Example 105 (General Procedure (A)) 3-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzoic acid methyl ester. TFA
  • [0801]
    Figure US20020161001A1-20021031-C00202
  • HPLC-MS (Method C) m/z=413 (M+1); R[0802] t=1.33 min.
    • Example 106 (General Procedure (A)) 4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzoic acid methyl ester. TFA
  • [0803]
    Figure US20020161001A1-20021031-C00203
  • HPLC-MS (Method C) m/z=413 (M+1); R[0804] t=1.31 min.
    • Example 107 (General Procedure (A)) 7-Biphenyl-2-ylmethyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0805]
    Figure US20020161001A1-20021031-C00204
  • HPLC-MS (Method C) m/z=431 (M+1); R[0806] t=1.55 min.
    • Example 108 (General Procedure (A)) 7-(4-tert-Butyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0807]
    Figure US20020161001A1-20021031-C00205
  • HPLC-MS (Method C) m/z=411 (M+1); R[0808] t=1.78 min.
    • Example 109 (General Procedure (A)) 1,3-Dimethyl-8-piperazin-1-yl-7-(4-trifluoromethoxybenzyl)-3,7-dihydropurine-2,6-dione. TFA
  • [0809]
    Figure US20020161001A1-20021031-C00206
  • HPLC-MS (Method C) m/z=439 (M+1); R[0810] t=1.65 min.
    • Example 110 (General Procedure (A)) 7-(3,4-Dichlorobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione. TFA
  • [0811]
    Figure US20020161001A1-20021031-C00207
  • HPLC-MS (Method C) m/z=424 (M+1); R[0812] t=2.87 min. Purity 98% (ELS)
    • Example 111 (General Procedure (A)) 1,3-Dimethyl-8-piperazin-1-yl-7-(4-[1,2,3]thiadiazol-4-ylbenzyl)-3,7-dihydropurine-2,6-dione. TFA
  • [0813]
    Figure US20020161001A1-20021031-C00208
  • HPLC-MS (Method C) m/z=439 (M+1); R[0814] t=2.47 min. Purity 80% (ELS)
    • Example 112 (General Procedure (A)) 4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl)-3-methoxybenzoic Acid Methyl Ester. TFA
  • [0815]
    Figure US20020161001A1-20021031-C00209
  • HPLC-MS (Method C) m/z=443 (M+1); R[0816] t=2.50 min. Purity >99% (ELS).
    • Example 113 (General Procedure (A)) 7-Cyclohexyl methyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione. TFA
  • [0817]
    Figure US20020161001A1-20021031-C00210
  • HPLC-MS (Method B): m/z=361 (M+1); R[0818] t=2.15 min.
    • Example 114 (General Procedure (C)) 7-Benzyl-8-(2,5-diaza-bicyclo[2.2.1]hept-2-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0819]
    Figure US20020161001A1-20021031-C00211
  • HPLC-MS (Method B): m/z=367; R[0820] t=1.76 min. TIC area 100%
    • Example 115 (General Procedure (A)) 8-(6-Benzyl-[1,4]diazepan-1-yl)-7-(2-iodo-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione. TFA
  • [0821]
    Figure US20020161001A1-20021031-C00212
  • HPLC-MS (Method B): m/z=585 (M+1); R[0822] t=2.87 min; purity-50%
    • Example 116 (General Procedure (A)) (S)-7-Benzyl-8-(3-hydroxymethylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
  • [0823]
    Figure US20020161001A1-20021031-C00213
  • The piperazine moiety was prepared according to the general procedure for preparation of piperazine derivatives. [0824]
  • MeOH-d4; d=7.1-7.4 (m; 5H); 5.4 (d; 2H); 3.5 (s; 3H); 3.45 (m; 2H); 3.25 (s; 3H); 2.9-3.2 (m; 3H); 2.0 (m; 1H); 1.2 (s br; 3H). HPLC-MS (Method B): m/z=385 (M+1); R[0825] t=1.65 min.
    • Example 117 (General Procedure (C)) 8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-oxo-2-pyrrolidin-1-yl-ethyl)-3,7-dihydro-purine-2,6-dione
  • [0826]
    Figure US20020161001A1-20021031-C00214
  • HPLC-MS (Method B): m/z=390; R[0827] t=2.93 min+0.43 min; 43+56%
    • Example 118 (General Procedure (C)) 7-(2-Iodo-benzyl)-1,3-dimethyl-8-(6-pyridin-2-ylmethyl-[1,4]diazepan-1-yl)-3,7-dihydro-purine-2,6-dione. TFA
  • [0828]
    Figure US20020161001A1-20021031-C00215
  • [0829] 1H NMR (CDCl3): δ 8.9 (s br, 2H); 8.65 (d, 1H); 8.2 (t, 1H); 7.85 (d, 1H); 7.15 (t, 1H); 7.5 (d, 1H); 7.3 (t, 1H); 7.0 (t, 1H); 6.75 (d, 1H); 5.45 (s, 2H); 3.05-3.8 (m, 3H); 3.5 (s, 3H); 3.3 (s, 4H); 2.8-3.25 (m, 7H). HPLC-MS (Method B): m/z=586 (M+1); Rt=2.25 min; Purity (UV)=97%.
    • Example 119 (General Procedure (A)) 7-(2-Bromo-benzyl)-1,3-dimethyl-8-(6-pyridin-2-ylmethyl-[1,4]diazepan-1-yl)-3,7-dihydro-purine-2,6-dione
  • [0830]
    Figure US20020161001A1-20021031-C00216
  • HPLC-MS (Method B): m/z=538 & 541 (M+1; M+2); R[0831] t=1.94 min
    • Example 120 (General Procedure (D)) (S) 7-Benzyl-8-(3-benzyl-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
  • [0832]
    Figure US20020161001A1-20021031-C00217
  • [0833] 1H-NMR (CDCl3): δ 7.24(m, 10H); 5.32 (m, 2H); 3.52(s, 3H); 3.11(m, 11H); 2.68(m, 2H).
  • HPLC-MS (Method B): m/z=445 (M+1), 354, 263; R[0834] t=4.13
    • Example 121 (General Procedure (D)) 7-Benzyl-1,3-dimethyl-8-(3-phenethyl-piperazin-1-yl)-3,7-dihydro-purine-2,6-dione
  • [0835]
    Figure US20020161001A1-20021031-C00218
  • [0836] 1H-NMR (DMSO-d6): δ 7.25(m, 10H); 5.41(s, 2H); 3.30(m, 15H); 1.88(m, 2H). HPLC-MS (Method B): m/z=481 (M+Na), 459/460(M+1); Rt=2.52 min.
    • Example 122 (General Procedure (D)) (R)-7-Benzyl-8-(3-benzylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
  • [0837]
    Figure US20020161001A1-20021031-C00219
  • [0838] 1H-NMR (CDCl3): δ 7.24(m, 10H); 5.34(m, 2H); 3.55(s, 3H); 3.34(m, 5H); 2.78(m, 7H); 1.70(s, 1H). HPLC-MS (Method B): m/z=445/446(M+1), 468(M+Na); Rt=2.56 min.
    • Example 123 (General Procedure (D)) 7-Benzyl-8-(3-(2-hydroxy-benzyl)-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
  • [0839]
    Figure US20020161001A1-20021031-C00220
  • [0840] 1H-NMR (MeOH-d4): δ 7.28(m, 3H); 7.11(m, 4H); 6.81(m, 2H); 5.43(m, 2H); 3.70(m,1H); 3.31(m, 14H); 2.88(s, 2H). HPLC-MS (Method B): m/z=461/462(m+1); 483(M+Na); Rt=2,409
    • Example 124 (General Procedure (D)) 7-Benzyl-8-(3-(2-methoxy-benzyl)-piperazin-1-yl)1,3-dimethyl-3,7-dihydro-purine-2,6-dione
  • [0841]
    Figure US20020161001A1-20021031-C00221
  • [0842] 1H-NMR (CDCl3): δ 7.22(m, 7H); 6.87(m, 2H); 5.32(m, 2H); 3.83(s, 3H); 3.54(s, 3H); 3.33(m, 5H); 2.79(m, 7H); 1.87(s, 1H) HPLC-MS (Method B): m/z=475,476,477 (M+1); Rt==2.57
    • Example 125 (General Procedure (D)) (R) 7-Benzyl-8-(3-(4-methoxy-benzyl)-piperazin-1-yl)1,3-dimethyl-3,7-dihydro-purine-2,6-dione
  • [0843]
    Figure US20020161001A1-20021031-C00222
  • [0844] 1H-NMR (CDCl3): δ 7.25(m, 5H); 7.08(m, 2H); 6.84(m, 2H); 5.34(m, 2H); 3.80(s, 3H); 3.55(s, 3H); 3.38(s, 3H); 3.29(m, 2H); 2.88(m, 5H); 2.52(m, 2H); 1.64(s, 1H) HPLC-MS (Method B): m/z=497(M+1), 475/476/477(M+1); Rt=2,368 min
    • Example 126 (General Procedure (D)) (R)-7-Benzyl-8-(3-(4-hydroxy-benzyl)-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
  • [0845]
    Figure US20020161001A1-20021031-C00223
  • [0846] 1H-NMR (DMSO-d6): δ 9.38(s, 1H); 8.86(s, 2H); 7.29(m, 3H); 7.13(m, 2H); 6.98(m, 2H); 6.72(m, 2H); 5.36(m, 2H); 3.09(m, 15H) HPLC-MS (Method B): m/z=943(2M+Na), 461/462(M+1); Rt=2.017
    • Example 127 (General Procedure (D)) (R)-7-Benzyl-1,3-dimethyl-8-(3-(4-nitro-benzyl)-piperazin-1-yl)-3,7-dihydro-purine-2,6-dione
  • [0847]
    Figure US20020161001A1-20021031-C00224
  • [0848] 1H-NMR (CDCl3): δ 8.17(m, 2H); 7.30(m, 7H); 5.34(s, 2H); 3.55(s, 3H); 3.00(m, 12H)
  • HPLC-MS (Method B): m/z=490/491 (M+1); R[0849] t=2.522
    • Example 128 (General Procedure (D)) (R)-7-Benzyl-8-(3-(4-fluoro-benzyl)-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
  • [0850]
    Figure US20020161001A1-20021031-C00225
  • [0851] 1H-NMR (CDCl3): δ 7.32(m, 2H); 7.08(m, 7H); 5.34(m, 2H); 3.55(m, 3H); 2.93(m, 12H)
  • HPLC-MS (Method B): m/z=947(2M+Na), 485(M+Na), 463/464(M+1) R[0852] t=2.35 min
    • Example 129 (General Procedure (D)) (R)-4-(4-(7-Benzyl-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-piperazin-2-ylmethyl)-benzonitrile
  • [0853]
    Figure US20020161001A1-20021031-C00226
  • [0854] 1H-NMR (CDCl3): δ 7.61(m, 2H); 7.26(m, 7H); 5.34(s, 2H); 3.53(s, 3H); 3.28(m, 5H); 2.83(m, 7H)
  • HPLC-MS (Method B): m/z=492(M+Na), 470/471 (M+1); R[0855] t=2.334
    • Example 130 (General Procedure (D)) (R)-6-(8-(3-Benzyl-piperazin-1-yl)-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-nicotinonitrile
  • [0856]
    Figure US20020161001A1-20021031-C00227
  • [0857] 1H-NMR (CDCl3): δ 8.67(m, 1H); 7.88(m, 1H); 7.22(m, 6H); 5.40(s, 2H); 3.55(m, 3H); 3.33(m, 5H); 2.85(m, 7H) HPLC-MS (Method B): m/z=963(2M+Na), 471/472(M+1); Rt=1.791 min.
    • Example 131 (General Procedure (D)) (R)-7-Benzyl-1,3-dimethyl-8-(3-thiazol-4-ylmethyl-piperazin-1-yl)-3,7-dihydro-purine-2,6-dione
  • [0858]
    Figure US20020161001A1-20021031-C00228
  • [0859] 1H-NMR(CDCl3): δ 8.77(m,1H); 7.26(m, 5H); 7.02(m, 1H); 5.35(m, 2H); 3.54(s, 3H); 2.74(m, 12H) HPLC-MS (Method B): m/z=452/453(M+1) Rt=2.220 min.
    • Example 132 (General Procedure (D)) (R)-2-[1,3-Dimethyl-2,6-dioxo-8-(3-thiophen-2-ylmethyl-piperazin-1-yl)-1,2,3,6-tetrahydro-purin-7-ylmethyl]-benzonitrile
  • [0860]
    Figure US20020161001A1-20021031-C00229
  • [0861] 1H-NMR (CDCl3): δ 7.70(s, 1H); 7.55(s, 1H); 7.40(s, 1H); 7.13(s, 2H); 6.88(s, 3H); 5.56(s, 2H); 3.58(s, 3H); 2.96(m, 12H) HPLC-MS (Method B): Ret.tid=2.40 min. m/z=489(M+Na), 476/477(M+1)
  • By use of the general methods described above, the following compounds can furthermore be made: [0862]
    • Example 133 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(tetrahydro-furan-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
  • [0863]
    Figure US20020161001A1-20021031-C00230
    • Example 134 7-Benzyl-1-(2-cyclohexyl-ethyl)-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0864]
    Figure US20020161001A1-20021031-C00231
    • Example 135 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1- (5-methyl-hexyl)-3,7-dihydro-purine-2,6-dione
  • [0865]
    Figure US20020161001A1-20021031-C00232
    • Example 136 7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(3-methyl-butyl)-3,7-dihydro-purine-2,6-dione
  • [0866]
    Figure US20020161001A1-20021031-C00233
    • Example 137 7-Benzyl-8-[1,4]diazepan-1-yl-1-(2-ethoxy-ethyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0867]
    Figure US20020161001A1-20021031-C00234
    • Example 138 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(tetrahydro-furan-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
  • [0868]
    Figure US20020161001A1-20021031-C00235
    • Example 139 7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-(tetrahydro-furan-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
  • [0869]
    Figure US20020161001A1-20021031-C00236
    • Example 140 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(tetrahydro-pyran-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
  • [0870]
    Figure US20020161001A1-20021031-C00237
    • Example 141 7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-(tetrahydro-pyran-2-ylmethyl)-3,7- dihydro-purine-2,6-dione
  • [0871]
    Figure US20020161001A1-20021031-C00238
    • Example 142 7-(2-Iodo-benzyl)-3-methyl-1-(2-phenoxyethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
  • [0872]
    Figure US20020161001A1-20021031-C00239
    • Example 143 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1-(2-methoxy-ethyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0873]
    Figure US20020161001A1-20021031-C00240
    • Example 144 7-(2-Iodo-benzyl)-1-(2-methoxy-ethyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
  • [0874]
    Figure US20020161001A1-20021031-C00241
    • Example 145 1-(2-Benzyloxy-ethyl)-8-[1,4]diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0875]
    Figure US20020161001A1-20021031-C00242
    • Example 146 1-(2-Benzyloxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
  • [0876]
    Figure US20020161001A1-20021031-C00243
    • Example 147 1-(3,5-Dimethoxy-benzyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
  • [0877]
    Figure US20020161001A1-20021031-C00244
    • Example 148 7-(2-Iodo-benzyl)-1-(3-methoxy-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
  • [0878]
    Figure US20020161001A1-20021031-C00245
    • Example 149 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(3-trifluoromethoxy-benzyl)-3,7-dihydro-purine-2,6-dione
  • [0879]
    Figure US20020161001A1-20021031-C00246
    • Example 150 7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-(3-trifluoromethoxy-benzyl)-3,7-dihydro-purine-2,6-dione
  • [0880]
    Figure US20020161001A1-20021031-C00247
    • Example 151 8-[1,4]Diazepan-1-yl-1-(2-hydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0881]
    Figure US20020161001A1-20021031-C00248
    • Example 152 8-[1,4]Diazepan-1-yl-1-(2,2-diethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0882]
    Figure US20020161001A1-20021031-C00249
    • Example 153 8-[1,4]Diazepan-1-yl-1-(2,2-dimethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0883]
    Figure US20020161001A1-20021031-C00250
    • Example 154 8-[1,4]Diazepan-1-yl-1-(2-[1,3]dioxolan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0884]
    Figure US20020161001A1-20021031-C00251
    • Example 155 1-(2-[1,3]Dioxolan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
  • [0885]
    Figure US20020161001A1-20021031-C00252
    • Example 156 1-[1,3]Dioxolan-2-ylmethyl-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
  • [0886]
    Figure US20020161001A1-20021031-C00253
    • Example 157 8-[1,4]Diazepan-1-yl-1-(2-[1,3]dioxan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0887]
    Figure US20020161001A1-20021031-C00254
    • Example 158 1-(2-[1,3]Dioxan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
  • [0888]
    Figure US20020161001A1-20021031-C00255
    • Example 159 8-[1,4]Diazepan-1-yl-1-(2,3-dihydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0889]
    Figure US20020161001A1-20021031-C00256
    • Example 160 1-(2,3-Dihydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
  • [0890]
    Figure US20020161001A1-20021031-C00257
    • Example 161 8-[1,4]Diazepan-1-yl-1-(3-hydroxy-2-methyl-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0891]
    Figure US20020161001A1-20021031-C00258
    • Example 162 1-(3-Hydroxy-2-methyl-propyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
  • [0892]
    Figure US20020161001A1-20021031-C00259
    • Example 163 8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-[3-(tetrahydro-pyran-2-yloxy)-propyl]-3,7-dihydro-purine-2,6-dione
  • [0893]
    Figure US20020161001A1-20021031-C00260
    • Example 164 8-[1,4]Diazepan-1-yl-1-(2-fluoro-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0894]
    Figure US20020161001A1-20021031-C00261
    • Example 165 7-Benzyl-8-[1,4]diazepan-1-yl-1-(3-hydroxy-propyl)-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0895]
    Figure US20020161001A1-20021031-C00262
    • Example 166 7-Biphenyl-2-ylmethyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione
  • [0896]
    Figure US20020161001A1-20021031-C00263

Claims (54)

1. A compound of formula I
Figure US20020161001A1-20021031-C00264
wherein
n and m is one or two independently;
R1 is C═O; C═S; C1-C2 alkyl; C2 alkenyl; C2 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl; heteroaryl-C1-C3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, or heteroaryl-C1-C3 alkyl is optionally substituted with one or more R4 independently;
R2 is H; C1-C7 alkyl; C2-C7 alkenyl; C2-C7 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR5; —SOR5; —SO2R5; carboxy; —CO2R4; —CON(R5)2; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, heteroaryl-C1-C3 alkyl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R11 independently;
R3 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; C1-C10alkyl-O-C1-C5alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl-C1-C3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system;
R4, R11, R12, and R17 are independently C1-C10 alkyl; C2-C10alkenyl; C2-C10alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R13)2; ═O; ═S; C1C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R8 independently; two R4 attached to the same carbon atom may form a spiroheterocyclic system, preferably hydantoine; thiohydantoine; oxazolidine-2,5-dione;
R5 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C5 alkyl; heteroaryl; heteroaryl-C1-C5 alkyl , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R14 independently;
R6 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R15 independently;
R7is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R16 independently;
R8, R14, R15, and R16 are independently H; nitro; —OCH3; cyano; halogen; —OH; —SH; —SCH3;
R9 is H; halogen; C1-C10 alkyl or aryl, wherein alkyl or aryl is optionally substituted with one or more R17 independently
R10 is H; halogen;
or, R9 and R10 may be connected to form a cyclopropyl ring;
R13 is H; C1-C10 alkyl or aryl;
or a salt thereof with a pharmaceutically acceptable acid or base;
with the exception of the following compounds:
1,3-dimethyl-7-(2-oxo-propyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
1,3,1′,3′,7′-pentamethyl-8-piperazin-1-yl-3,7,3′,7′-tetrahydro-7,8′-methanediyl-bis-purine-2,6-dione,
3,4,5-trimethoxy-benzoic acid 2-(1,3-dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydro-purin-7-yl)-ethyl ester,
7-[2-Hydroxy-3-(4-methoxy-phenoxy)-propyl]-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
7-[2-hydroxy-2-(4-nitro-phenyl)-ethyl]-3-methyl-8-piperazin-1-yl-3,7,8,9-tetrahydro-purine-2,6-dione,
7-Benzyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
7-(4-Chloro-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
7-(2-Chloro-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
7-Ethyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
3-Methyl-8-piperazin-1-yl-1,7-dipropyl-3,7-dihydro-purine-2,6-dione,
3-Methyl-7-(3-methyl-butyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
7-Butyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
3-Methyl-7-(3-phenyl-propyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
7-But-2-enyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
7-(3-Chloro-but-2-enyl)-3-methyl-8-piperazin- -yl-3,7-dihydro-purine-2,6-dione,
7-Heptyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
3-Methyl-7-(3-phenyl-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
3-Methyl-7-(3-methyl-benzyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione,
3-Methyl-7-propyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione, and
3-Methyl-7-pentyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione.
2. A compound of formula I
Figure US20020161001A1-20021031-C00265
wherein
n and m is one or two independently;
with the proviso that if n is 2 then m is also 2;
R1 is C═O; C═S; C1-C2 alkyl; C2 alkenyl; C2 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl; heteroaryl-C1-C3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, or heteroaryl-C1-C3 alkyl is optionally substituted with one or more R4 independently;
R2 is H; C1-C7 alkyl; C2-C7 alkenyl; C2-C7 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR5; —SOR5; —SO2R5; carboxy; —CO2R4; —CON(R5)2; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, heteroaryl-C1-C3 alkyl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R11 independently;
R3 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; C1-C10alkyl-O-C1-C5alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl-C1-C3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system;
R4, R11, R12, and R17 are independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R13)2; ═O; ═S; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R8 independently; two R4 attached to the same carbon atom may form a spiroheterocyclic system, preferably hydantoine; thiohydantoine; oxazolidine-2,5-dione;
R5 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C5 alkyl; heteroaryl; heteroaryl-C,-C5 alkyl , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R14 independently;
R6 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R15 independently;
R7 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R16 independently;
R8, R14, R15, and R16 are independently H; nitro; —OCH3; cyano; halogen; —OH; —SH; —SCH3;
R9 is H; halogen; C1-C10 alkyl optionally substituted with one or more R17 independently
R10 is H; halogen;
or, R9 and R10 may be connected to form a cyclopropyl ring;
R13 is H; C1-C10 alkyl or aryl;
or a salt thereof with a pharmaceutically acceptable acid or base;
3. A compound of formula I
Figure US20020161001A1-20021031-C00266
wherein
n and m is one or two independently;
R1 is C═O; C═S; C1-C2 alkyl; C2 alkenyl; C2 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl; heteroaryl-C1-C3 alkyl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, or heteroaryl-C1-C3 alkyl is optionally substituted with one or more R4 independently;
R2 is H; C1-C7 alkyl; C2-C7 alkenyl; C2-C7 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR5; —SOR5; —SO2R5; carboxy; —CO2R4; —CON(R5)2; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy, aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl, heteroaryl-C1-C3 alkyl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R11 independently;
R3 is C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C3 alkyl; heteroaryl-C1-C3 alkyl; heteroaryl; C1-C10alkyl-O-C1-C5alkyl; carboxy; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl-C1-C3 alkyl, heteroaryl-C1-C3 alkyl, heteroaryl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system;
R4, R11, R12, and R17 are independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; trifluormethyl; N(R13)2; ═O; ═S; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy; aryloxy; heteroaryloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy; alkenyloxy; alkynyloxy, aryloxy, or heteroaryloxy is optionally substituted with one or more R8 independently; two R4 attached to the same carbon atom may form a spiroheterocyclic system, preferably hydantoine; thiohydantoine; oxazolidine-2,5-dione;
R5 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; aryl-C1-C5 alkyl; heteroaryl; heteroaryl-C1-C5 alkyl , wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl is optionally substituted with one or more R14 independently;
R6 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R15 independently;
R7 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl, wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R16 independently;
R8, R14, R15, and R16 are independently H; nitro; —OCH3; cyano; halogen; —OH; —SH; —SCH3;
R9 is H; halogen; C1-C10 alkyl optionally substituted with one or more R17 independently
R10 is H; halogen;
or, R9 and R10 may be connected to form a cyclopropyl ring;
R13 is H; C1-C10 alkyl or aryl;
or a salt thereof with a pharmaceutically acceptable acid or base;
4. A compound according to any one of the claims 1 to 3 wherein R1 is C═O; C1-C2 alkyl; C2 alkenyl; C2 alkynyl ; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; or heteroaryl, wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl is optionally substituted with one or more R4 independently.
5. A compound according to claim 4 wherein R1 is C═O; C1-C2 alkyl; C3-C7 cycloalkyl; aryl; or heteroaryl, wherein each alkyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R4 independently.
6. A compound according to claim 5 wherein R1 is C═O or aryl optionally substituted with one or more R4 independently.
7. A compound according to claim 6 wherein R1 is aryl optionally substituted with one or more R4 independently.
8. A compound according to claim 7 wherein R1 is aryl.
9. A compound according to claim 8 wherein R1 is phenyl.
10. A compound according to any one of the claims 1 to 9 wherein R2 is H; C1-C7 alkyl; C2-C7 alkenyl; C2-C7 alkynyl; C3-C7 cycloalkyl; C3-C7 cycloheteroalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; —SH; —SR5; —SOR5; —SO2R5; —CO2R4; C1-C10 alkyloxy; C2-C10 alkenyloxy; C2-C10 alkynyloxy, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, alkyloxy, alkenyloxy, or alkynyloxy is optionally substituted with one or more R11 independently.
11. A compound according to claim 10 wherein R2 is H; C1-C7 alkyl; C3-C7 cycloheteroalkyl; aryl; cyano; halogen; nitro; —SR5; —SO2R5; —CO2R4; or C1-C10 alkyloxy; wherein each alkyl, cycloheteroalkyl, aryl, or alkyloxy is optionally substituted with one or more R11 independently.
12. A compound according to claim 11 wherein R2 is H; C1-C7 alkyl; C3-C7 cycloheteroalkyl; aryl; cyano; halogen; —CO2R4; or C1-C10 alkyloxy; wherein each alkyl, cycloheteroalkyl, aryl, or alkyloxy is optionally substituted with one or more R11 independently.
13. A compound according to claim 12 wherein R2 is H; C1-C7 alkyl; cyano; halogen; or C1-C10 alkyloxy; wherein each alkyl or alkyloxy is optionally substituted with one or more R11 independently.
14. A compound according to claim 13 wherein R2 is H; cyano or halogen.
15. A compound according to claim 14 wherein R2 is H.
16. a compound according to any one of the claims 1, 2 and 4 to 15 wherein R3 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; aryl; C1-C10alkyl-O-C1-C5alkyl; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
17. A compound according to claim 16 wherein R3 is H; C1-C10 alkyl; C1-C10alkyl-O-C1-C5alkyl; hydroxy; wherein alkyl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
18. A compound according to claim 17 wherein R3 is H or C1-C10 alkyl optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
19. A compound according to claim 18 wherein R3 is H or C1-C10 alkyl.
20. A compound according to claim 19 wherein R3 is methyl, ethyl, or isopropyl.
21. A compound according to claim 19 wherein R3 is H.
22. A compound according to claim 3 wherein R3 is C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; aryl; C1-C10alkyl-O-C1-C5alkyl; cyano; nitro; halogen; hydroxy; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
23. A compound according to claim 22 wherein R3 is C1-C10 alkyl; C1-C10alkyl-O-C1-C5alkyl; hydroxy; wherein alkyl, or alkyl-O-alkyl is optionally substituted with one or more R12 independently; two R3attached to the same carbon atom may form a spiro system.
24. A compound according to claim 23 wherein R3 is C1-C10 alkyl optionally substituted with one or more R12 independently; two R3 attached to the same carbon atom may form a spiro system.
25. A compound according to claim 24 wherein R3 is C1-C10 alkyl.
26. A compound according to claim 30 wherein R3 is methyl, ethyl, or isopropyl
27. A compound according to any one of the claims 1 to 26 wherein R4 is C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R8 independently.
28. A compound according to claim 27 wherein R4 is C1-C10 alkyl; C2-C10 alkenyl; or C2-C10 alkynyl; wherein each alkyl, alkenyl, or alkynyl is optionally substituted with one or more R8 independently.
29. A compound according to claim 28 wherein R4 is C1-C10 alkyl optionally substituted with one or more R8 independently.
30. A compound according to claim 29 wherein R4 is C1-C10 alkyl.
31. A compound according to claim 30 wherein R4 is methyl.
32. A compound according to any one of the claims 1 to 31 wherein R5 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; aryl; heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl is optionally substituted with one or more R14 independently.
33. A compound according to claim 32 wherein R5 is C1-C10 alkyl or aryl; wherein each alkyl or aryl is optionally substituted with one or more R14 independently.
34. A compound according to any one of the claims 1 to 33 wherein R6 is H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C7 cycloalkyl; or aryl; wherein each each alkyl, alkenyl, alkynyl, cycloalkyl, or aryl is optionally substituted with one or more R15 independently.
35. A compound according to claim 34 wherein R6 is H; C1-C10 alkyl; or C2-C10 alkenyl; wherein each each alkyl or alkenyl is optionally substituted with one or more R15 independently.
36. A compound according to claim 35 wherein R6 is H or C1-C10 alkyl optionally substituted with one or more R15 independently.
37. A compound according to claim 36 wherein R6 is H.
38. A compound according to claim 36 wherein R6 is C1-C10 alkyl optionally substituted with one or more R15 independently.
39. A compound according to claim 38 wherein R6 is C1-C10 alkyl.
40. A compound according to claim 39 wherein R6 is methyl.
41. A compound according to any one of the claims 1 to 40 wherein R7 is H; C1-C10 alkyl; C2-C10 alkenyl; or C2-C10 alkynyl, wherein each each alkyl, alkenyl, or alkynyl is optionally substituted with one or more R16 independently.
42. A compound according to claim 41 wherein R7 is C1-C10 alkyl optionally substituted with one or more R16 independently.
43. A compound according to claim 42 wherein R7 is C1-C10 alkyl.
44. A compound according to any one of the claims 1 to 43 wherein R8 is —OCH3.
45. A compound according to any one of the claims 1 to 44 wherein R9 is aryl.
46. A compound according to any one of the claims 1 to 45 wherein R11 is C1-C10 alkyl; aryl; cyano; halogen; wherein each alkyl or aryl is optionally substituted with one or more R8 independently.
47. A compound according to claim 46 wherein R11 is halogen.
48. A compound according to any one of the claims 1 to 47 wherein R12 is C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; aryl; heteroaryl; cyano; halogen; hydroxy, nitro; wherein each alkyl, alkenyl, alkynyl, aryl, heteroaryl is optionally substituted with one or more R8 independently.
49. A compound according to claim 48 wherein R12 is aryl; heteroaryl; or hydroxy; wherein each aryl and heteroaryl is optionally substituted with one or more R8 independently.
50. A compound according to claim 49 wherein R12 is phenyl, pyridyl, or pyrrolidinyl.
51. A compound according to claim 49 wherein R12 is hydroxy.
52. A compound according to any one of the claims 1 to 51 wherein R14 is halogen.
53. A compound that fulfils all of the following three criteria:
1. Contains the structural element of Formula III
Figure US20020161001A1-20021031-C00267
 wherein
n and m is one or two independently;
2. has a molecular weight of 500 daltons or less;
3. has a DPP-IV inhibition constant Ki of 500 nM or less
54. A compound according to any one of the preceding claims selected from the following:
7-Benzyl-8-(6-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione.
7-Benzyl-8-(6-hydroxy-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
7-Benzyl-8-(3-hydroxymethyl-[1,4]diazepan-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
7-Benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
1,3-Dimethyl-7-(4-methylbenzyl)-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
3-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzonitrile
2-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzonitrile
1,3-Dimethyl-7-(1-phenylethyl)-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
7-(2-Iodobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
1,3-Dimethyl-8-piperazin-1-yl-7-(2-trifluoromethylbenzyl)-3,7-dihydropurine-2,6-dione
1,3-Dimethyl-7-naphthalen-1-ylmethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
1,3-Dimethyl-7-naphthalen-2-ylmethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
7-(3-Bromobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
7-Benzyl-8-(3-isopropylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
7-Benzyl-8-[1,4]diazepan-1-yl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
1,3-Dimethyl-7-(2-oxo-2-pyrrolidin-1-yl-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
2-(8-[1,4]Diazepan-1-yl-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
7-(2-Difluoromethoxy-benzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
7-(2,3-Dimethoxy-benzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
1,3-Dimethyl-8-piperazin-1-yl-7-(2-trifluoromethoxy-benzyl)-3,7-dihydro-purine-2,6-dione
1,3-Dimethyl-8-piperazin-1-yl-7-(2-trifluoromethylsulfanyl-benzyl)-3,7-dihydro-purine-2,6-dione
4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydro-purin-7-yl)-butyronitrile
R)-7-Benzyl-8-(3-isopropylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
S)-7-Benzyl-8-(3-isopropylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
7-Benzyl-8-(6,9-diazaspiro[4.5]dec-9-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
7-Benzyl-8-(piperazin-3-spiro-3′-bicyclo[2,2,1]heptane-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-methoxy-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-naphthalen-1-ylmethyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-fluoro-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-methyl-benzyl)-3,7-dihydro-purine-2,6-dione
7-(2-Chloro-benzyl)-8-[1,4]diazepan-1-yl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
7-(2-Bromo-benzyl)-8-[1,4]diazepan-1-yl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-trifluoromethyl-benzyl)-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-nitro-benzyl)-3,7-dihydro-purine-2,6-dione
3-Benzyl-8-piperazin-1-yl-7-(2-trifluoromethyl-benzyl)-3,7-dihydro-purine-2,6-dione
3,7-Dibenzyl-1-(2-hydroxy-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
3-Benzyl-7-phenethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
3,7-Dibenzyl-8-[1,4]diazepan-1-yl-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione
3,7-Dibenzyl-8-[1,4]diazepan-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione
3,7-Dibenzyl-8-[1,4]diazepan-1-yl-1-(2-hydroxy-ethyl)-3,7-dihydro-purine-2,6-dione
2-(3,7-Dibenzyl-8-[1,4]diazepan-1-yl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-N,N-diethyl-acetamide
1,3,7-Tribenzyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
1,3,7-Tribenzyl-8-[1,4]diazepan-1-yl-3,7-dihydro-purine-2,6-dione
(S)-7-Benzyl-8-(3-benzyloxymethylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
3,7-Dibenzyl-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione
3,7-Dibenzyl-8-[1,4]diazepan-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione
3,7-Dibenzyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
3,7-Dibenzyl-8-[1,4]diazepan-1-yl-3,7-dihydro-purine-2,6-dione
2-(3-Benzyl-2,6-dioxo-8-piperazin-1-yl-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
2-(3-Benzyl-8-[1,4]diazepan-1-yl-2,6-dioxo-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
2-(3-Benzyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
2-(3-Benzyl-8-[1,4]diazepan-1-yl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
3-Benzyl-7-(2-iodo-benzyl)-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione
3-Benzyl-8-[1,4]diazepan-1-yl-7-(2-iodo-benzyl)-1-propyl-3,7-dihydro-purine-2,6-dione
3-Benzyl-7-(2-iodo-benzyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
3-Benzyl-8-[1,4]diazepan-1-yl-7-(2-iodo-benzyl)-3,7-dihydro-purine-2,6-dione
7-Benzyl-3-methyl-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-propyl-3,7-dihydro-purine-2,6-dione
7-Benzyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione
2-(3-Methyl-2,6-dioxo-8-piperazin-1-yl-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
2-(8-[1,4]Diazepan-1-yl-3-methyl-2,6-dioxo-1-propyl-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
2-(8-[1,4]Diazepan-1-yl-3-methyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-benzonitrile
7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-propyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-propyl-3,7-dihydro-purine-2,6-dione
7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
3-Benzyl-8-[1,4]diazepan-1-yl-(3-hydroxy-propyl)-7-(2-iodo-benzyl)-3,7-dihydro-purine-2,6-dione
3-Benzyl-8-[1,4]diazepan-1-yl-1-(2-ethoxy-ethyl)-7-(2-iodo-benzyl)-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(3-phenyl-allyl)-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(2-oxo-2-phenyl-ethyl)-3,7-dihydro-purine-2,6-dione
2-(7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-ylmethyl)-benzonitrile
(7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetonitrile
3-Methyl-7-(2-methyl-thiazol-4-ylmethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-3-methyl-7-(2-methyl-thiazol-4-ylmethyl)-3,7-dihydro-purine-2,6-dione
3-Methyl-7-(2-oxo-2-phenyl-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-3-methyl-7-(2-oxo-2-phenyl-ethyl)-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-3-methyl-7-phenethyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(3-hydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
1-(3-Hydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(2-ethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
1-(2-Ethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(2-phenoxy-ethyl)-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1-[2-(2-methoxy-ethoxy)-ethyl]-3-methyl-3,7-dihydro-purine-2,6-dione
7-(2-Iodo-benzyl)-1-[2-(2-methoxy-ethoxy)-ethyl]-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(3,5-dimethoxy-benzyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1-(3-methoxy-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
7-Biphenyl-2-ylmethyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione
7-(2-Bromo-benzyl)-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione
7-(2-Chloro-benzyl)-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-(3,5-dimethyl-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
7-(4-Methoxybenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-yl)-phenylacetic acid methyl ester
7-(5-Chloro-2-nitrobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzonitrile
7-(4-Methanesulfonylbenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
7-(2-Fluoro-6-nitrobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
7-(4-Benzyloxybenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
7-(2,4-Dichlorobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
1,3-Dimethyl-8-piperazin-1-yl-7-(4-trifluoromethylbenzyl)-3,7-dihydropurine-2,6-dione
7-Biphenyl-4-ylmethyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
3-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzoic acid methyl ester
4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl) benzoic acid methyl ester
7-Biphenyl-2-ylmethyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
7-(4-tert-Butylbenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
1,3-Dimethyl-8-piperazin-1-yl-7-(4-trifluoromethoxybenzyl)-3,7-dihydropurine-2,6-dione
7-(3,4-Dichlorobenzyl)-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione
1,3-Dimethyl-8-piperazin-1-yl-7-(4-[1,2,3]thiadiazol-4-ylbenzyl)-3,7-dihydropurine-2,6-dione
4-(1,3-Dimethyl-2,6-dioxo-8-piperazin-1-yl-1,2,3,6-tetrahydropurin-7-ylmethyl)-3-methoxybenzoic acid methyl ester
7-Cyclohexylmethyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-(2,5-diaza-bicyclo[2.2.1]hept-2-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
8-(6-Benzyl-[1,4]diazepan-1-yl)-7-(2-iodo-benzyl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
(S)-7-Benzyl-8-(3-hydroxymethylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
8-[1,4]Diazepan-1-yl-1,3-dimethyl-7-(2-oxo-2-pyrrolidin-1-yl-ethyl)-3,7-dihydro-purine-2,6-dione
7-(2-Iodo-benzyl)-1,3-dimethyl-8-(6-pyridin-2-ylmethyl-[1,4]diazepan-1-yl)-3,7-dihydro-purine-2,6-dione
7-(2-Bromo-benzyl)-1,3-dimethyl-8-(6-pyridin-2-ylmethyl-[1,4]diazepan-1-yl)-3,7-dihydro-purine-2,6-dione
(S) 7-Benzyl-8-(3-benzyl-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
7-Benzyl-1,3-dimethyl-8-(3-phenethyl-piperazin-1-yl)-3,7-dihydro-purine-2,6-dione
(R)-7-Benzyl-8-(3-benzylpiperazin-1-yl)-1,3-dimethyl-3,7-dihydropurine-2,6-dione
7-Benzyl-8-(3-(2-hydroxy-benzyl)-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-(3-(2-methoxy-benzyl)-piperazin-1-yl)1,3-dimethyl-3,7-dihydro-purine-2,6-dione
(R) 7-Benzyl-8-(3-(4-methoxy-benzyl)-piperazin-1-yl)1,3-dimethyl-3,7-dihydro-purine-2,6-dione
(R)-7-Benzyl-8-(3-(4-hydroxy-benzyl)-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
(R)-7-Benzyl-1,3-dimethyl-8-(3-(4-nitro-benzyl)-piperazin-1-yl)-3,7-dihydro-purine-2,6-dione
(R)-7-Benzyl-8-(3-(4-fluoro-benzyl)-piperazin-1-yl)-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
(R)-4-(4-(7-Benzyl-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-piperazin-2-ylmethyl)-benzonitrile
(R)-6-(8-(3-Benzyl-piperazin-1-yl)-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-ylmethyl)-nicotinonitrile
(R)-7-Benzyl-1,3-dimethyl-8-(3-thiazol-4-ylmethyl-piperazin-1-yl)-3,7-dihydro-purine-2,6-dione
(R)-2-[1,3-Dimethyl-2,6-dioxo-8-(3-thiophen-2-ylmethyl-piperazin-1-yl)-1,2,3,6-tetrahydro-purin-7-ylmethyl]-benzonitrile
7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(tetrahydro-furan-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
7-Benzyl-1-(2-cyclohexyl-ethyl)-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(5-methyl-hexyl)-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-[1,4]diazepan-1-yl-3-methyl-1-(3-methyl-butyl)-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-[1,4]diazepan-1-yl-1-(2-ethoxy-ethyl)-3-methyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(tetrahydro-furan-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-(tetrahydro-furan-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(tetrahydro-pyran-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-(tetrahydro-pyran-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
7-(2-Iodo-benzyl)-3-methyl-1-(2-phenoxy-ethyl)-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-1-(2-methoxy-ethyl)-3-methyl-3,7-dihydro-purine-2,6-dione
7-(2-Iodo-benzyl)-1-(2-methoxy-ethyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
1-(2-Benzyloxy-ethyl)-8-[1,4]diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
1-(2-Benzyloxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
1-(3,5-Dimethoxy-benzyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
7-(2-Iodo-benzyl)-1-(3-methoxy-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-(3-trifluoromethoxy-benzyl)-3,7-dihydro-purine-2,6-dione
7-(2-Iodo-benzyl)-3-methyl-8-piperazin-1-yl-1-(3-trifluoromethoxy-benzyl)-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(2-hydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(2,2-diethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(2,2-dimethoxy-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(2-[1,3]dioxolan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
1-(2-[1,3]Dioxolan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
1-[1,3]Dioxolan-2-ylmethyl-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(2-[1,3]dioxan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
1-(2-[1,3]Dioxan-2-yl-ethyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(2,3-dihydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
1-(2,3-Dihydroxy-propyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(3-hydroxy-2-methyl-propyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
1-(3-Hydroxy-2-methyl-propyl)-7-(2-iodo-benzyl)-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-7-(2-iodo-benzyl)-3-methyl-1-[3-(tetrahydro-pyran-2-yloxy)-propyl]-3,7-dihydro-purine-2,6-dione
8-[1,4]Diazepan-1-yl-1-(2-fluoro-ethyl)-7-(2-iodo-benzyl)-3-methyl-3,7-dihydro-purine-2,6-dione
7-Benzyl-8-[1,4]diazepan-1-yl-1-(3-hydroxy-propyl)-3-methyl-3,7-dihydro-purine-2,6-dione
7-Biphenyl-2-ylmethyl-8-[1,4]diazepan-1-yl-3-methyl-3,7-dihydro-purine-2,6-dione
US09/935,149 2000-07-04 2001-08-22 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV Abandoned US20020161001A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/935,149 US20020161001A1 (en) 2000-07-04 2001-08-22 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US10/621,302 US7235538B2 (en) 2000-07-04 2003-07-17 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200001040 2000-07-04
DKPA200001040 2000-07-04
US22324000P 2000-08-04 2000-08-04
PCT/DK2001/000467 WO2002002560A2 (en) 2000-07-04 2001-07-04 Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
US09/935,149 US20020161001A1 (en) 2000-07-04 2001-08-22 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000467 Continuation WO2002002560A2 (en) 2000-07-04 2001-07-04 Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/621,302 Continuation US7235538B2 (en) 2000-07-04 2003-07-17 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV

Publications (1)

Publication Number Publication Date
US20020161001A1 true US20020161001A1 (en) 2002-10-31

Family

ID=26068848

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/935,149 Abandoned US20020161001A1 (en) 2000-07-04 2001-08-22 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US10/621,302 Expired - Fee Related US7235538B2 (en) 2000-07-04 2003-07-17 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/621,302 Expired - Fee Related US7235538B2 (en) 2000-07-04 2003-07-17 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV

Country Status (8)

Country Link
US (2) US20020161001A1 (en)
EP (1) EP1301187B1 (en)
JP (1) JP2004502690A (en)
AU (2) AU2001268958B2 (en)
HU (1) HUP0301622A3 (en)
MX (1) MXPA02012272A (en)
PL (1) PL360856A1 (en)
WO (1) WO2002002560A2 (en)

Cited By (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199528A1 (en) * 2001-09-19 2003-10-23 Kanstrup Anders B. Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2003104229A1 (en) 2002-06-06 2003-12-18 エーザイ株式会社 Novel fused imidazole derivative
US20030232987A1 (en) * 2002-05-31 2003-12-18 Schering Corporation Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof
US20040077645A1 (en) * 2001-02-24 2004-04-22 Frank Himmelsbach Xanthine derivatives,production and use thereof as medicament
US20040097510A1 (en) * 2002-08-21 2004-05-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20040138215A1 (en) * 2002-11-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138214A1 (en) * 2002-11-08 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040152745A1 (en) * 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
US20040166125A1 (en) * 2002-08-22 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US20050187227A1 (en) * 2004-02-23 2005-08-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US20050203095A1 (en) * 2004-03-13 2005-09-15 Boehringer Ingelheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US20050234108A1 (en) * 2004-02-18 2005-10-20 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20050261352A1 (en) * 2004-05-10 2005-11-24 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US20060004074A1 (en) * 2004-06-24 2006-01-05 Boehringer Ingelheim International Gmbh New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US20060058323A1 (en) * 2004-09-11 2006-03-16 Boehringer Ingelheim International Gmbh New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060079541A1 (en) * 2004-09-14 2006-04-13 Boehringer Ingelheim International Gmbh 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060142310A1 (en) * 2004-11-05 2006-06-29 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070027168A1 (en) * 2005-07-30 2007-02-01 Waldemar Pfrengle 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US20070082908A1 (en) * 2003-08-29 2007-04-12 Dainippon Sumitomo Pharma Co., Ltd. Bicycle pyrazole derivative
US20070219178A1 (en) * 2003-12-04 2007-09-20 Eisai Co., Ltd. Preventive or therapeutic agents for multiple sclerosis
US20070259900A1 (en) * 2006-05-04 2007-11-08 Peter Sieger Polymorphs
US20070281940A1 (en) * 2006-05-04 2007-12-06 Klaus Dugi Uses of dpp-iv inhibitors
US20080107731A1 (en) * 2006-05-04 2008-05-08 Anja Kohlrausch Dpp iv inhibitor formulations
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20090088569A1 (en) * 2004-04-10 2009-04-02 Matthias Eckhardt 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation, and their use as pharmaceutical compositions
US20090110647A1 (en) * 2007-10-24 2009-04-30 Peter Richardson Method of preventing adverse effects by glp-1
US7550455B2 (en) 2003-11-27 2009-06-23 Boehringer Ingelheim International Gmbh 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2010080964A1 (en) * 2009-01-08 2010-07-15 Mannkind Corporation Method for treating hyperglycemia with glp-1
WO2010079197A1 (en) * 2009-01-07 2010-07-15 Boehringer Ingelheim International Gmbh Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
US7825242B2 (en) 2004-07-16 2010-11-02 Takeda Pharmaceutical Company Limted Dipeptidyl peptidase inhibitors
US20110092510A1 (en) * 2008-06-03 2011-04-21 Boehringer Ingelheim International Gmbh Dpp-iv inhibitors for use in the treatment of nafld
US20110112069A1 (en) * 2007-08-17 2011-05-12 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US20110206766A1 (en) * 2008-04-03 2011-08-25 Boehringer Ingelheim International Gmbh Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US8071583B2 (en) 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500308A (en) 2001-06-20 2005-01-06 メルク　エンド　カムパニー　インコーポレーテッド Dipeptidyl peptidase inhibitors for the treatment of diabetes
CA2450579A1 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
ATE370943T1 (en) 2001-06-27 2007-09-15 Smithkline Beecham Corp FLUOROPYRROLIDINE AS DIPEPTIDYL-PEPTIDASE INHIBITORS
IL158923A0 (en) 2001-06-27 2004-05-12 Smithkline Beecham Corp Fluoropyrrolidines as dipeptidyl peptidase inhibitors
JP4300108B2 (en) 2001-06-27 2009-07-22 スミスクライン ビーチャム コーポレーション Pyrrolidines as dipeptidyl peptidase inhibitors
EP1404675B1 (en) * 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20070197552A1 (en) * 2002-01-11 2007-08-23 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
AU2003231805A1 (en) 2002-06-17 2004-02-09 Glaxo Group Limited Purine derivatives as liver x receptor agonists
WO2004007468A1 (en) 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
EP2070539A1 (en) * 2002-08-21 2009-06-17 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine
DE10238470A1 (en) * 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
DE10238477A1 (en) * 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New purine derivatives, their production and their use as medicines
US20060039974A1 (en) * 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
AU2003266559B2 (en) * 2002-09-26 2008-01-24 Eisai R&D Management Co., Ltd. Combination drug
WO2004032836A2 (en) 2002-10-07 2004-04-22 Merck & Co., Inc. Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors
AU2003269850A1 (en) * 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
JP4352001B2 (en) 2002-10-18 2009-10-28 メルク エンド カムパニー インコーポレーテッド Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004048379A1 (en) * 2002-11-01 2004-06-10 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
RU2005117383A (en) 2002-11-07 2006-01-20 Мерк энд Ко., Инк. (US) Phenylalanine derivatives as dipepididyl peptidase inhibitors for the treatment or prevention of diabetes
DE10251927A1 (en) * 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity
UY28103A1 (en) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma NEW IMIDAZO-PIRIDINONAS REPLACED, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS
US7109192B2 (en) 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
US7265128B2 (en) 2003-01-17 2007-09-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7388019B2 (en) 2003-01-31 2008-06-17 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CN1894234A (en) * 2003-03-25 2007-01-10 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
EA009291B1 (en) 2003-05-05 2007-12-28 Пробиодруг Аг Use of effectors of glutaminyl and glutamate cyclases
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
EP2206496B1 (en) 2003-05-05 2014-09-17 Probiodrug AG Screening of inhibitors of formation of pyroglutamic acid in amyloid beta peptide
CA2524531A1 (en) 2003-05-14 2004-12-02 Merck And Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2526770A1 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2527806A1 (en) 2003-06-17 2004-12-29 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE10327439A1 (en) * 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazopyridazinone and imidazopyridone derivatives, their production and their use as pharmaceuticals
DE602004018503D1 (en) 2003-07-31 2009-01-29 Merck & Co Inc HEXAHYDRODIAZEPINONE AS INHIBITORS OF DIPEPTIDYLPEPTIDASE-IV FOR TREATMENT OR PREVENTION OF DIABETES
MXPA06001601A (en) 2003-08-13 2006-08-25 Takeda Pharmaceutical 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors.
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20050065144A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
BRPI0415409A (en) 2003-10-15 2006-12-05 Probiodrug Ag use of glutaminyl and glutamate cyclase effectors
EP1680120A2 (en) 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
KR20140089408A (en) 2003-11-17 2014-07-14 노파르티스 아게 Use of dipeptidyl peptidase iv inhibitors
US7217711B2 (en) 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10359098A1 (en) * 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2- (piperazin-1-yl) and 2 - ([1,4] diazepan-1-yl) imidazo [4,5-d] pyridazin-4-ones, their preparation and their use as pharmaceuticals
PT1715893E (en) 2004-01-20 2009-10-20 Novartis Pharma Ag Direct compression formulation and process
CN1918131B (en) 2004-02-05 2011-05-04 前体生物药物股份公司 Novel inhibitors of glutaminyl cyclase
PT1758905E (en) 2004-02-18 2009-07-16 Boehringer Ingelheim Int 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a ddp-iv inhibitor
CN102079743B (en) 2004-03-15 2020-08-25 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
WO2005108382A1 (en) 2004-05-04 2005-11-17 Merck & Co., Inc. 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2005116029A1 (en) 2004-05-18 2005-12-08 Merck & Co., Inc. Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2008507541A (en) * 2004-07-23 2008-03-13 ロイヤルティ，スーザン・マリー Peptidase inhibitor
DE102004038268A1 (en) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituted, bicyclic 8-pyrrolidino-xanthines, process for their preparation and their use as medicaments
DE102004038270A1 (en) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituted bicyclic 8-amino-xanthines, process for their preparation and their use as medicaments
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
BRPI0607863B8 (en) 2005-02-18 2021-05-25 Mitsubishi Pharma Corp 3-{(2s,4s)-4-[4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl crystalline salt }thiazolidine and its preparation process
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
FR2889189A1 (en) * 2005-07-28 2007-02-02 Cerep Sa HYDANTOIN-DERIVED COMPOUNDS AND THEIR USE AS MCHR-1 ANTAGONISTS
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
PL1931350T5 (en) * 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
KR100792275B1 (en) * 2006-02-22 2008-01-08 영진약품공업주식회사 Cyclic hydrazide derivatives having ?-amino group, its pharmaceutical acceptable salts and preparation process thereof
JP2009531456A (en) * 2006-03-28 2009-09-03 武田薬品工業株式会社 Preparation of (R) -3-aminopiperidine dihydrochloride
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
AR060406A1 (en) 2006-04-11 2008-06-11 Arena Pharm Inc METHODS FOR USING THE GPR119 RECEIVER IN THE IDENTIFICATION OF USEFUL COMPOUNDS TO INCREASE THE OSEA MASS IN AN INDIVIDUAL
JP2009533393A (en) 2006-04-12 2009-09-17 プロビオドルグ エージー Enzyme inhibitor
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CA2663279C (en) * 2006-09-13 2016-05-17 Takeda Pharmaceutical Company Limited Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
SI2091948T1 (en) 2006-11-30 2012-07-31 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CL2008002427A1 (en) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AU2010212867B2 (en) 2009-02-13 2013-05-16 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
AU2010294214B2 (en) 2009-09-11 2015-05-07 Vivoryon Therapeutics N.V. Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
CN102918027A (en) 2010-04-06 2013-02-06 艾尼纳制药公司 Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2015003881A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
JP6901976B2 (en) * 2015-06-25 2021-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング How to prepare xanthine-based compounds
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT313916B (en) * 1971-10-28 1974-03-11 Degussa Process for the preparation of new basic substituted theophyllines and their acid addition salts
US4719245A (en) * 1984-03-08 1988-01-12 The Dow Chemical Company Flexible polyisocyanurate-urethane foam
US4636229A (en) * 1984-03-26 1987-01-13 Nippon Oil Company, Limited Selective gas separation membrane
FR2654935B1 (en) * 1989-11-28 1994-07-01 Lvmh Rech USE OF XANTHINES, WHICH MAY BE INCORPORATED IN LIPOSOMES, TO PROMOTE PIGMENTATION OF THE SKIN OR HAIR.
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
FR2668150B1 (en) * 1990-10-17 1994-11-18 Theramex NOVEL DERIVATIVES OF TERBUTYLPHENYL 1-AMINO 4-HYDROXYBUTANE, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
AU766219B2 (en) 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
US6815446B1 (en) * 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
PT1368349E (en) * 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Xanthine derivative, production and use thereof as a medicament
NZ532816A (en) * 2001-11-09 2005-11-25 Cv Therapeutics Inc A2B adenosine receptor antagonists
US7074798B2 (en) * 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
BR0311697A (en) * 2002-06-06 2005-03-22 Eisai Co Ltd New Condensed Imidazole Derivatives
US7879316B2 (en) * 2002-06-12 2011-02-01 L'oreal Cosmetic composition containing a polyorganosiloxane polymer
FR2841346B1 (en) * 2002-06-19 2004-11-05 Eastman Kodak Co METHOD FOR DEVELOPING A HIGH CONTRAST PHOTOGRAPHIC PRODUCT CONTAINING A POLYHYDRAZIDE NUCLEATING AGENT

Cited By (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
US20040152745A1 (en) * 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
US20110144083A1 (en) * 2001-02-24 2011-06-16 Boehringer Ingelheim International Gmbh Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
US20100204250A1 (en) * 2001-02-24 2010-08-12 Boehringer Ingelheim Pharma & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040087587A1 (en) * 2001-02-24 2004-05-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20100173916A1 (en) * 2001-02-24 2010-07-08 Boehringer Ingelheim International Gmbh Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
US20060247226A1 (en) * 2001-02-24 2006-11-02 Frank Himmelsbach Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040077645A1 (en) * 2001-02-24 2004-04-22 Frank Himmelsbach Xanthine derivatives,production and use thereof as medicament
US20110144095A1 (en) * 2001-02-24 2011-06-16 Boehringer Ingelheim Pharma & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20030199528A1 (en) * 2001-09-19 2003-10-23 Kanstrup Anders B. Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US7786301B2 (en) * 2002-05-31 2010-08-31 Schering Corporation Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof
US20030232987A1 (en) * 2002-05-31 2003-12-18 Schering Corporation Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof
US20060205943A1 (en) * 2002-05-31 2006-09-14 Schering Corporation Process for preparing xanthine phosphodiesterase V inhibitors and precursers thereof
US7074923B2 (en) * 2002-05-31 2006-07-11 Schering Corporation Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof
US7772226B2 (en) 2002-06-06 2010-08-10 Eisai R&D Management Co., Ltd. Condensed imidazole derivatives
WO2003104229A1 (en) 2002-06-06 2003-12-18 エーザイ株式会社 Novel fused imidazole derivative
US20090018331A1 (en) * 2002-06-06 2009-01-15 Eisai R&D Management Co., Ltd. Condensed imidazole derivatives
US20060063787A1 (en) * 2002-06-06 2006-03-23 Eisai Co., Ltd. Condensed imidazole derivatives
US20040116328A1 (en) * 2002-06-06 2004-06-17 Eisai Co., Ltd. Condensed imidazole derivatives
US20060100199A1 (en) * 2002-06-06 2006-05-11 Seiji Yoshikawa Novel condensed imidazole derivatives
US9108964B2 (en) 2002-08-21 2015-08-18 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8119648B2 (en) 2002-08-21 2012-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20040097510A1 (en) * 2002-08-21 2004-05-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10023574B2 (en) 2002-08-21 2018-07-17 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US20080255159A1 (en) * 2002-08-21 2008-10-16 Boehringer Ingelheim Pharma Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10202383B2 (en) 2002-08-21 2019-02-12 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8178541B2 (en) 2002-08-21 2012-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20040166125A1 (en) * 2002-08-22 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7838529B2 (en) 2002-08-22 2010-11-23 Boehringer Ingelheim International Gmbh Xanthine derivates, their preparation and their use in pharmaceutical compositions
US20090131432A1 (en) * 2002-08-22 2009-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivates, their preparation and their use in pharmaceutical compositions
US20100144703A1 (en) * 2002-11-08 2010-06-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7696212B2 (en) 2002-11-08 2010-04-13 Boehringer Ingelheim Pharma Gmbh And Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138214A1 (en) * 2002-11-08 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7560450B2 (en) 2002-11-21 2009-07-14 Boehringer Ingelheim Pharma Gmbh & Co., Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138215A1 (en) * 2002-11-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US8034941B2 (en) 2003-06-18 2011-10-11 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US20090258856A1 (en) * 2003-06-18 2009-10-15 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
US9078866B2 (en) 2003-08-01 2015-07-14 Mannkind Corporation Method for treating hyperglycemia with GLP-1
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070082908A1 (en) * 2003-08-29 2007-04-12 Dainippon Sumitomo Pharma Co., Ltd. Bicycle pyrazole derivative
US7550455B2 (en) 2003-11-27 2009-06-23 Boehringer Ingelheim International Gmbh 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition
US20070219178A1 (en) * 2003-12-04 2007-09-20 Eisai Co., Ltd. Preventive or therapeutic agents for multiple sclerosis
US20090137801A1 (en) * 2004-02-18 2009-05-28 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20050234108A1 (en) * 2004-02-18 2005-10-20 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7645763B2 (en) 2004-02-23 2010-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US20050187227A1 (en) * 2004-02-23 2005-08-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US20050203095A1 (en) * 2004-03-13 2005-09-15 Boehringer Ingelheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7432262B2 (en) 2004-03-13 2008-10-07 Boehringer Ingelheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US20090088569A1 (en) * 2004-04-10 2009-04-02 Matthias Eckhardt 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation, and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US7667035B2 (en) 2004-05-10 2010-02-23 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US20050261352A1 (en) * 2004-05-10 2005-11-24 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060004074A1 (en) * 2004-06-24 2006-01-05 Boehringer Ingelheim International Gmbh New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US20080312243A1 (en) * 2004-06-24 2008-12-18 Matthias Eckhardt Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US7470716B2 (en) 2004-06-24 2008-12-30 Boehringer Ingelheim International Gmbh Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US7906539B2 (en) 2004-06-24 2011-03-15 Boehringer Ingelheim International Gmbh Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US7825242B2 (en) 2004-07-16 2010-11-02 Takeda Pharmaceutical Company Limted Dipeptidyl peptidase inhibitors
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US10130685B2 (en) 2004-08-23 2018-11-20 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US7495003B2 (en) 2004-09-11 2009-02-24 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060058323A1 (en) * 2004-09-11 2006-03-16 Boehringer Ingelheim International Gmbh New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060079541A1 (en) * 2004-09-14 2006-04-13 Boehringer Ingelheim International Gmbh 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495002B2 (en) 2004-09-14 2009-02-24 Boehringer Ingelheim International Gmbh 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US20060142310A1 (en) * 2004-11-05 2006-06-29 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US20090192314A1 (en) * 2004-11-05 2009-07-30 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US7820815B2 (en) 2004-11-05 2010-10-26 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US8541450B2 (en) 2004-11-05 2013-09-24 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US20070027168A1 (en) * 2005-07-30 2007-02-01 Waldemar Pfrengle 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8106060B2 (en) 2005-07-30 2012-01-31 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8637530B2 (en) 2005-07-30 2014-01-28 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US9446001B2 (en) 2005-09-14 2016-09-20 Mannkind Corporation Increasing drug affinity for crystalline microparticle surfaces
US9717689B2 (en) 2005-09-14 2017-08-01 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US10143655B2 (en) 2005-09-14 2018-12-04 Mannkind Corporation Method of drug formulation
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US10130581B2 (en) 2006-02-22 2018-11-20 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8673927B2 (en) 2006-05-04 2014-03-18 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US9173859B2 (en) 2006-05-04 2015-11-03 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US11919903B2 (en) 2006-05-04 2024-03-05 Boehringer Ingelheim International Gmbh Polymorphs
US11291668B2 (en) 2006-05-04 2022-04-05 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US11084819B2 (en) 2006-05-04 2021-08-10 Boehringer Ingelheim International Gmbh Polymorphs
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US10301313B2 (en) 2006-05-04 2019-05-28 Boehringer Ingelheim International Gmbh Polymorphs
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US20110065731A1 (en) * 2006-05-04 2011-03-17 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
US20070259900A1 (en) * 2006-05-04 2007-11-08 Peter Sieger Polymorphs
US20070281940A1 (en) * 2006-05-04 2007-12-06 Klaus Dugi Uses of dpp-iv inhibitors
US20080107731A1 (en) * 2006-05-04 2008-05-08 Anja Kohlrausch Dpp iv inhibitor formulations
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
US8071583B2 (en) 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
US20110112069A1 (en) * 2007-08-17 2011-05-12 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US20090110647A1 (en) * 2007-10-24 2009-04-30 Peter Richardson Method of preventing adverse effects by glp-1
US8377869B2 (en) 2007-10-24 2013-02-19 Mannkind Corporation Method of preventing adverse effects by GLP-1
US10022379B2 (en) 2008-04-03 2018-07-17 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US20110206766A1 (en) * 2008-04-03 2011-08-25 Boehringer Ingelheim International Gmbh Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10973827B2 (en) 2008-04-03 2021-04-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US20110092510A1 (en) * 2008-06-03 2011-04-21 Boehringer Ingelheim International Gmbh Dpp-iv inhibitors for use in the treatment of nafld
US10201672B2 (en) 2008-06-13 2019-02-12 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9339615B2 (en) 2008-06-13 2016-05-17 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9446133B2 (en) 2008-06-13 2016-09-20 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9511198B2 (en) 2008-06-13 2016-12-06 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US10751488B2 (en) 2008-06-13 2020-08-25 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US10675421B2 (en) 2008-06-20 2020-06-09 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US10034877B2 (en) 2008-08-06 2018-07-31 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US9212183B2 (en) 2008-12-23 2015-12-15 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US9655850B2 (en) 2008-12-29 2017-05-23 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US10172850B2 (en) 2008-12-29 2019-01-08 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
WO2010079197A1 (en) * 2009-01-07 2010-07-15 Boehringer Ingelheim International Gmbh Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
WO2010080964A1 (en) * 2009-01-08 2010-07-15 Mannkind Corporation Method for treating hyperglycemia with glp-1
EP2853268A1 (en) * 2009-01-08 2015-04-01 Mannkind Corporation Treatment of hyperglycemia with GLP-1
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10092571B2 (en) 2009-11-27 2018-10-09 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US10004747B2 (en) 2010-05-05 2018-06-26 Boehringer Ingelheim International Gmbh Combination therapy
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US10130709B2 (en) 2011-06-17 2018-11-20 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US10258664B2 (en) 2011-10-24 2019-04-16 Mannkind Corporation Methods and compositions for treating pain
US9610351B2 (en) 2011-10-24 2017-04-04 Mannkind Corporation Methods and compositions for treating pain
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US10195203B2 (en) 2012-05-14 2019-02-05 Boehringr Ingelheim International GmbH Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10772865B2 (en) 2015-03-09 2020-09-15 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Also Published As

Publication number Publication date
US7235538B2 (en) 2007-06-26
AU2001268958B2 (en) 2006-03-09
JP2004502690A (en) 2004-01-29
WO2002002560A2 (en) 2002-01-10
EP1301187A2 (en) 2003-04-16
WO2002002560A3 (en) 2002-04-25
HUP0301622A3 (en) 2006-05-29
AU6895801A (en) 2002-01-14
PL360856A1 (en) 2004-09-20
EP1301187B1 (en) 2005-07-06
HUP0301622A2 (en) 2003-09-29
MXPA02012272A (en) 2003-04-25
US20040034014A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
EP1301187B1 (en) Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
AU2001268958A1 (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
US7192952B2 (en) Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US20030199528A1 (en) Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1404675B1 (en) Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
EP1496877B1 (en) Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
WO2004033455A2 (en) Hemisuccinate salts of heterocyclic dpp-iv inhibitors
US7074798B2 (en) Xanthine derivative and DPPIV inhibitor
KR101446692B1 (en) Hydrochlorides and hydrates of 1-[(3-cyanopyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-aminopiperidin-1-yl)xanthine, their preparation and their use as medicaments
US7495002B2 (en) 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7906539B2 (en) Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US6977300B2 (en) A2B adenosine receptor antagonists
US20070197552A1 (en) Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
JP2007531780A (en) Novel 2-amino-imidazo [4,5-D] pyridazin-4-one and 2-amino-imidazo [4,5-C] pyridazin-4-one, their preparation and use as pharmaceuticals
US6187780B1 (en) Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
EP0559893A1 (en) Xanthine derivative
EP1561752A1 (en) Heterocyclic compounds that are inhibitors of the enzyme DPP-IV

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVO NORDISK A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KANSTRUP, ANDERS BENDTZ;CHRISTIANSEN, LISE BROWN;LUNDBECK, JANE MARIE;AND OTHERS;REEL/FRAME:012279/0575;SIGNING DATES FROM 20010913 TO 20010920

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION